Echocardiographic assessment of cardiac function in patients with atrial fibrillation by Bunting, Karina V





Title: Echocardiographic assessment of 
cardiac function in patients with atrial 
fibrillation 
 
By Karina Valerie Bunting BSc MSc 
A thesis submitted to the University of Birmingham 
for the degree of  
DOCTOR OF PHILOSOPHY 
 
Institute of Cardiovascular Sciences 
College of Medical and Dental Sciences 
 University of Birmingham  















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 




2 | P a g e  
 
Abstract 
Echocardiography plays an essential role in the management of patients with atrial fibrillation 
(AF) and the diagnosis of heart failure in these patients.  Assessment of systolic and diastolic 
function is challenging in AF due to the irregular RR interval, resulting in variability from 
beat to beat.  In this thesis, I have compared the reproducibility and validity of an index beat 
approach (similar RR intervals for the two prior beats before measurement) versus 
conventional averaging of three, five and ten consecutive beats in patients with permanent AF 
and symptoms of heart failure. 
Transthoracic echocardiography was performed at baseline in 160 patients enrolled in the 
RAte control Therapy Evaluation in permanent AF randomised controlled trial 
(NCT02391337).  Measurements of Simpson’s biplane left ventricular ejection fraction 
(LVEF), global longitudinal strain (GLS) and the diastolic parameter E/e’ were obtained using 
three index beats and 3, 5 and 10 consecutive beats.  All measurements were analysed offline 
with the analyser blinded to clinical details and with no pre-exclusions to image quality.  
The index beat method was shown to have a significantly lower within beat variability 
compared to consecutive beats and a single index beat measuring GLS and E/e’ was more 
reproducible or equally reproducible to averaging 10 consecutive beats when assessing intra 
and inter-operator reproducibility.  Using a single index beat did not impact on the validity of 
LVEF, GLS or E/e’ when correlated with natriuretic peptides and substantially shortened the 
time taken for measurement of E/e’ (64% quicker than assessing 10 consecutive beats). 
This approach can enhance the reliability and efficiency of measurements for both systolic 
and diastolic left ventricular function in patients with AF.  
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1.1   Atrial Fibrillation, heart failure and concomitant disease 
Atrial fibrillation (AF) is defined as a supraventricular tachyarrhythmia with disorganised 
atrial activation resulting in loss of effective atrial contraction.(1)  It is characterised by a 
chaotic pattern of atrial activity which suppresses the sinus activity, resulting in irregular 
activation of the ventricle.(2)  Diagnosis of AF requires an electrocardiogram (ECG), which 
shows irregular R to R intervals and no recognizable, distinct P waves.(3)  
1.1.1 Epidemiology and Risk Factors 
AF is the most common age related cardiac arrhythmia, with 1-2% of the world’s population 
having been diagnosed with this condition.(4)  The incidence of AF increases progressively as 
the population ages, with 10% of octogenarians suffering from AF.(5)   The prevalence of AF 
has increased over recent years and it is likely to increase exponentially with an ageing 
population.(6, 7)  AF not only increases the risk of mortality and morbidity, but also reduces 
quality of life and functional performance in these patients.  Therefore, it is critical that 
correct management decisions can be made to improve prognosis of these patients.(8) 
Multiple conditions can predispose a patient to AF.  The list of causative factors is extensive 
including: increased age, male gender, hypertension, valvular heart disease, heart failure, 
coronary artery disease, congenital heart disease, obesity, pericardial fat, sleep apnoea, 
chronic kidney disease, alcohol consumption, smoking, diabetes, thyroid disorders, vigorous 
physical activity, infection, inflammation, and finally genetic factors.(4) 
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1.1.2  Pathophysiology 
The pathophysiology of AF is complex and ultimately occurs when there are structural or 
electrophysiological abnormalities affecting the conduction pathways in the atria.  AF is 
generated by rapidly firing foci usually originating from the pulmonary veins.  The foci form 
the substrate of complex multi-circuit re-entry currents, which propagate as multiple wavelets 
around the atrial myocardium.  Where there are areas of fibrosis, barriers are formed which 
slow conduction and help maintain the foci.  Scarring can also damage the ion channels, 
resulting in increased potassium outward currents and reduced calcium inward currents.  This 
change in membrane potential reduces the duration of the action potential and so refractory 
period, promoting the generation and maintenance of re-entry circuits.  These changes 
implemented by the arrhythmia itself and structural remodelling negatively affect the heart by 
altering the haemodynamics, disrupting atrioventricular synchrony which results in a 
progressive decline in atrial and ventricular function.(4, 9) 
 
1.1.3  Effect of Atrial Fibrillation on the Cardiac Cycle 
To understand the effect of atrial fibrillation on the cardiac cycle it is first important to 
understand the four key phases of the pressure-volume loop on the cardiac cycle.  Phase I 
begins during diastole when the ventricle is relaxing and the valves are shut resulting in a 
ventricular pressure of 0 mmHg and volume ~45ml (this will vary according to body size).  
Meanwhile blood is returning via the systemic and pulmonary veins to the atria.  The atria 
continue to fill, until the pressure in the atria exceeds that of the ventricles causing the mitral 
and tricuspid valve to open, initiating the process of ventricular filling.  The ventricle will 
continue to fill until it reaches a volume of ~115ml (end diastolic volume) and the pressure 
would have risen to 5 mmHg (end diastolic pressure).  At the end of atrial systole the atria 
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depolarise (represented as a P wave on the ECG), resulting in atrial contraction which causes 
a further increase in ventricular pressure.  At this stage the ventricles are full and this triggers 
the start of Phase II, which is known as the isovolumic contraction phase.  The ventricles 
depolarise (represented by the QRS wave on the ECG), which causes the ventricular 
myocardium to contract.  As the ventricle contracts the ventricular pressure rises, causing the 
mitral and tricuspid valve to shut.  The ventricle continues to contract, further increasing 
ventricular pressure.  Phase III begins at the point in which the ventricular pressure exceeds 
that of the pressure in the aorta and pulmonary artery, causing the aortic and pulmonary valve 
to open.  This is the ejection period in which the blood leaves the heart, to supply blood to the 
body and lungs via the aorta and pulmonary artery.  The ventricular volume falls and the 
aortic and pulmonary valve close at which point phase IV begins.  Phase IV is known as the 
period of isovolumic relaxation; the ventricle repolarizes (seen as the T wave on the ECG) 
resulting in ventricular relaxation.  The pressure in the ventricle falls, meanwhile the atria 
continue to fill until their pressure exceeds that of the ventricles causing the mitral and 
tricuspid valve to open and so Phase I begins again.(10)             
In AF there is no atrial contraction and so the filling of the ventricle relies entirely on passive 
filling from the atria (Figure 1).  Following the Frank-Starling mechanism the greater the 
ventricular volume, the greater the myocardial stretch and so the greater the force of 
contraction, which results in a greater ejection fraction and so larger stroke volume.  
Therefore the length of the R to R interval significantly affects the end-diastolic volume, 
contractility and stroke volume.  This means with short R to R intervals there is decreased 
filling time, causing a reduction in left ventricular (LV) systolic function due to reduced 
preload subsequently resulting in reduced LV contraction and so there is a reduced stroke 
volume.(11, 12)
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Figure 1.  Schematic diagram of the cardiac cycle in AF.  The relationship of pressure and volume in the ventricle, aorta and atria in 
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1.1.4  Management of Atrial Fibrillation  
Atrial Fibrillation significantly increases mortality, hospitalisation and risk of cardiovascular 
events as well as reducing quality of life.  The management of AF is strongly guided by the 
degree of ventricular function, which is most commonly assessed using 
echocardiography.(13)  The risk of stroke is increased 5-fold in patients with AF and in those 
who do suffer strokes caused by AF, the consequences are more severe with increased risk of 
morbidity, mortality and poor functional outcome.  The main cause of stroke is from thrombi 
originating from the left atrial appendage embolizing to the brain.  The pathophysiology of 
AF forms perfect conditions for Virchow’s triad for thrombus formation:  dilated atria and 
loss of atrial contraction results in blood stasis, endothelial injury from the erratic fibrillating 
atrium and an increase in hemoconcentration from raised atrial natriuretic peptide (ANP) 
levels.(14)     
Stroke risk in AF patients is calculated using the CHA2DS2-VASc score, which is determined 
according to age, gender and whether the patient has congestive heart failure, diabetes, 
hypertension, vascular disease or a history of a cerebrovascular event.  The European Society 
of Cardiology (ESC) guidelines 2016 recommend the use of oral anticoagulants (OAC) in 
men with a score of 1 or more and in women with a score of 2 or more.(3)  LV function 
assessment using echocardiography is an important determinant for the heart failure criterion, 
which is defined by the ESC guidelines 2016 as “Signs/symptoms of heart failure or objective 
evidence of reduced left-ventricular ejection fraction”.(3)    
Rate control is recommended to improve symptoms and maintain haemodynamic stability.  
The choice of therapy will significantly depend on left ventricular ejection fraction.  For acute 
rate control the heart rate should be aimed to get below 110 bpm.  The choice of medication 
will depend on whether the LVEF (Left Ventricular Ejection Fraction) measured is ≥40% or 
<40%.  For long-term rate control the aim is to achieve a heart rate <80 bpm at rest and <110 
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bpm during moderate exercise.  Similarly to acute rate control the choice of medication is 
determined according to whether the patient has an LVEF ≥40% or <40% (see  
Figure 2). 
Figure 2.  The ESC guidelines on acute rate control according to LVEF (top) and long 
term rate control (bottom) (reproduced and adapted with permission from Kirchhof P. 
et al, 2016) (3)  
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If rate-control medication fails to control heart rate and symptoms the alternative is rhythm 
control or to ablate the atrio-ventricular node and implant a permanent ventricular sensing-
ventricular pacing- inhibitory response (VVI) pacemaker.  In the case of patients with reduced 
LVEF a biventricular pacemaker or implantable cardioverter defibrillator (ICD) may also be 
implanted depending on the patient’s clinical background.(3) 
Rhythm therapy is indicated in patients who despite being adequately rate controlled; still 
suffer from symptoms related to the AF.  The choice of therapy depends on how long the 
patient has been in AF.  In AF of recent onset urgent electrical cardioversion is recommended 
in those who are haemodynamically unstable, otherwise the choice between pharmacological 
cardioversion and electrical cardioversion is guided by the patient’s choice.  The choice of 
which pharmacological treatment to use is largely guided by the presence and severity of 
structural heart disease, which is often assessed by echocardiography; this particularly 
involves the challenge of classifying heart failure according to ejection fraction (see Figure 
3).   
Figure 3.  ESC guidelines recommendations on rhythm control therapy (reproduced and 
adapted with permission from Kirchhof P.et al, 2016)(3) 
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Catheter ablation is recommended as a second-line therapy to restore and maintain sinus 
rhythm in patients with symptomatic persistent, paroxysmal and long-standing persistent AF, 
in which pharmacological rhythm control, has either been ineffective or to which the patient 
has become intolerant.(3)      
1.2   Atrial Fibrillation and Heart Failure  
AF and heart failure are two of the most common cardiac diseases in the population.  Both 
conditions have increased in prevalence causing increased morbidity, including 
hospitalisation and mortality.(15)  AF and heart failure often co-exist together and can be 
responsible for causing each other, with 30-50% of patients having both AF and heart 
failure.(16)  
Heart failure is defined as a condition in which the heart is unable to pump a sufficient 
amount of blood to provide adequate blood flow to the body’s organs such as the lungs, brain 
and kidneys.  Heart failure may present as: Heart failure with a preserved ejection fraction 
(HFpEF) which is defined as having an LVEF ≥50% and heart failure with reduced ejection 
fraction (HFrEF), which is defined as having an LVEF ≤40%.  Heart failure with an ejection 
fraction that falls between these two categories is known as Heart Failure with a mid-range 
ejection fraction (HFmrEF).(17) 
In HFrEF as the name suggests the ejection fraction is reduced (<40%).  It is most commonly 
caused by coronary artery disease but there are many other causes such as viral infection, 
alcohol or drug abuse, chemotherapy and idiopathic dilated cardiomyopathy.  As a result of 
damage to the myocardium, contractility is impaired.(18, 19)  
 HFpEF manifests itself as a normal ejection fraction but the pathophysiology of heart failure 
remains under debate as it may be caused by impaired diastolic dysfunction and/or reduced 
longitudinal function.  Diastolic dysfunction presents as prolonged isovolumic LV relaxation, 
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slow LV filling and stiffening of the left ventricle.  Stiffening follows excessive collagen 
deposition in the extracellular matrix, which occurs due to external stressors such as high 
blood pressure.  As a result of the stiffness there is slow LV filling, which causes the stroke 
volume to reduce due to a lower preload, resulting in a lower cardiac output.  This may be 
worsened with faster heart rates as the ventricle has less time to fill with blood, causing a 
blunted increase in preload volume on exertion.  As the name suggests the ejection fraction 
remains normal, however longitudinal function may be impaired, suggesting some 
dysfunction in myocardial contractility.  However it has been found on exertion that there is 
no increase in LVEF due to a failure to increase end-diastolic volume and no change in end-
systolic volume, meaning that stroke volume cannot increase.  (20)  
Both AF and heart failure share similar risk factors which cause myocardial, extracellular, 
electrophysiological and neurohormonal changes, resulting in a similar pathophysiology that 
results in a cycle of negative events on the heart, with one perpetuating the other causing an 
incremental decline in left ventricular (LV) function (Figure 4).  As a result of low cardiac 
output either due to reduced contractile function (HFrEF) or ventricular stiffening (HFpEF) in 
heart failure, the renin-angiotensin-aldosterone system (RAAS) is activated to increase blood 
flow back to the heart, in an attempt to compensate failing contractility.  This however has a 
negative effect on the heart, causing raised filling pressures and increased afterload.  This 
results in increased left atrial pressure, causing the atria to dilate and areas of fibrosis may 
form.  These areas of scar act as foci which initiate and maintain AF.  Fibrosis leads to re-
entry circuits, as a result of abnormal distribution of gap junctions and delayed after 









 current.  The increase in catecholamines and 
angiotensin II causes interstitial fibrosis, which contribute to impaired intracellular calcium 
handling due to down-regulation of the ryanodine receptor channel and Ca
2+
-ATPase pump 
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found on the sarcoplasmic reticulum.  Also as a result of increased atrial pressure, ionic 
currents are activated  by stretch that cause  dispersion of refractoriness and changes in 
conduction properties further encouraging AF.  The induction of AF causes a loss of atrial 
systole, which reduces LV filling and so reduces cardiac output, which then further activates 
the RAAS perpetuating the cycle.  This is worsened during faster ventricular rates because 
there is even less diastolic filling.   
Fast ventricular rates can also lead to tachycardia-induced cardiomyopathy.  The mechanism 
of this condition is unclear, but may be due a combination of reduced blood flow to the 
coronaries causing myocardial ischaemia, myocardial energy depletion and abnormalities in 
calcium regulation.  Thus the cycle continues as the maintenance of AF worsens the severity 
of the heart failure and the risk of AF onset increases with worsening heart failure.(6, 15, 21, 
22)  
The presence of AF strongly increases the risk of the development of heart failure: Hazard 
ratio (HR) of 2.3 for HFrEF and 2.5 for HFpEF.  HFpEF and AF share more 
pathophysiological mechanisms; hence they are more likely to co-exist.(22)  
Echocardiography is the primary imaging tool for assessment of heart failure and its 
aetiology; therefore it is important that clinicians can rely on measurements made to stratify 
an appropriate treatment plan.  Patients with AF who develop heart failure have a poor 
prognosis; the SOLVD trial concluded that patients in with a LVEF <35% AF is an 
independent predictor of all-cause mortality, progressive ventricular failure and death or 
hospitalisation for heart failure.  Therefore it is essential that the onset of heart failure is 
detected early.(15, 23) 
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Figure 4.  The pathophysiology of AF and heart failure.  Abbreviations: RAAS, Renin-Angiotensin-Aldosterone-System; TR, Tricuspid 
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1.3  Role of Echocardiography in atrial fibrillation 
The ESC 2016 guidelines have made a class 1 recommendation for all AF patients in need of 
treatment to undergo a transthoracic echocardiogram (TTE).(24)  The assessment of LV 
function is crucial to guide the management of patients in AF in deciding anticoagulation 
therapy, whether it is safe to proceed with cardioversion, ablation and the choice of 
medication (both rate and rhythm control).  Therefore accurate assessment of systolic and 
diastolic parameters is essential, so that clinicians can make appropriate management choices 
for the patient.  It also plays an important role in establishing any structural cause for the 
onset of atrial fibrillation, for example; valve disease, previous myocardial infarction, 
hypertensive heart disease or restrictive cardiomyopathy.(24, 25)    
1.3.1 Parameters typically used in AF patients to assess systolic function 
There are several different parameters used to assess systolic function, all of which have their 
own advantages and disadvantages, see Table 1.  
 
Fractional shortening (FS) (Figure 5).  This method assesses LV systolic function by 
measuring the change in LV diameter (from the parasternal long axis view) during systole and 
diastole.  This method is flawed because it only measures in one plane and in only two walls.  
Therefore, it does not represent global ventricular function, but only basal antero-septal and 
inferolateral contractility.  It is also significantly affected by preload and afterload, so will 
vary according to the haemodynamics of the heart, therefore in atrial fibrillation the FS will 
be variable from beat to beat.(26) 
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Figure 5.  Fractional Shortening.  Red arrows depict measurements of the left 
ventricular internal diameter in diastole and systole, which are used to calculate 
fractional shortening.  
 
Stroke Volume (SV) (Figure 6).  This method measures the volume of blood leaving the heart 
in systole; in patients with reduced LV function the stroke volume is low.  SV is derived from 
the Left ventricular outflow tract velocity time integral (LVOT VTI) trace and the cross-
sectional area of the LVOT using the equation: 
SV=   LVOT area x LVOT VTI 
This method relies on correct measurement of the LVOT diameter, which should be measured 
in mid-systole 0.5-1 cm below the aortic valve’s annulus and correct positioning of the pulsed 
wave Doppler to measure the LVOT VTI (at the point where you measured the LVOT 
diameter).  This measurement is significantly affected by heart rate, afterload and preload, so 
will vary with irregular cardiac cycle lengths.(26) (27) 
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Figure 6.  Stroke Volume.  Measurement of the LVOT diameter (left) and measurement 
of the LVOT VTI (right) with the equation to calculate stroke volume below    
 
Simpson’s Biplane Ejection Fraction (Figure 7).  This measurement does not directly 
measure myocardial function, but instead assesses systolic function according to the change in 
chamber volume over a cardiac cycle.  This method is limited by the geometric assumption 
that every ventricle is cylindrical and it will not incorporate regional wall motion 
abnormalities or distortions in other planes.  It also relies on good endocardial definition to 
accurately delineate the size of the cavity in end-systole and end-diastole.(28, 29)  As it relies 
on volume, it will be affected by preload and afterload.  In patients with AF, ventricular filling 
is more dependent on the length of the R to R interval compared to patients in sinus rhythm 
therefore the end-diastolic volume and so ejection fraction will vary according to the R to R 
interval.(30) 
Stroke volume= LVOTarea x LVOTvti 
LVOT area= ᴨ x LVOT diameter LVOTvti trace 
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Figure 7.  Simpson’s Biplane LVEF.  Simpson’s volume of the ventricle in diastole from 
the apical 4 chamber (top-left) and apical 2 chamber (bottom-left) and then Simpson’s 
volume of the ventricle in systole from the apical 4 chamber (top-right) and apical 2 
chamber (bottom-right) 
 
3-D Volume Ejection Fraction (Figure 8).  3-D This method possesses the advantage of 
incorporating the entire ventricle in every plane, so that there are no geometric assumptions 
and the ventricle can be assessed in every plane, including regional wall motion abnormalities 
and distortions.  This method is also semi-automated, which may reduce inter-observer 
variability.  The limitations of this method are firstly that to achieve a 3-D dataset with good 
spatial and temporal resolution, the sub-volumes of the ventricle may need to be taken over 
four beats of equal length with minimal cardiac motion.  In order for this to be carried out the 
patient needs to be in a regular heart rhythm and have the ability to hold their breath for a few 
seconds.  For patients with irregular heart rhythms or with breathing difficulties, the dataset 
will be prone to stitch artefact, which disrupts the acquisition of a 3-D volume.  To over-come 
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this problem a single-beat acquisition can be used, but the temporal and spatial resolution, as 
well image quality will be compromised.(31, 32) 
Figure 8.  3D volume LVEF with x-plane imaging of the left ventricle (top) and 3D 
volumes and ejection fraction calculated (below).
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Tissue Doppler Indices (TDI) (Figure 9).  Measurements from this parameter can be used to 
evaluate both systolic (s’) and diastolic function (e’).  The normal ranges for tissue Doppler 
velocities vary with age and sex.  
Figure 9.  Tissue Doppler Indices (TDI).  Lateral annulus (top) and septal annulus 
(bottom) systolic (s’) and diastolic (e’) tissue Doppler velocities 
The advantage of this method is that it is easy to perform and does not rely on image quality 
to the same extent as 2D and 3D measurements.  It also measures longitudinal function, which 
tends to deteriorate first in LV dysfunction.  However it is limited by its angle dependence; if 
the angle of incidence is more than 15
o
 there will be a ~4% underestimation in the velocity 
measured.  It is also unable to distinguish areas of normal myocardial contractility from areas 
of damaged myocardium, which may appear normal due to tethering from other functioning 
areas.  It is also important to be aware that in patients with severe mitral annulus calcification 





19 | P a g e  
 
function of the ventricle.  This method has some load dependency and so with AF patients the 
variable R to R interval will result in variation in longitudinal function from beat to beat, 
causing different values of s’ from beat to beat (33-35)  
Left Ventricular Strain (Figure 10).  This is a relatively new method and is gradually being 
incorporated more and more into clinical practice.  It provides a quantitative assessment of 
left ventricular deformation during contraction.  There are two methods of assessing strain: 
speckle tracking and tissue Doppler tracking.  Tissue Doppler measures the speed of the 
myocardium as a marker of function.  However it is limited by angulation and noise artefact, 
which can impact on its accuracy.(94)  Speckle tracking works by tracking two points within 
the myocardium (speckles), as they move away and towards each other.  When the speckles 
move towards each other, this represents myocardial shortening and so contraction, producing 
a negative value; the more negative the value, the greater the contraction.  The advantages of 
this method is that it assesses all walls, is angle independent and has been shown to be more 
sensitive at detecting myocardial dysfunction in presence of a normal ejection fraction.(36)  
The limitations of this method are that in the presence of a high heart rate, low frame rate or 
poor image quality, tracking of the speckles may deteriorate resulting in inaccurate indices of 
strain and strain rate.  This method is still relatively load dependent and so in AF with longer 
preceding R to R intervals there will be a greater degree of contractility compared to shorter R 
to R intervals, resulting in varying strain from beat to beat (37)  
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Figure 10.  Global Longitudinal Strain.  Longitudinal strain of the apical 4 chamber (top left), apical 2 chamber (top right), apical 3 
chamber (bottom left) and global longitudinal strain displayed as bulls-eye (bottom right)
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Table 1.  Advantages and Disadvantages of measurements used to assess systolic 
function.  
 




High temporal resolution 
Single plane 
Ignores RWMA in other walls 





Relies on correct positioning of 
sample volume (LVOT VTI) and 
correct measurement of LVOT 
diameter 
LVOT is assumed to be circular  
Cannot be performed with high 





Performed in two planes 
LVEF calculated from volumes 
instead of diameter 
Requires clear endocardial boarder  
Ignores RWMA in the apical 3 
chamber and reliant on geometric 
assumptions   
Apex frequently fore-shortened 
3D volume LVEF 
(%)  
Assesses volumes in every plane  
No geometric assumptions  
Unaffected by foreshortening 
Good echo windows are required  
Lower temporal resolution  
Difficult in patients with 
arrhythmias or those unable to 
breath-hold 
Tissue Doppler s’ 
(cm/s) 
Measures longitudinal function  
 
Velocities must be parallel to the 
ultrasound beam 
Cannot differentiate between active 
contraction and tethering effects 
Unreliable if there has been mitral 
valve surgery or there is heavy 
mitral annulus calcification   
GLS (%) Can detect early systolic 
dysfunction before the ejection 
fraction reduces 
Angle independent  
Strain values differ between vendors 
Relies on adequate frame rate for 
speckles to be accurately tracked  
Load dependent  
Abbreviations: 3D= three dimensional; GLS= global longitudinal strain; LVEF= left 
ventricular ejection fraction; LVOT= left ventricular outflow tract; RWMA= Regional Wall 
Motion Abnormalities; VTI= velocity time integral  
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1.3.2 Parameters typically used to assess diastolic function  
There are several different parameters which can be used to assess diastolic function in AF 
patients, all of which have their own advantages and disadvantages, see Table 2. 
Mitral E wave and deceleration time.  The E wave measures the speed of blood as it passes 
between the left atrium (LA) and LV in early diastole.  It represents the filling pressures 
within the ventricle.  As the patient ages, the E wave reduces in velocity and the deceleration 
time of the E wave profile increases in length; this correlates with a gradual impairment in LV 
relaxation.  It is affected by left atrial pressure and the speed of LV relaxation.  Deceleration 
time of the E wave is affected by how quickly the LV relaxes and the LV diastolic 
pressure.(36)  The variable R to R interval in AF patients will cause a change in filling time 
from beat to beat, which will result in an inconsistent E wave and deceleration time measured.  
E wave and E/e’ (Figure 11).  The E/e’ ratio is the mitral E wave (described above) divided 
by the Tissue Doppler Indice (TDI) e’.  e’ is the speed of the myocardium during diastole; on 
a TDI trace it is seen as the negative deflection during diastole.  E/e’ ratio correlates well with 
pulmonary capillary wedge pressure (PCWP) even in AF patients.(37)  A PCWP greater than 
12 indicates raised left ventricular end-diastolic pressure (LVEDP).(38)  Both the E wave and 
e’ are affected by preload and so with AF the variable R to R interval will result in a variation 
in E/e’ from beat to beat.  
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Figure 11.  E/e’.  Measurements of peak mitral valve flow E wave divided by the TDI velocity e’ taken from the lateral and septal 
annulus    
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E/Vp (Figure 12).  This is the E wave divided by the speed of blood propagating from the 
mitral annulus to the apex (Vp) during early diastole.  This is a measure of diastolic function, 
which correlates with ventricular filling pressure.  If the ratio of E/Vp is increased, this will 
indicate raised ventricular filling pressures.(39) AF will affect the E wave value as this will 
vary according to the length of the preceding R to R interval.  
Figure 12. E/ Vp. Peak mitral flow E wave (right) divided by the velocity of blood 
through the ventricle from base to apex during diastole which is measured by the slope 
of the blue wave indicated by the red arrows (left).  
 
Pulmonary Venous Doppler (Figure 13).  In patients with sinus rhythm pulsed wave Doppler 
will present an S wave which represents atrial relaxation during ventricular contraction, D 
wave which represents atrial filling, LV relaxation and compliance and the A wave which 
represents atrial contraction.  The ratio of S/D can be used to detect raised left atrial pressures; 
as LA pressure increases the ratio of S/D.  However in patients with atrial fibrillation the A 
wave disappears and the S wave comes late making it difficult to measure.  More recent 
studies have examined the validity of pulmonary venous diastolic deceleration time.  This was 
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parameters derived from mitral inflow.(40, 41)  As with E/e’, pulmonary vein deceleration 
time is associated with invasive filling pressures in patients with AF, although the clinical 
utility of this measure is currently unknown.(37)  
Figure 13.  Pulmonary venous Doppler flow with measurements of systolic, diastolic flow 
and the deceleration time of the diastolic wave.    
 
Isovolumic Relaxation Time (IVRT) (Figure 14).  This is a measurement which can be used to 
detect impaired LV relaxation and raised left atrial pressures.  It is the time interval between 
when the aortic valve closes and when the mitral valve opens.  Changes in filling pressures 
will result in a change in IVRT.  If the IVRT is raised, this suggests that there is impaired LV 
relaxation present.  If the IVRT is shortened, this suggests that left atrial pressures are raised 
and may be indicative of a restrictive cardiac disease.  The limitations of this method are that 
it is affected by heart rate and arterial pressure and so in AF patients with variable R to R 
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Figure 14.  IVRT.  Measurements of IVRT indicated as red arrows from the end of 
systole to the start of diastole.  
 
LA Biplane volume (Figure 15).  This is most commonly measured by the Simpson’s volume 
method.  The volume of the LA is a marker of the effect of increased LV filling pressures.  
LA dilatation has been found to be an independent predictor of death, AF, heart failure and 
ischaemic stroke.(36) The limitation of LA volume is that it relies on good visualisation of the 
LA wall; as the atria are the furthest away from the transthoracic probe image quality declines 
making it difficult to accurately differentiate the LA wall, hence intra and inter observer 
reproducibility has been found to be poor.(43) Using LA size to assess diastolic function is 
limited in AF patients, as the majority of patients have dilated atria; hence studies have shown 
a poor correlation with PCWP in AF patients.(44) 
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Figure 15.  LA biplane volume.  Volumes of the left atrium measured in the apical 4 and 2 chamber view using the area-length method.
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Table 2.  Advantages and disadvantages of measurements used to assess diastolic 
function.  
Parameter Advantages  Disadvantages  
  
E wave (cm/s)  Feasible in most patients 
In patients with reduced LVEF it 
correlates better with LV filling 
pressures, functional class and 
prognosis than LVEF 
Affected by LV volumes and 
elastic recoil 
Age dependent 
Variable with arrhythmias 
Deceleration time 
(ms) 
Feasible in most patients  
A short deceleration time in 
reduced LVEF indicates 
increased LVEDP 
Unable to measure if there is E 
and A wave fusion (high heart 
rates) 
Not applied in atrial flutter 
Age dependent 
Not related to LVEDP in normal 
LVEF 
Tissue Doppler e’ 
(cm/s) 
Less load dependent than other 
parameters 
Feasible in most patients  
LV filling pressures have 
minimal effect on e’ in the 




Need to sample at least two sites 
Limited accuracy in patients with 
CAD, regional dysfunction, 
significant MAC, mitral valve 
surgery and pericardial disease  
E/Vp Only reliable index of LV 
relaxation in patients with 
reduced LVEF and dilated 
ventricles 
E/Vp >2.5 predicts PCWP >15 
mmHg in patients with reduced 
LVEF 
 
Relies on accurate angulation of 
M-mode through colour  
Difficult to acquire 
Vp can appear normal in patients 
with normal LV and LVEF 
Pulmonary venous 
Doppler S/D  
Deceleration time of diastolic 
velocity can be used to estimate 
mean PCWP in patients with AF 
S/D <1 suggests increased LA 
pressures  
Difficult to obtain in some patients 
Limited accuracy in patients with 
normal LVEF, AF, mitral valve 
disease and HCM 
IVRT (ms) Overall feasible and reproducible  
Combined with E/A it can be 
used to measure LV filling 
pressures in patients with HFrEF 
It can be combined with LVEDP 
to estimate the time constant of 
Affected by heart rate and arterial 
pressure 
Difficult to measure in the 
presence of tachycardia  
Different results according to 
whether continuous or pulsed 
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LV relaxation (τ) wave Doppler is used 
LA biplane volume 
(ml) 
Feasible in most patients 
Provides diagnostic and 
prognostic information about LV 
diastolic dysfunction  
Technically challenging in poor 
image quality and in the presence 
of a prominent aorta or large 
interatrial septal aneurysm 
LA dilatation is seen in well-
trained athletes, bradycardia, high-
output states, heart transplants, 
atrial arrhythmias and mitral valve 
disease despite normal diastolic 
function  
Abbreviations: LVEDP= Left Ventricular End Diastolic Pressure; LVEF=left ventricular 
ejection fraction; CAD= coronary artery disease; MAC= mitral annulus calcification; HCM= 
hypertrophic cardiomyopathy; PCWP= Pulmonary capillary wedge pressure; LA= Left atrial   
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1.4   Practical guide to assessing reproducibility in echocardiography  
In this section, I develop the rationale for my reproducibility studies in further chapters.  
Before considering patients with AF specifically, I have first reviewed methods for achieving 
reproducible echocardiographic measures in general.  This has been published in Bunting et 
al., Journal of the American Society of Echocardiography 2019;32(12):1505-15(45).  I was 
the first author for this paper and so carried out the literature searches for the information 
provided in this review, wrote the manuscript with input from the co-authors.  All figures and 
tables were created by myself and formatted with the help of Dr Kotecha.  The concept of the 
website link and embedded equations were formulated by myself, however the creation of the 
website was done by Luke Slater.      
Echocardiography is a key cardiac investigation that has contributed to improvements in the 
diagnosis and management of cardiovascular disease (CVD).(46, 47)  The use of 
echocardiography continues to grow, not only in number, but also in the type of 
measurements, from M-mode to two-dimensional (2D) imaging, Doppler echocardiography, 
three-dimensional (3D) imaging and speckle tracking.  However, inpatient hospital data 
suggests that echocardiography continues to be under-utilised in critical CVD conditions, and 
is an operator-dependent technique that is prone to variable reproducibility.(48)  Defining a 
reproducible measurement from echocardiography is challenging due to intrinsic biological 
variation, and the difference in measurement and interpretation between operators. 
1.4.1 Terminology and clinical need 
The term reproducibility covers many overlapping concepts.  It is explicitly defined as the 
variation of the same measurement made on a subject under changing conditions, but in real-
life practice also includes changes in measurement method, observer, time-frame, 
instrumentation, location and/or environment.  Repeatability can be separately considered as 
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the variation in repeat measurements made on the same subject under identical conditions, 
whereas reliability describes the magnitude of error between measurements.(49)  It is 
inevitable that there will be some degree of error in clinical measurements, and the acceptable 
amount will depend on particular circumstances.(50-52)  The correct statistical tests to 
determine these forms of reproducibility are often poorly considered, with the potential to 
mislead and confound clinical decision-making.(52)   
As clinical indications for echocardiography increase, it is essential that these measurements 
can be relied upon for accurate diagnosis and serial assessment of cardiac function.(53, 54)  In 
the following sections I have reviewed the literature on reproducibility, repeatability and 
reliability in the practical context of echocardiography.  In Table 3, I have provided a 
summary of statistical tests to assess reproducibility, repeatability and reliability.  Table 4 
highlights the application of these tests, giving examples specific to echocardiography.  The 
aim is to provide echocardiographers and clinicians with the tools to appraise their own 
measurements, reduce inconsistencies within and between operators, and improve the 
reliability of echocardiography in clinical practice.  To enable assessment in routine clinical 
care, I have provided an online calculator for key statistical tests and graphs, allowing users to 
input measurements and easily assess reproducibility: http://sono.lokero.xyz/.
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Table 3:  Terms of reference.  Abbreviations: SD = standard deviation; SEM = standard error of the mean. 
Term Explanation Examples of practical application in echocardiography Most valuable statistical tests 
Reproducibility Variation of the 
same 
measurement 






Comparing measurements of aortic valve peak velocity on the 
same patient by two different echocardiographers. 
Correlation coefficients for association: Pearson 
or Spearman correlation (r) and linear regression 




Comparing the grade of mitral regurgitation by two 
echocardiographers as none/mild/moderate/severe. 
 
Measure of the agreement between two operators: 
Cohen kappa (or weighted kappa for degree of 
disagreement). k=(total number of agreements - 
total agreements due to chance) / (total 
observations - total agreements due to chance). 
Comparing the difference in measurement of ejection fraction 
made by 2D Simpson’s biplane and 3D volumes. 
Agreement: Bland and Altman limits of 
agreement = bias (average difference between 
measurements) ± 1.96 x SD. 
 
Assessing the correlation of left-ventricular outflow tract 
diameter measured by multiple operators in the echo 
department. 
Intraclass correlation coefficient (requires 
complex computation). 
Repeatability  Variation in 
repeat 
measurements 




Assessing the difference in consecutive beats by the same 
operator for tissue Doppler E/e’. 
  
Repeatability coefficient = within-subject SD x 
√2 x 1.96. 




Assess within a department the variation in mitral 
regurgitation effective regurgitant orifice area between 
operators. 
Minimal detectable change = 1.96 x √2 x SEM. 






measurement)/ average x 100. 
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1.4.2 Reproducibility 
Reproducibility assesses the degree of variation in a measurement when conditions are 
changed.  In echocardiography, this could be used to assess the variability in different 
operators, between different echo sessions or across separate patients with the same condition.  
When assessing reproducibility, statistical tests can assess correlation, bias and agreement; 
together these are used to form a conclusion as to whether a study is reproducible (see Table 3 
for a summary of terms).  Correlation is defined as how well one variable can be used to 
predict the other, bias is whether there is a systematic difference from the expected value 
(either under- or over-estimated), and agreement is defined as how close two measurements 
are from each other when on the same scale.(50, 55) 
I have explored these three aspects in detail below, along with their limitations, using the 
example of biplane Simpson’s left ventricular ejection fraction (LVEF) assessed by two 
operators (Figure 16). 
Association 
Association assesses the relationship between groups of data, with higher values (either 
positive or negative) suggesting a closer association.  The choice of association statistic 
depends on the type of data available, and below we discuss four main options.   
Correlation coefficient 
The correlation coefficient (r) simply measures the linear relationship between two variables.  
The most commonly used methods are the Pearson correlation coefficient (for normally 
distributed variables) and the Spearman correlation coefficient (for skewed variables, using a 
ranking of the measurements).  An r value of 0 implies no correlation between the variables at 
all.  If there was a perfect correlation between two variables, the r value would equal 1 (or 
minus 1 if perfectly and inversely correlated).(56, 57)  In reality, no clinical variables could 
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attain this level of correlation, but an r value above 0.8 shows very strong correlation and 
between 0.6 and 0.8 strong correlation.(58)  It should be emphasized that correlation is not a 
good measure of agreement (discussed later), and will depend on the range of the 
measurement in question.(59)  Statistical tests can be used to determine if these correlations 
are likely due to chance; p-values in this context do not refer to the strength of correlation, but 
instead indicate whether the sample size is large enough to have confidence in the correlation 
coefficient.  Figure 16A, B and C demonstrates strong or very strong correlation between the 
two operators for LVEF, in contrast to Figure 16D where correlation is relatively weak.  
These methods are best used for paired parameters, such as intra-observer variability (the 
same operator taking an echo measure twice on the same subject and assessing the variation) 
or inter-observer variability (two operators taking the same measure on the same subject and 
assessing their variation).   
Linear regression 
Regression analysis describes how well one variable can be used to predict the value of 
another, or the strength of their relationship.  With enough data points, a “line of best fit” can 
be created based on the regression equation: VARIABLE 1 = constant value + coefficient * 
VARIABLE 2.  Given the two variables, the regression model provides the constant value and 
the coefficient by trying to minimise the difference between the true observed value and the 
value predicted from the model (also known as the residual).  This method requires data that 
is normally distributed (not skewed) and can be affected by outlying values.  It only measures 
to what extent two variables are linearly related (in many cases, the association can be more 
complex).(54, 60)  The value of linear regression is limited, but can be useful to visualise the 
association of paired data prior to other statistical tests.  As with any statistical measurement, 
there is some variability.  The 95% confidence interval gives us an idea of the bounds of 
uncertainty around the calculated estimate. 
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Figure 16A shows a very close relationship between the values from the two operators, with a 
regression coefficient of 0.90.  This means that for every 1.0% increase in LVEF ratings in the 
future by operator 1, we would expect that the corresponding average LVEF measurement of 
operator 2 would increase by 0.9%.  The confidence interval suggests that if repeated samples 
are taken, there is a 95% chance that the true regression coefficient will lie in the interval 
between 0.45 and 1.34.  Conversely, Figure 16D shows a very variable relationship, with a 
regression coefficient of 0.15 and a broad confidence interval (from -0.28 to 0.60).  This 
confidence interval includes the value of zero, meaning that there may be no association 
between the operators at all.   
   
Intraclass correlation coefficient (ICC) 
The ICC is often used to determine the reproducibility of numerical measurements organised 
into groups beyond a simple pairing, for example different operators measuring the same 
variable in different patients.  The formulae for ICC are complex, but essentially they pool 
data and compare within and across operators based on an analysis of variance.  The choice of 
analysis of variance model will depend on whether the patient is assessed by a random pool of 
operators (one-way random effects model) or each patient is assessed by the same operators 
(two-way random effects model).(61) This divides the total variability into actual difference 
and error, and the ICC is an average of all the correlations based on all the possible pairs of 
data.(62)  ICC can be used to assess variability both within a single operator (intra-observer), 
between different operators (inter-observer), or across different time points.  It possesses the 
advantage of being able to compare more than two groups of variables (more than two 
operators) and may be superior to Pearson and Spearman correlation coefficients as it 
considers systematic differences.  Pearson and Spearman correlation is a linearity index 
measuring to what extent one variable predicts the other variable, whereas ICC is an additivity 
36 | P a g e  
 
index measuring to what extent one variable cane be equated to another(63, 64)  The 
disadvantage of ICC is that it has limited value for comparing reproducibility of results in 
different populations.  As the ICC is a dimensionless value, the outcome will vary according 
to the dependent variables in the population sampled; data with a wide range of values will 
generate a high ICC value whereas data with a narrow range of values will result in a low 
ICC.(56, 61, 65)  ICC is unhelpful if the indices show poor agreement, as there is no 
indication as to the source of the error.  Whilst there is no strict ICC value which marks the 
cut-off for appropriate correlation(52, 57), values between 0.75 and 1.00 suggest excellent 
correlation, between 0.60 and 0.74 good correlation, and less than 0.4 suggests poor 
correlation.(66)  Interpretation of the ICC is demonstrated when comparing Figure 16A and 
B.  Whereas the standard correlation coefficient is similar (0.82 and 0.70), the ICC is 
considerably different (0.90 and 0.48) due to greater variance between the two operators in 
example B.  However both are statistically significant in contrast to Figure 16D. 
With the online calculator, this method can be more widely used as it allows for the 
assessment of reproducibility in more than two groups.  For example, it can be used to assess 
inter-observer variability across all members of the echocardiography department.    
 
Bias 
Bias indicates to what extent there is a true difference in two data points that has not resulted 
from chance.  These statistical tests can help to determine if there are significant differences 
in paired data, for example two recordings of left ventricular outflow tract diameter.  A small 
probability (often p<0.05, which is less than 1 in 20) suggests there is evidence for a 
difference in the two measurements (i.e. we reject the null hypothesis which is of no 
difference in values).(67)  It is important to note that the strength of statistical significance is 
37 | P a g e  
 
not related to the extent of bias, but rather whether there is confidence in the rejection of a 
chance effect.  Paired t-tests are used for normally-distributed data and the Wilcoxon test for 
skewed data.  In our example, the bias assessment is not significant for Figure 16 A and D, 
whereas there is a systematic bias in Figure 16B which is highly statistically-significant at 
p=0.004 and gives evidence for a true difference between the two operators.  If the data points 
are clustered equally around the line of equality, this suggests that there is no systematic bias.  
Of note, Figure 16C shows a proportional bias, and so a t-test is likely to be inaccurate in this 
case.  Proportional bias occurs when the difference between measurements is dependent on 
the value of the measurement taken.(68)  
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Figure 16:  Reproducibility assessment between two operators (taken from Bunting KV et al, 2019)(45) 
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Agreement 
Agreement defines the degree of consensus between different measurements, and different 
statistical comparisons are available according to whether the data are continuous or 
categorical. 
Bland and Altman plot 
The Bland and Altman plot is widely used to visualise the difference in two continuous 
measurements from the same individual, graphed according to the average value of the two 
measures.  In terms of echocardiography, this is highly valuable to assess measurements taken 
on the same patient by two different echocardiographers.  This method can also be used for 
assessing two measurements made by the same operator, or two measurements using different 
techniques or in different environments.   
Creating the Bland and Altman plot is straightforward and requires plotting: (1) the difference 
in the pair of measurements against their mean; (2) the bias (the mean of the differences); and 
(3) the upper and lower limits of agreement (bias ± 1.96 * standard deviation of difference).  
The limits of agreement indicate where the true mean (and future measurements) are likely to 
lie and interpretation will depend on the clinical magnitude of the limits (56, 57, 69)  If values 
are consistently outside the confidence limits, it may indicate a lack of agreement or a true 
biological difference that is not just due to sampling error.(50, 69, 70) Figure 17 shows the 
examples from Figure 16 constructed into Bland and Altman plots.  Figure 17A shows a 
small degree of bias (-0.67) and narrow limits of agreement (-8.3 to 6.9), whereas Figure 17B 
shows a systematically higher LVEF in operator 2 for each measurement.  In Figure 17C 
there is evidence of a proportional error, with increasing difference between measurements at 
both extremes of LVEF.  Figure 17D shows very wide limits of agreement (-35.6 to 36.8) 
that are likely to be highly clinically relevant. 
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Figure 17:  Bland and Altman plots for agreement between two tests or operators (taken from Bunting KV.et al 2019)(45)
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Kappa statistics 
The Cohen kappa is used to assess the agreement between categorical data (measurements 
with different levels, such as the severity of valve disease or categories of left ventricular 
dysfunction).  The result ranges from 0 (no agreement) to 1 (perfect agreement), with values 
<0.6 indicating weak agreement and >0.8 strong agreement.  Cohen’s kappa takes into 
account disagreement between the two operators and also agreement by chance.  A modified 
approach, the weighted kappa, can be used to determine the degree of disagreement using a 
predefined table of weights.(52)  Figure 18A demonstrates strong agreement between the two 
observers (k=0.89) as for each case they made a similar grading for the severity of mitral 
regurgitation in the same patients.  In contrast, Figure 18B shows almost no agreement 
between the two observers across the severity of mitral regurgitation, (k=0.05).  Figure 18C 
shows that there is reasonable agreement between the two observers for cases at the extreme 
ends of the categories (“none” and “severe”), but overall the agreement is weak due to a lack 
of consistent results in those graded with “mild” or “moderate” disease (k=0.27).  Figure 18D 
shows overall moderate agreement across all cases (k=0.65) despite there being 100% 
agreement for patients with no mitral regurgitation.  Note that Cohen’s kappa is not the only 
statistic which can be used to assess agreement for categorical data, and other measures are 
available to address some of its assumptions and shortcomings.  These include percent 
agreement, Scott's PI, Gwet's AC1 and Fleiss's generalized Kappa among others.(71)
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Figure 18.  Cohen kappa to assess the inter-observer variability of mitral regurgitation assessment by two observers (taken from Bunting 
KV, 2019)(45) 
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1.4.3  Repeatability 
Repeatability studies are used to ensure minimal variation exists when the measurement is 
retested on the same subject or group - the smaller the variation, the more reliable the results.  
When carrying out test-retest procedures, if the conditions in which the measurement are 
taken are kept exactly the same, then any variation detected can be attributed to the accuracy 
of the measurement.  The time interval between repetitions should be short enough to exclude 
any biological change, but long enough to prevent any interference from the preceding test.  
The appropriate time interval will vary depending on the situation,(57) however for 
echocardiography, repeating measurements on the same day with at least a few minutes 
interval would seem appropriate.  For calculations which require multiple echocardiographic 
measurements for calculation, such as aortic valve area, it is important to obtain 
measurements under similar haemodynamic conditions.  Therefore in the context of any 
cardiac arrhythmias, similar cardiac cycle lengths should be selected for measurement.(72)  
Variability of results within a single patient can be assessed statistically by the repeatability 
coefficient (using the standard deviation of differences), the coefficient of variation (discussed 
further below), or an ICC.  The advantage of the repeatability coefficient is that its value is in 
the same units as the measurement, allowing easier interpretation to guide decision 
making.(65)   
Figure 19 shows an example for peak aortic valve velocity in four patients undergoing ten 
consecutive measurements by the same operator for possible aortic stenosis.  Figure 19 A 
demonstrates a repeatability coefficient of 13cm/s, meaning that the variation in future 
measurements for aortic valve peak velocity are small (by that echocardiographer on that 
particular patient).  Figure 19B shows proportional bias for velocity to increase in value as 
the observer takes more measurements, whereas Figure 19C displays clinically-relevant 
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variation (perhaps due to a patient factor like atrial fibrillation).  In Figure 19D we see major 
issues in repeatability (for example, due to equipment problems).  
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Figure 19.  Repeatability and reliability assessment (taken from Bunting KV et al, 2019)(45)
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1.4.4 Reliability 
To be a reliable measurement, the magnitude of the difference between repeated 
measurements should be within a clinically-acceptable limit.  The test should be precise 
enough to give us confidence that we can differentiate between normal or abnormal in a given 
population, or between different patients or populations.  The minimal detectable change 
(MDC) can be used to assess reliability when measurements are repeated over a short time 
interval.(73)  It is expressed as a percentage and represents the minimal change required to be 
sure that the differences observed reflect a real change rather than measurement error (with 
higher percentages suggesting a less reliable method).(74)  The coefficient of variation is a 
common method to compare reliability between tests.  It is calculated as the ratio of standard 
deviation to mean, with a smaller percentage indicating a more precise method.(54, 75)  This 
would be useful in echocardiography for assessing the variation in parameters within a certain 
patient population; for example, different measures of left atrial dilatation in the same patients 
with hypertension, or reliability of averaging different numbers of cardiac cycles in those with 
atrial fibrillation  
Simple assessment of reliability can also be calculated, such as the absolute or percentage 
change in two measurements.  However, these tests have limited statistical power to 
determine differences, are unable to account for inherent variation, and the results are highly 
dependent on the value at baseline.(76, 77)  Whatever method is used, echocardiographers 
need to consider whether the change in measurement is due to the reliability of the test, or if a 
biological change in the patient could explain the difference (for example, worsening of valve 
disease over the time period). 
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Table 4:  Statistical methods useful in echocardiography.  
Statistical 
Method 





distributed data (Pearson) 
and skewed data (Spearman).  
Can only account for linear 
relationships. 
Sensitive to outlying values. 
n=17 with heart failure or dilated cardiomyopathy. Very strong 
inter-operator association between LVEF and GLS: Pearson’s 
correlation coefficient r= 0.89 for LVEF and r= 0.97 for GLS.(78)  
 
Linear regression The regression line can be 
used to predict the value of 
one variable from another. 
Analysis of the difference 
between the observed and 
predicted values (residuals). 
Can only be used if the data are 
normally distributed. 
Assumes the same degree of 
variance across the whole 
variable. 
Sensitive to outlying values. 
n=31 patients clinically indicated for cardiac CT. Strong 
correlations seen between different imaging modalities when 
measuring volumes and LVEF. For CT vs. CMR, linear regression 
r
2
=0.85; regression equation y=0.97x -1.3. For 3D TTE vs. CMR, 
r
2




Assess how closely variables 
are related to each other. 
Best for a large number of 
observations. 
Accounts for a change in the 
mean over time. 
Independent of the scale of 
measurement and size of 
error. 
As with other measures above, 
shows correlation not causation. 
No fixed clinical interpretation 
for level of agreement. 
Cannot be used to compare 
reliability of measurements 
between different studies. 
Effected by the size of the range 
of data. 
n=183 patients with hypertension, comparing two measurements 45 
days apart. Excellent correlation between first and second study: 
ICC 0.90 for indexed LV mass and 0.85 for septal diameter.(80) 
Bias 
T-test Provides a p-value for paired 
data sets. 
For normally distributed data 
only. 
 
n=88 patients prior to chemotherapy. Differences in intra and inter-
observer variability of LVEF and volumes were assessed using a t-
test, with p<0.001 considered statistically significant. Non-contrast 
3D echocardiography had significantly lower variability than 2D 
Simpson’s method, 2D triplane, or studies using contrast.(81)  





Can be used for skewed data. Uses ranking, therefore 
assessment of raw data needed to 
interpret the p-value. 
n=284 children with evaluation of MAPSE using B-mode and M-
mode. M-mode MAPSE had significantly lower variability than B-
mode lateral MAPSE for both inter (p <0.001) and intra (p<0.001) 




Demonstrates degree of 




Unable to detect proportional 
bias. 
Assumes normal distribution. 
Numerical data only. 
A clinical decision needs to be 
made as to whether there is good 
agreement based on the width of 
confidence limits. 
n=50 herceptin patients comparing two scans a minimum of 14 days 
apart by the same operator, showing better agreement for GLS than 
Simpson’s biplane LVEF. For GLS, bias -0.1 between the two time 
periods; limits of agreement -1.8 to 1.7.  For LVEF, bias 0.5; limits 
of agreement -11.2 to 12.1.(83)  
Cohen’s kappa Measures agreement and 
takes into account the 
amount of agreement which 
is there by chance. 
Dependent on the prevalence of a 
condition. 
Doesn’t account for degree of 
disagreement. 
n=146 enrolled in the Multi-Ethnic Study of Atherosclerosis trial 
with echocardiography and CMR on the same day. For classification 
of hypertrophy (normalized for body surface area), there was weak 
agreement between modalities, albeit statistically significant 
(Cohen’s kappa 0.37; p<0.001).(84)  
Weighted kappa Weights the degree of 
agreement and disagreement 
between data sets. 
Requires a predefined table of 
weights. 
n=80 with clinical aortic stenosis undergoing cardiac CT and TEE. 
Weak agreement between modalities for grading aortic valve 




Uses the units of the 
variable. 
Assumes normally distributed 
data. 
Unsuitable if the extent of 
agreement depends on the value 
of the measurement. 
n=67 pregnant women with measurement of transabdominal 
Doppler ultrasound of the ductus venosus at 10-14 weeks of 
gestation. Intra-observer repeatability was better for pulsatility index 









To assess reliability of 
measurements. 
Simple method to detect 
change. 
 
Suited more for short intervals 
between repeated measurements. 
n=56 patients referred for echocardiography before beginning 
Herceptin treatment. Lowest intra and inter-observer variability for 
assessing LVEF shown with 3D without contrast (MDC= 0.048% 




Optimal method if the 
standard deviation is 
proportional to the mean. 
Suboptimal method if there is a 
large difference between the 
highest and lowest possible 
values. 
Limited if the degree of error is 
not associated with the value of 
the measurement. 
Cannot be used if there are both 
positive and negative values. 
n=60 (n=20 with heart failure, n=20 with LVH and n=20 with 
normal structure). CV values comparing CMR vs. TTE show lower 
variation with CMR: for LVEF 2.4-7.3% using CMR vs. 8.6-19.4% 
with TTE; for LVM 2.8-4.8% vs. 11.6-15.7% respectively.(87) 
Percentage 
change   
Scale independent. 
Simple to interpret. 
Low statistical power compared 
to other methods. 
Does not correct for imbalance 
between groups. 
n=608 with Marfan’s syndrome assessing inter-observer assessment 
of aortic root dimensions. Measurements using a single beat were 
less reliable than taking the average of 3 beats (percentage error 
3.9% ± 3.0 vs. 3.6% ± 2.6%; p=0.0002).(88) 
Abbreviations: AoR= Aortic root; CT= Cardiac computed tomography; CMR= Cardiac magnetic resonance; GLS=Global longitudinal strain; 
HFpEF = Heart failure with preserved ejection fraction; LVEF= Left ventricular ejection fraction; MAPSE = Mitral annular plane systolic 
excursion; LVH= Left ventricular hypertrophy; LVM= Left ventricular mass; TEE= Transoesophageal echocardiogram.
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1.4.4  Discussion 
To ensure that the methods we use in echocardiography are useful for clinical decisions, 
reproducibility, repeatability and reliability should be assessed.  Unreliable estimates have the 
potential to impact on patient management and outcomes, as well as leading to a waste of time 
and resources.  The challenge for the echocardiographer is not only to identify a change in a 
biological parameter, but then to know whether that change is real or clinically significant.  
For example, is there a true change in cardiac structure and/or function that would require 
additional treatment, or is the change inconsistent or accounted for by changes to 
environment, operator or other factors?(89)  
In contrast to clinical practice, there is already awareness in imaging research of the need to 
quantify intra- and inter-operator reproducibility, thereby providing some idea of 
generalisability to routine care.  Design of research studies that formally evaluate 
reproducibility, repeatability or reliability should clearly delineate what variation is 
specifically being assessed, with clear use of terminology to avoid confusion.  To accurately 
measure reproducibility, these data should not be gathered as an accessory to other data, but 
with a distinct study plan.  Similar to other study outcomes, prior ascertainment of required 
sample size is vital so that a sufficient number of observations are obtained for quantification 
beyond the play of chance.  (90, 91)  Other important considerations are the method of subject 
sampling and whether this is consecutive, random or by convenience (with implications on 
statistical method and potential inclusion of bias), the degree of blinding possible, and 
appropriate reporting of all facets of the study.(92)   
 
To identify any significant variability in echocardiographic parameters within a department, 
intra- and inter-observer variability can be measured.(54, 93)  The possibility of measurement 
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error should be minimized as much as possible by ensuring that all equipment is accurately 
calibrated, adequate training is given to echocardiographers, and standardised guidelines are 
followed.(52)  In clinical practice, a patient being serially assessed will likely be scanned by 
different echocardiographers on each occasion, hence the importance of ensuring no 
significant variation between operators.  For numerical data (such as LVEF or Doppler 
values), the degree of agreement can be assessed by either the Bland and Altman plot or the 
ICC.  Pure measures of association (such as correlation and linear regression) provide limited 
information, but are essential components of understanding and visualising data to assess for 
outliers and points which influence the trend of the data.  When assessing a categorical result 
(such as quantifying the severity of mitral regurgitation), a kappa test can be used.(52, 54)    
Repeatability and reliability measurements are as important, and give confidence that the 
values obtained can be used to make clinical decisions.  Repeatability coefficients and the 
coefficient of variation are commonly used and can be calculated without difficulty.(52)  For 
assessment of within-subject variation, three repeat measurements are usually considered 
appropriate (52, 94), translated into echocardiography as the average of three Doppler indices.  
This is probably appropriate for sinus rhythm, however in the case of atrial fibrillation, the 
assessment of reproducibility is even more challenging because of the variation in ejection 
time and volume between consecutive heart beats.  Loss of atrial contraction and irregular 
ventricular contraction lead to beat-to-beat changes in pre-load, and hence variation in load-
dependent echocardiography variables.(95)  Although echocardiographers are recommended 
to average multiple consecutive beats in patients with atrial fibrillation, a systematic review 
by our group showed that isolating and averaging beats with similar cardiac cycle length (the 
index beat approach) could improve the overall reproducibility of measurement in atrial 
fibrillation.(37)  
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In my thesis, I use the techniques described in this section to explore the reproducibility, 
repeatability and reliability of the index beat method verses the averaging of consecutive 
beats.   
 
 
1.5   Difficulty of assessing systolic and diastolic function in patients with 
atrial fibrillation  
Determining accurate quantitative measurements of systolic and diastolic parameters is 
difficult in the setting of AF.  AF is characterised by an irregular ventricular response, so 
there is continual haemodynamic variation from beat to beat altering preload, strength of 
contraction and afterload.  This results in different systolic and diastolic parameters from 
beat-to-beat, due to a continual differing length of the R to R interval.  The length of the R to 
R interval will determine the ventricular pre-load and via the Frank-starling mechanism; with 
more pre-load there is greater stretch and so in turn a more forceful contraction and also a 
greater stroke volume.  This was investigated by Gosselink et al. who sought to determine 
how the length of the preceding R to R intervals will affect the end-diastolic volume and 
ejection fraction.  Ejection fraction was influenced by not only the preceding cycle length but 
also the pre-preceding cycle length.  Ejection fraction is enhanced when there is a short cycle 
length followed by a longer cycle length, as a result of post-extrasystolic potentiation.(96, 97)  
Patients with AF are also prone to getting AF with an uncontrolled fast ventricular response, 
which makes the study more difficult.  At faster heart rates there is increased beat-to-beat 
variability,(98) therefore more difficulty in obtaining reproducible results.  Also due to 
reduced filling, as a result of shorter R to R intervals there is a reduced stroke volume.  This 
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results in a general underestimation of LV function, despite normal intrinsic contractility.(98, 
99) 
1.5.1  Validity of systolic and diastolic parameters in patients with atrial fibrillation 
A recent systematic review was carried out by Kotecha et al. to assess the validity and 
reproducibility of echocardiographic systolic and diastolic parameters for patients in AF(37). 
There was a lot more information on the validity of diastolic function in AF patients.  Several 
studies have compared invasive pulmonary capillary wedge pressure (PWCP) with diastolic 
indices derived from echocardiography.  E/e’ was shown to correlate well with PCWP with r 
values ranging from 0.46 to 0.79.(100-104) The correlations derived from these studies are 
similar to studies performed in patients with sinus rhythm, with correlations ranging from 
r=0.46 to 0.86.(105-107)  IVRT has also been found to correlate strongly with PCWP with 
correlations ranging from r= -0.70 to -0.95.(44, 108-110).  Mitral Valve E wave deceleration 
time has been correlated with PCWP with r values ranging from no correlation found to 
strong correlations of -0.70.(44, 100, 101, 108, 110-112).  E/vp was found to strongly 
correlate with PCWP with r values ranging from 0.63 to 0.65.(44, 113)  The pulmonary 
venous flow diastolic wave deceleration time had a very strong correlation with PCWP with r 
values of -0.91 and -0.80(111, 112) and the pulmonary venous S/D had a moderate correlation 
of r= 0.5.(106) There have also been studies comparing indices of diastolic function with 
other clinical parameters.  An elevated E/e’ has been shown to correlate with several factors, 
which predict a worse patient prognosis.(100)  Okura et al carried out a retro-spective study 
analysing the mortality of patients with a septal E/e’ >15 and <15.  The patient group with an 
E/e’ >15 had a higher all cause and cardiovascular mortality rate, suggesting E/e’ is 
proportional to risk of mortality.(107) Oyama et al. assessed the relationship between E/Vp 
and levels of Brain Naturetic Peptide (BNP) using linear regression analysis.  It was found 
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that the E/Vp correlated with levels of BNP; a higher E/Vp (cm/s) predicts higher levels of 
BNP.(108) 
The number of studies assessing the validity of echocardiographic systolic parameters were 
far fewer.  Surprisingly, there have been no studies comparing echocardiographic systolic 
parameters with other modalities, for example CMR or nuclear imaging.  However there have 
been studies comparing different echocardiographic measurements for patients in AF.  For 
example Thavendiranathan et al. assessed the relationship between ventricular volumes and 
LVEF measured by 2-D Simpson’s biplane and 3-D volume imaging in patients with atrial 
fibrillation.  The two modalities correlated highly with each other when both consecutive 
beats were averaged and on a single-beat basis(114).  There have also been comparisons made 
with other clinical outcomes to determine the clinical utility of echocardiographic systolic 
measurements(37).  Su H.M. et al compared global left ventricular strain with cardiovascular 
events.  It was found that reduced longitudinal strain (>-12.5%) was independently associated 
with an increased risk of cardiovascular events(115).  
However there is still a lack of clarity as to whether systolic measurements for patients in AF 
are valid.  An individual patient data-meta analysis has been conducted by the Beta Blockers 
in Heart Failure Collaborative Group, to determine the effect of beta-blockers on patient 
prognosis according to the baseline LVEF.(116)  As demonstrated in Table 5, patients in 
sinus rhythm have a worse outcome as baseline LVEF falls, with higher risk of all-cause 
mortality (HR 1.24 per 5% lower LVEF, 95% C.I. 1.21-1.28) and cardiovascular death (HR 
1.20 per 5% lower LVEF, 95% C.I.1.22-1.30 ).  In patients with atrial fibrillation on their 
ECG at randomisation, the association of LVEF with mortality was still significant, but much 
reduced compared to those in sinus rhythm HR 1.09, C.I. 1.03-1.15 and HR 1.10, C.I. 1.05-
1.18 respectively.(117)  
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Table 5.  Baseline LVEF and hazard ratios for all-cause and cardiovascular mortality in 
patients with sinus rhythm and atrial fibrillation (taken from Cleland JGF., Bunting 
KV., et al, 2018 (117)) 
 All-cause mortality Cardiovascular death  
 Number (events / 
patients 
HR, 95% CI; p-
value 
Number (events / 
patients 
HR, 95% CI; p-
value 
Sinus rhythm; 
per 5% lower 
LVEF at 
baseline 
2,160 / 14,261 
1.24, 1.21-1.28; 
p<0.0001 





per 5% lower 
LVEF at 
baseline 
609 / 3,034 
1.09, 1.03-1.15; 
p=0.002 
498 / 3,034 
1.10, 1.05-1.18; 
p<0.0001 
This data suggests that the systolic parameter LVEF is not as strongly associated with patient 
outcomes in AF, when compared to patients in sinus rhythm.  This calls into question whether 
this is due to a biological property of AF, or whether this can be explained by LVEF lacking 
reproducibility and validity in the context of AF.  Therefore studies need to be carried out to 
compare systolic measurements derived from echocardiography with other modalities 
measuring the same parameter in AF.  We should not assume that echocardiographic 
measures designed for sinus rhythm will apply equally to those with irregular cardiac cycles.  
Parameter values which defined “normal” for patients in sinus rhythm also need to be 
validated in patients in AF.  The reference values for normal LVEF have typically been based 
on population-based studies which have excluded patients with AF.(117)  
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1.5.2  Other Imaging Modalities and Atrial Fibrillation 
Magnetic Resonance Imaging (MRI) 
MRI is considered the gold-standard method for assessing left ventricular function in sinus 
rhythm.(118)  Cardiac MRI delivers an unrestricted field of view with good temporal and 
spatial resolution without exposing the patient to any ionizing radiation.  The standard method 
of measuring volumes and ejection fraction by MRI is to acquire a series of steady-state free 
precession cine images (SSFP) from the base to the apex of the heart.  These are contiguous 
slices with minimal or no gap, that are then analysed by drawing the endocardial surface to 
produce a volume (Figure 20).  Cine images are acquired over 10-15 phases, with data from 
each phase filling k space.  In the context of AF, the irregularity of cycle length both varies 
the extent of filling from a given cardiac cycle, and also leads to ‘mis-matching’ of data 
across the stack, so that the diastolic and systolic images may be taken or drawn at different 
times.(119-121)  
Figure 20.  SSFP short axis slice of the left ventricle. Image quality of a patient in sinus 
rhythm (left) verses poorer quality for patient in AF (right)  
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Computed Tomography (CT) 
CT has superior spatial resolution and can rapidly acquire images, however it exposes the 
patient to ionising radiation.  It uses retro-spective or prospective ECG gating to reconstruct 
images of the ventricle through all phases of the cardiac cycle.  Similarly to CMR the 
endocardial boarders of the LV is traced to quantify LV size and function.  In AF image 
quality of the endocardial and epicardial definition can be compromised due to misregistration 
artefact, resulting in difficulty in accurately measuring LV volumes and ejection 
fraction.(118)   
Radionuclide Angiography 
Also referred to as the multi-gated acquisition (MUGA) scan uses the radioactive compound 
technetium 99m pertechnetate to label red blood cells.  The change in radioactivity between 
end-diastole and end-systole is measured to determine the LVEF; the greater change in 
radioactivity, the greater LVEF, as more red blood cells are leaving the heart.  Again the 
acquisition of these images is gated by the patient’s ECG, as it averages the acquisitions over 
time assuming a regular R to R interval; therefore if it measured on short R to R intervals it 
may underestimate the LVEF over time and vice versa for a longer R to R interval.(122)  
 
This chapter has outlined the need for valid and reproducible echocardiographic parameters to 
assess systolic and diastolic function in AF patients, to guide clinical decisions in AF patients.  
Obtaining reproducible measurements using echocardiography is challenging and there is 
uncertainty of what method should be used to achieve reproducible and valid measurements.  
The following results chapters explore the validity and reproducibility of systolic and diastolic 
measurements.   
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Specifically, in the following results chapter I investigate the validity and reproducibility of 
systolic parameters across all cardiovascular imaging modalities.  Then in chapter 4 I answer 
a key clinical question about what is the most reproducible method of measuring systolic and 
diastolic parameters.  This data is from a randomised controlled clinical trial with blinded 
echocardiography in all-comers with permanent AF, to demonstrate the real-world value of 
the index beat method verses conventional averaging of consecutive beats.  This is followed 
by chapter 5 in which I compare the validity of the index beat verses averaging of 
consecutive beats using NTproBNP and patient-reported quality of life. 
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Aims and Rationale 
Currently when performing an echocardiogram in patients with AF, there is a lack of clarity 
of how to perform a study to accurately assess ventricular systolic and diastolic function 
which is both reproducible and clinically valid.  
The systematic review by Kotecha et al has revealed a lack of validity studies for the 
assessment of systolic measurements using echocardiography in patients in AF at the time of 
imaging.(37)  To date there has not been a systematic review assessing the validity of systolic 
measurements using other cardiac imaging modalities.  Therefore the first aim is to perform a 
systematic review of all cardiac imaging studies assessing the validity and reproducibility of 
systolic measurements derived from patients in AF at the time of imaging.  
Current guidelines on how many beats to measure to achieve a reproducible result are derived 
from minimal evidence.  The introduction of the index beat method into routine clinical 
practice could provide reproducible and time-efficient results.  Therefore the second aim is to 
determine the most reproducible method of obtaining systolic and diastolic parameters by 
comparing the intra and inter-operator variability of averaging up to 10 consecutive beats with 
the index beat method.   
 
The validity of the index beat has not been compared with measurements made by 
conventional averaging of consecutive beats.  There are also very few or no studies in which 
systolic and diastolic parameters have been compared against the clinical biomarkers N-
terminal pro-brain naturetic peptide (NTproBNP) and patient symptoms.  The third aim is to 
compare the systolic parameters of LVEF and GLS and the diastolic indice E/e’ with NT-pro-
BNP and to examine patient reported quality of life, the physical component score (PCS) of 
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the SF-36 tool and the atrial fibrillation effect on quality of life test (AFEQT) score derived 
from patient reported quality of life questionnaires will be used.   
Hypothesis 1:  On systematic review, there have been sufficient studies for cardiac imaging 
of all modalities for measurements of systolic function to be valid and reproducible in patients 
in AF at the time of imaging.  
Hypothesis 2:  Measuring on an index beat is a more reproducible method than averaging 
several consecutive beats when taking parameters of systolic and diastolic function.  
Hypothesis 3:  Echocardiographic parameters of systolic and diastolic function in patients 
with AF correlate with NTproBNP and the physical component score and atrial fibrillation 
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Chapter 2:  Systematic review of imaging methods to 
assess systolic function in AF patients 
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2.1  Introduction 
As well as impacting on quality of life and increasing the risk of stroke, hospital admission, 
cognitive dysfunction and mortality, AF is strongly associated with the development and 
progression of heart failure.(123)  Reduction in left-ventricular ejection fraction (LVEF) is a 
common finding in AF patients, particularly in those with persistent or permanent AF.(124)  
To enable clinicians to provide appropriate therapy and improve prognosis, it is essential that 
systolic function can be accurately assessed.  In clinical practice, echocardiography, 
cardiovascular magnetic resonance imaging (CMR), computed tomography (CT), invasive 
angiography and nuclear scintigraphy are all used to assess systolic function, with each 
technique possessing advantages and limitations.  As discussed in chapter 1, cardiac imaging 
in patients with AF is challenging due to the variation in ejection time, force of contraction 
and filling period.(124)  There is varied susceptibility of each imaging modality to R-R 
interval irregularity and/or elevated heart rate, with validity and reproducibility reduced by 
difficulties in acquiring diagnostic-quality images or the interpretation or results.  The 
assumption that parameters used in sinus rhythm to quantify systolic dysfunction have the 
same validity in AF may not be correct.(37) As outlined in chapter 1 in heart failure patients 
with AF, conventional LVEF measurements are significantly associated with all-cause 
mortality, but with a substantially reduced relationship compared to sinus rhythm.(117)  
A systematic review of all studies assessing the validity and/or reproducibility of systolic 
function measurements, in patients in AF at the time of cardiac imaging was performed.  The 
systematic review synthesised conclusions from all evidence available, minimising bias and at 
the same time reliably identifying areas for further investigation.  The knowledge gaps 
identified will guide the aim of future results chapters.  The aim of this systematic review was 
to determine if different imaging modalities of systolic assessment have clinical value in 
patients with AF, to assist in the diagnosis of heart failure and guide optimal management for 
63 | P a g e  
 
patients.  To assess this, the evidence for the reproducibility and validity of systolic 
measurements made in patients in AF, was examined across cardiac imaging modalities.
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2.2  Methods 
The systematic review of imaging modalities in patients with AF was performed 
prospectively and published on PROSPERO 
(https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=91674) and reported 
according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines.   
2.2.1  Eligibility criteria & search strategy 
All studies reporting validity or reproducibility data on left ventricular (LV) systolic function 
in AF patients were examined.  There was no restriction on study design, however only 
human populations with AF at the time of imaging were included.  Exclusion criteria included 
case reports, studies that were only published in abstract form, and those in a language other 
than English.  All editorials, commentaries and informal reviews of other literature were also 
excluded.  An online search of PubMed, Embase and MEDLINE through the OVID library 
(inception to February 2019) was performed, including the broad terms “atrial fibrillation”, 
“angiography”, “computed tomography”, “cardiac magnetic resonance”, “nuclear imaging” 
and “echocardiography” using MESH headings and title/abstract searches, including syntax 
variations (see Table 6).  A manual screening of relevant reviews and reference lists was also 
conducted.  
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Table 6: Example of search criteria  
Search Operators: 


















































Example of search strategy for Cardiac Magnetic Resonance: 
 ("atrial fibrillation"[MeSH Terms] OR ("atrial"[All Fields] AND "fibrillation"[All Fields]) OR "atrial fibrillation"[All Fields]) AND ((("heart"[MeSH Terms] OR "heart"[All Fields] OR "cardiac"[All Fields]) AND 
("magnetic resonance imaging"[MeSH Terms] OR ("magnetic"[All Fields] AND "resonance"[All Fields] AND "imaging"[All Fields]) OR "magnetic resonance imaging"[All Fields] OR "mri"[All Fields])) OR ("Calif 
Manage Rev"[Journal] OR "cmr"[All Fields]) OR ("magnetic resonance imaging"[MeSH Terms] OR ("magnetic"[All Fields] AND "resonance"[All Fields] AND "imaging"[All Fields]) OR "magnetic resonance 
imaging"[All Fields] OR "mri"[All Fields]) OR (("heart"[MeSH Terms] OR "heart"[All Fields] OR "cardiac"[All Fields]) AND ("magnetic resonance imaging"[MeSH Terms] OR ("magnetic"[All Fields] AND 
"resonance"[All Fields] AND "imaging"[All Fields]) OR "magnetic resonance imaging"[All Fields])) OR (("heart"[MeSH Terms] OR "heart"[All Fields] OR "cardiac"[All Fields]) AND ("magnetic resonance 
spectroscopy"[MeSH Terms] OR ("magnetic"[All Fields] AND "resonance"[All Fields] AND "spectroscopy"[All Fields]) OR "magnetic resonance spectroscopy"[All Fields] OR ("magnetic"[All Fields] AND 
"resonance"[All Fields]) OR "magnetic resonance"[All Fields])) 
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2.2.2 Outcomes 
The primary outcomes of interest were the validity and reproducibility of LV systolic 
assessment in AF patients using different imaging modalities.  For echocardiography, these 
included LVEF (measured either by Simpson’s biplane method or three-dimensional [3D] 
volume assessment), fractional shortening, stroke volume derived from left ventricular 
outflow tract (LVOT) pulsed wave Doppler, tissue Doppler velocities, pre-ejection period 
derived myocardial performance index (MPI), peak longitudinal systolic strain (PLSS) and 
global longitudinal strain (GLS).  For CMR, this included volume-derived LVEF, GLS using 
either feature tracking or myocardial tagging, and stroke volume derived from flow mapping 
in the aortic root.  For nuclear medicine, this included measurements of LVEF derived from: 
radionuclide equilibrium angiography, gated single photon positron emission tomography 
(SPECT) and gated positron emission tomography (PET).  Data was extracted systematically 
using a standardised extraction form to ascertain: (1) validity against other imaging modalities 
(external validation); (2) association with clinical or surrogate endpoints; (3) comparison 
within an imaging modality (internal validity); and (4) measurements of intra- and inter-
operator reproducibility. 
 
2.2.3  Data collection and quality assessment 
Two investigators independently assessed inclusion at full text level and extracted relevant 
variables (KB and KO).  Disagreements were resolved by consensus review and additional 
independent adjudication (DK).  Variables of interest for validity were strength of association 
using correlation (r) and intra-class correlation coefficient (ICC), and agreement using Bland 
and Altman analysis.  For association with clinical parameters, hazard ratios, chi-squared 
tests, area under the curve and Kaplan-Meier analysis were also included.  Variables of 
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interest for reproducibility were agreement using Bland and Altman analysis and mean 
difference, association measured using correlation coefficients, linear regression (r
2
) and ICC, 
and variability measured using percentage change, coefficient of variation and repeatability 
coefficient. 
Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 
(QUADAS-2).(125) Risk of bias was similarly assessed by two investigators independently 
with adjudication, covering bias and applicability on the level of patient selection, the index 
test, reference standard and study flow and timing (Figure 22).  
 
2.2.4  Data synthesis and statistical analysis 
Baseline demographics were pooled from all studies providing suitable data (including 
variance where applicable), and are summarized as a weighted mean according to sample size.  
Outcomes were synthesized qualitatively.  Meta-analysis of comparative data between AF and 
sinus rhythm was not possible due to the limited studies available and a lack of published data 
on the variance of outcome measures. 
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2.3  Results 
From the search strategy, a total of 7382 papers were identified of which 7058 were excluded 
mainly due to a lack of relevance to the assessment of systolic function in patients with AF.  
After the full text was screened, a further 310 studies were excluded leaving a total of 24 
studies which were then sorted into each imaging modality (Figure 21).  Overall risk of bias 
is presented in Figure 22, highlighting concern about patient selection bias.  Results of 
cardiac imaging in AF are categorised according to external validity (Table 7), internal 
validity (Table 8) association with clinical or surrogate endpoints (Table 9), and 
reproducibility (Table 10).  In the text below, results are summarised according to imaging 
modality (see Table 11). 
 
2.3.1 Cardiac Magnetic Resonance Imaging  
Three CMR studies were included which either assessed stroke volume or LVEF derived 
from breath-hold cines with steady-state free precession imaging (SSFP) of the LV to 
calculate end-diastole and end-systole short-axis volumes.  I identified no studies assessing 
the reproducibility or validity of phase mapping or strain imaging in patients with AF at the 
time of imaging.  The method of patient selection and flow and timing of data obtained was 
unclear for these studies and so the risk of bias was unclear.  
One study externally validated CMR parameters of LVEF and stroke volume against invasive 
catheter angiography in 13 AF patients; three of the patients were excluded due to frequent 
ventricular ectopy, frequent need to void and data corruption.  CMR-derived LVEF was 
shown to correlate strongly with left ventriculography (r=0.85, with a mean difference of 0, 
SD 0.08; p= 0.37).  CMR-derived stroke volume correlated strongly with both left 
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ventriculography (r=0.90, with a mean difference of 4 ml SD 13 ml; p= 0.24) and 
thermodilution techniques (r= 0.95, with a mean difference of -5 ml SD 10; p= 0.06).(126)   
Figure 21.  Systematic review flowchart. Flow chart to show the number of papers included 
and excluded at each stage of the screening process. 
 
Abbreviations: AF= atrial fibrillation; CT= computed tomography; MRI= magnetic resonance 
imaging 
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One study internally validated LVEF by comparing compressed sensing and parallel imaging 
with conventional SSFP in 20 patients with AF.  A strong correlation was observed between 
LVEF measured by this method and conventional SSFP (ICC=0.97, 95% CI 0.93-0.99, 
p=0.14) with a small mean difference between methods (-4%± 11%), although heart rate at 
the time of LV assessment was not stated.(127)  
Two studies examined the reproducibility of systolic parameters using CMR.  LVEF inter-
observer reproducibility was higher using CMR when compared to angiography; for CMR the 
standard error was 8% versus 14% with left ventriculography.  This was also shown for stroke 
volume; a standard error of 9mL for CMR versus 24mL with left ventriculography.(126)  
Heart rate was not stated.  The reproducibility of LVEF using SSFP was examined in 10 
patients with permanent AF and a mean heart rate of 82 bpm (range from 57-109), in which 
intra-observer reproducibility was good with r
2
= 0.97, repeatability coefficient was 3.8 and a 
Bland and Altman bias of -1.9 % 2SD 4.2.  Inter-study reproducibility was also good with r
2
= 
0.99, repeatability coefficient 1.3 and Bland and Altman bias of 0.5 % 2SD 3.(128)  
 
2.3.2  Nuclear Imaging  
No studies were identified in which systolic parameters were externally validated or 
correlated with other clinical parameters in patients with AF.  Three nuclear imaging studies 
were included that addressed reproducibility.  The method of patient selection and degree of 
blinding to the index and reference test was not stated clearly in these studies, making the risk 
of bias unclear.  
Gating errors are a well-known limitation of SPECT imaging in patients with AF, and in one 
study of 35 AF patients with suspected coronary artery disease, gating errors from AF were 
simulated and compared with a control group of 35 patients in AF.  AF gating errors 
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significantly affected the measurement of wall thickening (60% ± 299%) and myocardial 
perfusion (76% ± 352%).  This study also showed that gated SPECT had a strong correlation 
with equilibrium radionuclide angiocardiography (r= 0.89, p=<0.0001), however LVEF 
measured by SPECT was consistently lower by 3-4%.(129) 
In gated pool studies, cycle length windowing is used as a way to overcome the altering 
cardiac cycle length in patients with AF.  In a study of 20 AF patients, LVEF values from the 
windowed studies were slightly higher compared to non-windowed, but this was not 
statistically significant (p=0.16) and the correlation between the two methods was very strong 
(r= 0.97).(130) The reproducibility of measuring volumes and LVEF was assessed in 115 
patients with AF using myocardial perfusion gated SPECT, with low inter and intra observer 
variability and low variation between two consecutively taken studies (inter-assay) using two 
different quantitative parameters.(131)  
 
2.3.3  Echocardiography 
Eighteen echocardiography studies were included, of which 15 examined validity either 
against external modalities, clinical parameters or internal measures, and 8 studies assessed 
reproducibility.  There were no studies identified which directly compared measurements of 
systolic function with another imaging modality.  The method of patient selection for most 
echocardiography studies incurred a high risk of bias, due to the exclusion of patients with 
inadequate echocardiographic windows. 
Two studies externally validated echocardiographic systolic parameters against dP/dt derived 
from invasive angiography, with GLS found to have a strong correlation with averaged dP/dt 
(r=0.94; p<0.001).(132) Tissue Doppler s’ was shown to correlate strongly with dP/dt (r=0.88, 
p<0.0001) which was accentuated in AF patients with heart failure (r=0.90, p<0.0001).(133)  
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Nine studies compared echocardiographic indices of systolic function with clinical parameters 
or surrogate biomarkers.  In 1293 AF patients who had suffered a myocardial infarction, 
lower LVEF (estimated using an echocardiographic wall motion score) was associated with 
an increase in the risk of 30-day mortality (8% for patients with LVEF >50%, 10% for LVEF 
36-50%, 24% for LVEF 26-35% and 40% for LVEF <25%).  However, lower LVEF (<0.25) 
did not affect long-term mortality in AF patients.(134)   Reduced GLS was associated with 
adverse CV events in two studies of 196 and 204 AF patients, (135, 136) with similar results 
seen with global circumferential strain and when GLS was corrected for R to R interval.(137) 
Myocardial performance index was associated with cardiovascular events in 196 patients with 
a hazard ratio of 1.10 per 0.1 unit increase (95% CI 1.03-1.18; p= 0.004).(138)  In 104 AF 
patients, LVEF derived from Simpson’s biplane correlated weakly with B-type natriuretic 
peptide (r= -0.25; p= 0.07).(139)  In 67 patients with AF, LVEF derived from the Teichholz 
formula was shown to weakly correlate with atrial natriuretic peptide (r=-0.42, p=0.01).(140)  
Four studies have internally validated systolic parameters with other echocardiographic 
parameters (Table 8), showing  strong correlation of real-time 3D full-volume and Simpson’s 
biplane LVEF in 24 patients on both a beat-to-beat level (r=0.92; p<0.001) and patient level 
(r=0.91; p<0.001)(141), and reasonable correlation of M-mode mitral annulus motion with 
LVEF (20 patients) (142) and LVOT stroke volume with fractional shortening (18 
patients).(99) Myocardial performance index derived from pre-ejection period was found to 
correlate moderately with LVEF (r= -0.586, p<0.001) and TDI s’ (r=0.601, p=<0.001).(143) 
 There have been no echocardiographic studies comparing the reproducibility of systolic 
parameters directly with other imaging modalities.  A variety of small studies have 
demonstrated low levels of intra and inter-observer variability for LVEF, GLS and myocardial 
performance index when reassessing systolic function in AF patients using echocardiography 
(Table 10).  3D measurement of LVEF was shown to be more reproducible when calculated 
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using a single-beat analysis compared to 4-beat averaging (intra-observer variability 4.8% 
versus 8.3%; inter-observer 5.6% versus 17.9%).(144) An index beat approach, whereby 
measurement is made following  two R to R intervals of similar length results in lower intra 
and inter observer variability compared to conventional averaging of consecutive beats (132, 
135, 145) 
 
2.3.4  Computed Tomography  
There were no studies assessing validity, association with clinical endpoints or reproducibility 
of systolic function in patients with AF. 
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Figure 22.  Risk of bias overall studies according to QUADAS-2 assessment. Bar chart (left panel) to display the proportion of studies with low, high 
or unclear bias according to the categories work flow, reference test, index test and patient selection. Bar chart (right panel) to display the proportion of studies 
with low, high or unclear concerns of applicability according to the categories reference test, index test and patient selection. 
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Table 7.  External validity of systolic parameters against another modality in AF 
Abbreviations: AF= atrial fibrillation; CMR= cardiovascular magnetic resonance imaging; GLS= global longitudinal strain; HR= hazard ratio; 
LS= longitudinal strain; LV= left ventricular; LVEF= left ventricular ejection fraction; MBP= mean blood pressure; SD= standard deviation; 
SV= stroke volume; TDI= Tissue Doppler imaging; TTE= Transthoracic Echocardiography; 
Parameter Study Number of patients Mean heart rate 
± SD (bpm) 
Blood pressure 






LVEF (%) Hundley 
(1996)(126) 
10 patients with AF 
(3 were excluded) & 
13 patients in sinus 
rhythm 





In AF patients 
LVEFMRI  vs LVEFcath 
r= 0.85;  mean 
difference= 0% SD 
0.08%, p= 0.37 
Kusunose 
(2012)(132) 
25 AF patients with 
dyspnoea, angina or 
LV asynergy 
74 (± 15) 131/ 76 
(±16/12) 
TTE Invasive LV 
peak pressure 
(dP/dt) 







10 patients with AF 
(3 were excluded)  & 
13 patients in sinus 
rhythm 





SVMRI vs SVThermo  r= 
0.9; mean difference= 
-5ml SD 10ml, p=0.06 
; SVMRI vs   SVcath , r = 
0.95, mean 
difference= 4 ml SD 
13ml, p= 0.24 
GLS (%) Kusunose 
(2012)(132)  
25 AF patients with 
dyspnoea, angina or 
LV asynergy 
74 (± 15) 131/ 76 
(±16/12) 
TTE LV peak 
pressure 
(dP/dt) 
Index beat LSTTE with 
peak +dP/dt (r = 0.73, 







39 AF patients with 
no significant valve 
disease or regional 
LV wall synergy 
Lone AF 78 (±18) 
AF with a dilated 
LV 80 (±15) 
AF only MBP  
92 (±8) Dilated 
MBP 90 (±11) 
TTE LV peak 
pressure 
(dP/dt) 
S’TTE vs dP/dt, r=0.88, 
p= <0.0001.   
Kusunose 
(2012)(132) 
25 AF patients with 
dyspnoea, angina or 
LV asynergy 
74 (± 15) 131/ 76 
(±16/12) 
TTE LV peak 
pressure 
(dP/dt) 
S’TTE vs dP/dt r=0.56, 
p=0.03 
76 | P a g e  
 
Table 8: Internal validity of systolic parameters in AF 
Parameter Study Number of patients  Mean heart 
rate ± SD 
(bpm)  
Blood 












20 patients with 
persistent AF 





ICC comparing both 
sequences, for LVEF 
ICC= 0.90, 95% C.I.= 
0.93 to 0.99) and SV 
ICC= 0.80, 95%  C.I.= 
0.75 to 0.96  
Nichols K 
(1999)(129) 
36 AF patients with 
suspected coronary 
artery disease 
[not stated] [not stated] ERNA 
nuclear 
imaging 
SPECT r= 0.89, p<0.0001. 
Wallis, 
(1991)(130)  






Windowed LVEF slightly 
higher than non-
windowed LVEF. r= 
0.97, standard error of the 
estimate= 3.5 
Thavendiranathan
, (2012) (141) 
24 AF patients. 
Excluded for poor 
echocardiographic 
image quality 




r =0.92 at a beat-to-beat 
level; at patient level r= 
0.91 (p<0.001). Bland 
and Altman analysis bias 
(± limits of agreement)= -








20 AF & 20 sinus 
rhythm patients. 
Excluding poor image 
quality  
83 ±15 [not stated] TTE LVEF 
Simpson’s 
Biplane method 
LVEF vs MAM, AF r= 
0.66, p= <0.01 vs SR 
r=0.84,p<0.001. 
Conversion factor from 
LVEF to MAM, AF=7,.2 
(±1.8) vs SR= 5.1 (±0.9), 
p=0.001.  
LVOT peak Ko, (2005)(147)  18 AF patients. Normal LV Normal 119.4/ TTE Fractional Fractional shortening vs 
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Abbreviations: 2D= two dimensional; 3D-RT-VTTE= real-time full-volume 3-dimensional transthoracic echocardiography; AF= atrial 
fibrillation; CMR= cardiovascular magnetic resonance imaging; C.I.= confidence interval; ERNA= Equilibrium Radionuclide 
Angiocardiography; ICC= intra-class correlation coefficient; LVEF= left ventricular ejection fraction; LVOT= left ventricular outflow tract; 
MAM= mitral annulus motion; MBP= mean blood pressure; MRI= magnetic resonance imaging; RR1= preceding R to R interval; RR2= pre-
preceding R to R interval; Sa= peak systolic mitral annular velocity; SPARSE-SENSE  =compressed sensing and parallel imaging ; SPECT= 
single-photon emission computed tomography; SR= sinus rhythm; SV= stroke volume; SV= stroke volume; TTE= Transthoracic 




Excluded those with R-












shortening the LVOT peak velocity 
(where RR1= 1 second) 
r= -0.6, p= 0.008 and vs 
LVOT peak velocity 





Su (2011) (143) 54 patients with 
permanent AF 




LVEF and Sa 
Vs LVEF: r= -0.586, 
p<0.001 & β= -0.26 
p=0.024. Vs Sa r=0.601, 
p=<0.001, β=-0.141, 
p=0.336.  
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Table 9.  Clinical associations of systolic parameters in AF 
Parameter Study Number of 
patients  
Mean heart 
rate ± SD 
(bpm) 







LVEF (%) Kim, 
(2007)(148)  
104 with chronic 
AF 
[not stated] 127.4/78.5 
(±13.8/8.9) 






196 AF patients. 
Exclusion: severe 
valve disease and 
inadequate echo 
windows. 
83 (±20) 132/76.5 (±21/12) TTE CV events (death, 
non-fatal stroke & 
hospitalisation for 
heart failure) 
Univariate analysis of HR= 0.97 







67 patients with 
persistent AF. 
Excluded if: 







the preceding 3 
months, anaemia, 








ANP  Univariate analysis r=-0.42, 
p=0.01 





6232 patients who 
had suffered a 
myocardial 
infarction. 1293 
with AF and 4953 
without AF   
[not stated] [not stated] TTE LV 
wall motion 
index 
Mortality  In patients with LVEF <0.25 
presence of AF increased risk of 
in hospital mortality, OR= 1.8 
(1.1-.3.2, p <0.05) but no effect 
on long term mortality. In 
patients with LVEF 0.25 to 
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Parameter Study Number of 
patients  
Mean heart 
rate ± SD 
(bpm) 







<=0.35 the presence of AF 
increased risk of in-hospital 
mortality, OR = 1.7 (1.3-2.3, 
p<0.001) and 30 day mortality 












Reduced GLS increased risk of 
adverse outcome. Unadjusted 
GLS per 1% increase= HR 1.14 
(1.07-1.21, p=<0.001); 
GLS/√(RR) per 1%/sec 




151 AF patients 
with HFrEF 
80.3 ± 20.4 MAP 93.4 (±14.2) TTE All-cause 
mortality 
R-R corrected GLS (GLSc) and 
GCS (GCSc) predicts all-cause 
mortality. GLSc: HR= 1.19 (CI 
1.06-1.33) per 1% decrease, p= 
0.003 and GCSc: HR=1.17 (C.I. 




196 AF patients. 
Exclusion: severe 
valve disease and 
inadequate echo 
windows. 
83 (±20) 132/76.5 (±21/12) TTE CV events (death, 
non-fatal stroke & 
hospitalisation for 
heart failure) 
Multivariate analysis showed a 
lower GLS increased risk of CV 
events HR= 1.12, CI 1.02 to 
1.23, p<0.014. Kaplan-Meir 
GLS >-12.5% predicts 





196 AF patients. 
Exclusion: severe 
valve disease and 
inadequate echo 
windows. 
83 (±20) 132/76.5 (±21/12) TTE CV events (death, 
non-fatal stroke & 
hospitalisation for 
heart failure) 
Univariate analysis HR 0.680 
(0.560 to 0.826), p<0.001. 
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Parameter Study Number of 
patients  
Mean heart 
rate ± SD 
(bpm) 












196 patients with 










heart failure)  
PEPa-derived MPI ≥0.72 
increased cardiovascular events. 
Per 0.1 increase in PEPa-
derived MPI increase CV events 







107 Patients in AF. 
Exclusion: Patients 
with most RR 




stenosis or aortic 
stenosis 
76.9 (±11.7) [not stated] TTE Heart failure Areas under the receiver 
operating characteristics curve 
of slope/Vpe-1 for identifying 
heart failure were 0.72 (95% 
confidence interval 0.63 to 0.82, 
p<0.000) and 0.74 (95% 
confidence interval 0.62 to 0.85, 
p <0.001) in all patients and in 
patients with normal LV size 
and without significant 
regurgitation, respectively 
Abbreviations: 2D= two dimensional; 3D-RT-VTTE= real-time full-volume 3-dimensional transthoracic echocardiography; AF= atrial fibrillation; ANP= 
atrial natriuretic peptide; BNP= brain natriuretic peptide; C.I.= confidence interval; CMR= cardiovascular magnetic resonance imaging; CV= cardiovascular; 
ERNA= Equilibrium Radionuclide Angiocardiography; HFrEF= heart failure with reduced ejection fraction; HR= hazard ratio; GCS= global circumferential 
strain; GLS= global longitudinal strain; LVEF= left ventricular ejection fraction; MAM= mitral annulus motion; MAP= mean arterial pressure; MRI= 
magnetic resonance imaging; NYHA= New York Heart Association; OR= odd’s ratio; PEPa-derived MPI= Pre-ejection period derived myocardial 
performance index; SD= standard deviation; SPECT= single-photon emission computed tomography; TTE= Transthoracic Echocardiography; Vpe= Left 
ventricular peak ejection velocity
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Table 10: Reproducibility of systolic measurements in AF 
Parameter Study Number of 
patients  
Mean heart rate 
± SD (bpm)  
Blood 







LVEF (%) Goebel 
(2017)(127) 
20 patients with 
persistent AF 
[not stated] [not stated] CMR SSFP and real-
time SPARSE 
CMR 
Bland and Altman for intra 
observer SSFP = -0.6% (-6.0 to 
4.8) and real-time SPARSE = 
0% (-3.8 to 3.8). Inter observer: 
SSFP= 0.4% (-17.2 to 18.1) and 
real-time SPARSE= -1.1% (-
15.9 to 13.6) 
Hundley 
(1996)(126) 
13 patients with 
AF & 13 patients 
in sinus rhythm  
[not stated] [not stated] CMR Gradient echo 
MRI 
n= 10 in AF (3 excluded). Inter-
observer variability (standard 
error): 8%  
13 patients with 
AF & 13 patients 
in sinus rhythm 
[not stated] [not stated] Angiography Average of 3 
measurements  
n= 10 in AF (3 excluded). Inter-




19 permanent AF 
patients 
82 (57-109) 148/86  (111-
186)/(61-117) 
CMR 15 beats per 
slice 
n=10 AF in analysis, Intra-
observer variability: LV EF: R
2
= 
0.97, RC= 3.8 and bias= -1.9 ± 
4.2 2SD. Inter-study variability: 
LV EF: R
2
= 0.99, RC= 1.3 and 




115 with chronic 
AF referred for 
myocardial SPECT 
Gated SPECT 1: 
74.9 (±15.2) 
Gated SPECT 2: 
73.0(±15.57) 
[not stated] Gated 
SPECT 
QGS and ECT  SPECT Inter-observer 
variability: 0.47% (0.19-1.14) 
&intra-observer variability: 
0.22% (0.08-0.94)  
Inter-session variability 
between first and second 
SPECT study, using QGS 
r=0.948 (C.I. 0.926-0.964) 
and ECT r=0.951 (C.I. 0.930-
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Parameter Study Number of 
patients  
Mean heart rate 
± SD (bpm)  
Blood 
















[not stated] 118/76 (±18/9) TTE Not specified N= 10 randomly selected AF 
patients. Average difference in 
measurements, inter-observer= -
0.12% (r=0.97) and intra 




59 AF patients 


















N=20 patients randomly 
selected. ICC intra-reader for 
two observers 0.96 and 0.98 and 
for inter-reader was 0.9. 
Shahgaldi, 
(2010)(144)  
23 AF patients and 
55 patients with 
sinus rhythm 
97 (±27) [not stated] TTE 3D  Single beat vs 4 beat 3D 
analysis: Intra observer 
variability: 4.8% vs 8.3 % 
(p<0.001). Inter observer 







13 patients with 
AF & 13 patients 
in sinus rhythm 




n= 10 in AF (3 excluded).Inter 
observer: Standard error= 9mL  
13 patients with 
AF & 13 patients 
in sinus rhythm 
[not stated] [not stated] Angiography  Average of 3 
beats using 
thermodilution 
n= 10 in AF (3 excluded).Inter 




20 patients with 
persistent AF 
[not stated] [not stated] CMR SSFP and real-
time SPARSE 
Bland and Altman for intra 
observer SSFP= -0.5 (-9.7 to 
8.7) and real-time SPARSE = -
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Parameter Study Number of 
patients  
Mean heart rate 
± SD (bpm)  
Blood 







0.1 (-6.0 to 5.8). Inter observer: 
SSFP= 7.2 (-17.4 to 31.8) and 
real-time SPARSE= 4.3 (-22.4 
to 31.1) 
Longitudina
l Strain (%) 
Lee, 
(2012)(154)  
98 Patients with 
persistent or 
permanent AF and 
resting ventricular 
rates ≤ 105 bpm 
76 (±13) 135/ 79 
(±24/11) 
TTE Index beat vs 
15 average 
beats  
N= 15 randomly selected 
patients. The intra-observer and 
inter-observer mean percentage 
errors for  PLSSavg: 2.4 ± 1.4% 
and 2.7 ± 1.7%; and for 




25 AF patients 
with dyspnoea, 
angina or LV 
asynergy  
74 (± 15) 131/ 76 
(±16/12) 
TTE average over 
10 seconds  
N= 10. The intra-observer 
variability for mean percentage 
error of LS was 6.6 ± 8.8%, and 
the inter-observer variability was 
7.2 ± 9.1%. 
Dons, 
(2018)(136) 
204 patients in AF 90 ± 21 [not stated] TTE indexed the 
strain 
measurements 
with the square 
root of the RR-
interval 
N=20 randomly selected 
patients. Intra and inter-observer 
variability for GLS/√(RR had a 
mean difference ±1.96 SD: 
−0.12±2.37 and −1.36±3.87. 
GLS/√(RR) had the lowest 
variability with a coefficient of 
variation of 13% for intra- and 




196 AF patients. 
Exclusion: severe 
valve disease and 
inadequate echo 
83 (±20) 132/76.5 
(±21/12) 
TTE The index beat N=30 randomly selected 
patients. Mean percent errors for 
intra-observer= 5.3 ± 3.5% and 
for inter-observer= 6.2 ± 3.8%. 
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Parameter Study Number of 
patients  
Mean heart rate 
± SD (bpm)  
Blood 




























80.4 (±13.7) 133/81 
(±18/12) 
TTE Average of 13 
beats  
N=13 randomly selected 
patients. Intra-observer and 
inter-observer mean percent 
errors 5.2 ± 3.1% and 7.3 ± 3.3% 
respectively. 
Abbreviations: 3D= three dimensional; AF= atrial fibrillation; CMR= cardiac magnetic resonance; ECT= Emory Cardiac Toolbox; GLS= global 
longitudinal strain; LBBB= left bundle branch block; LV= left ventricular; LVEF= left ventricular ejection fraction; PEPa-derived MPI= Pre-
ejection period derived myocardial index; PLSS= peak longitudinal systolic strain; QGS= Cedar-Sinai quantitative gated SPECT ; RC= 
repeatability coefficient; SD= standard deviation; SSFP= Steady-state free precession cine images; SPECT= single-photon emission computed 
tomography; TTE=transthoracic echocardiography
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2.4  Discussion 
This is the first systematic review of the validity and reproducibility of systolic measurements 
made using standard cardiovascular imaging modalities for patients in AF at the time of 
assessment.  The data comparing validity and reproducibility between different imaging 
modalities in AF are extremely limited, meaning that measurements of systolic LV function in 
common usage cannot reliably be interchanged.  The data on external validation against 
clinical events or surrogate outcomes are also lacking, meaning that the clinical utility of 
measurements of systolic function in AF are uncertain.  To clarify, assessment of systolic 
function in patients with AF is performed in every cardiac centre globally, and yet the use of 
these techniques is unsupported by scientific data on measurement quality or validity. 
 
A lack of validation hampers clinical application of imaging results in AF. Most of the studies 
included in this systematic review addressed echocardiography, with limited examination of 
other modalities.  Even with echocardiography however, there is a clear lack of external 
validation.  CMR is generally considered the gold-standard method for assessing systolic 
function in terms of volume derived ejection fraction(155), however in terms of measuring 
contractility directly the gold-standard is considered to be the end-systolic pressure volume 
relation obtained from a high fidelity pressure catheter in the left ventricle.(156) There have 
been no studies externally validating LVEF in AF patients, which is a concern given that this 
measurement is used as key parameter to guide patient management.(3) In patients with sinus 
rhythm, LVEF is closely related to clinical outcomes, with each 5% lower LVEF increasing 
the risk of all-cause mortality by 24% (n=14261 patients ; 95% CI 21-28%; p<0.0001).(117) 
However, in patients with AF, the relationship of LVEF with clinical outcomes is less 
substantial, with a 9% increase in mortality per 5% lower LVEF (95% CI 3-15%; p=0.002), 
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likely reflecting higher variability in AF patients.  LVEF thresholds guide management 
decisions for patients; for example an LVEF ≤35% is used as a cut-off value to consider 
implantation of a cardiac resynchronization therapy  device(157), and a value of <40% 
determines the choice of rate and rhythm control therapy in AF patients.(3) This highlights 
the importance of understanding the accuracy and validity of systolic function assessment in 
patients with AF; unfortunately the review suggests that this is far from secure. 
 
2.4.1  Reproducibility in patients with AF  
The reproducibility of LVEF appears to be reasonable in these AF studies, with low levels of 
intra and inter observer variability.  However, the patients included were selected for good 
quality imaging (158, 159) and reproducibility assessment did not include the full range of 
testing (for example, repeatability and reliability).(45) These studies are unlikely to represent 
the AF population scanned in routine practice, as AF patients usually have multiple co-
morbidities such as obesity and airways disease limiting image quality. Moreover, the same 
images were often re-analysed, rather than the study itself repeated, thereby excluding the 
inter-session variability in measurements that would be expected in clinical practice. 
Recommended calculation of parameters in patients with AF typically involves averaging 
large numbers of consecutive beats, which is time-consuming and is often not completed in 
routine care.(138)  In contrast, the use of an index beat has been shown to be reproducible and 
could have advantages over averaging beats in AF which each have a different volume and 
ejection time.(136, 144, 145) 
 
2.4.2  Value of imaging parameters and acquisition methods to identify systolic 
dysfunction 
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AF patients often suffer with heart failure with preserved ejection fraction, presenting as a 
normal ejection fraction and impaired diastolic dysfunction, or features of reduced 
longitudinal function that may be a precursor to overtly impaired ejection fraction.(160) In 
echocardiography, GLS has been shown to predict CV events in those with AF(135), but 
other indices of longitudinal LV function such as mitral annulus motion are more strongly 
associated with LVEF in patients with sinus rhythm compared to AF.(142)  There were very 
few studies in which systolic measurements have been compared using CMR and nuclear 
imaging. Both modalities usually rely on the R wave to trigger image acquisition.  In CMR, 
the presence of AF makes acquisition challenging due to the irregular R to R interval, causing 
artefact when reconstructing the images. Despite this, the intra and inter observer 
reproducibility has been shown to be high. Nuclear gated blood pool studies to assess LVEF 
sum the blood counts of a representative cardiac cycle, therefore assuming that all R-R 
intervals are similar in length. (161, 162) Although internal validity of nuclear imaging seems 
reasonable in patients with AF (130), there have been no studies providing external validation. 
Finally, in all studies where heart rate was reported, values were within a well-controlled 
range of 60-90 beats per minute. There have been no studies assessing the validity or 
reproducibility of systolic parameters when heart rates are outside this range.   
 
2.4.3  Outlook and Limitations 
There is a clear need for external validation of systolic measurements in patients with AF and 
also inter-operator/inter-session studies to better assess reproducibility.  Data on the validity 
of measurements in CMR, nuclear imaging and CT was extremely limited, making it difficult 
to draw any conclusions.  A major limitation of the reproducibility studies was the lack of 
blinding of observers, making the risk of bias for work flow, index and reference values 
uncertain.  Moving forward, we urgently need prospective, blinded comparison studies in AF 
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patients, with imaging not restricted to a selected patient group with high quality images.  
Hence, in the following chapters the echocardiographic study performed as part of a 
randomised controlled trial in which all echocardiograms were blinded and no exclusions 
were made for patient entry according to image quality.  This means that the outcome will 
apply to all AF patients regardless of imaging quality and observer bias will be minimised.   
 
This chapter has highlighted the limited information we have on the validity and 
reproducibility of systolic measurements we use every day to assess systolic function in 
cardiac imaging.  There remains a significant lack of evidence for the other imaging 
modalities, which require future studies.  However, for purpose of this thesis the focus is 
initially on echocardiography, as this is generally used in clinical practice echocardiography 
as a first-line imaging tool to direct management in AF patients (and is real time).
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Figure 23. Summary of findings from each imaging modality. CMR still of a mid-short axis slice acquired by SSFP retrospective gated imaging (top left 
panel); TTE three-dimensional imaging of the left ventricle in the apical window (bottom left panel);  radionuclide ventriculography imaging of the left ventricle 
with contours drawn mapping the left ventricle (top right panel); cardiac CT image of the left ventricle (bottom right panel). Abbreviations: CMR= cardiac 
magnetic resonance; SSFP= standard steady state free precession; TTE= transthoracic echocardiography; CCT= cardiac computed tomography  
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Table 11:  Summary of included studies 
Study Number 
with AF 




115 Patients with chronic AF  Reproducibility To assess the reproducibility of EDV, ESV 
and LVEF using gated SPECT in patients with 
AF. 
Inter and intra observer variability 
was very low, with small bias and 
narrow limits of agreement. 
Nichols, (1999)(129) 36 Patients referred for 
evaluation of coronary artery 
disease 
Validity  To compare SPECT and ERNA derived LVEF 
in AF type gating errors and to determine 
percentage change in LV volumes, LVEF, 
wall thickening and myocardial perfusion 
according to gating error type  
 ERNA correlated highly with 
SPECT when measuring LVEF.  
Gating errors significantly 
affected wall thickening and 
myocardial perfusion.  
Wallis, (1991) (130)  20 Patients with AF at the time 
of their resting gated blood 
pool study 
Validity  Assess differences in LVEF with and without 
windowing  
High correlation between 
windowed and non-windowed 
LVEF, with no significant 
difference. 
Echocardiography 
Chu, (2015) (150)  196 Patients with persistent AF.  
Excluding significant valve 
disease and inadequate echo 
windows 
Validity To examine the ability of PEPa-derived MPI 
to predict CV events outcome using an index 
beat method. 
Increased PEPa-derived MPI was 
associated with increased risk of 
CV events; cut off-value for 
PEPa-derived MPI was 0.72.  
Dons (2018) (136) 204 Patients in AF at time of 
echocardiogram 
Validity  To evaluate whether GLS predicts risk of CV 
events (all-cause mortality, incident heart 
failure, stroke and myocardial infarction).  
Reduced GLS increased risk of 
CV events 
Egami, (2010) (152) 27 Hypertensive patients with 
persistent AF who had 
previously been successfully 
cardioverted  
Reproducibility Intra-observer and inter-observer variabilities 
of LADd and LVEF  assessed in 10 randomly 
selected patients 
High intra and inter-observer 
reproducibility for measurement 
of LVEF.  




Population Assessment Aims and methods Main findings related to AF 
Emilsson, (2000) 
(142) 
20 20 AF, 20 SR patients. 
Exclusion: pacemaker insitu, 
left/right bundle branch 
block, cardiac surgery hx or 
septal/posterior wall 
thickness>14mm, poor 
image quality for 
endocardial definition 
Validity To investigate the relationship between LVEF 
measured by Simpson’s biplane and mitral 
annulus motion (MAM) in patients with AF.  
Patients with AF had a reduced 
MAM when compared to SR 
group. MAM correlated better 
with LVEF in the SR group 
compared to the AF group.   
Henrard, (2013) 
(153) 
59 AF patients taking part in 
the AF-CHF 
echocardiographic sub-study 
Reproducibility  To assess intra and inter-observer 
reproducibility of LVEF measured by the 
modified Simpson’s method. 
The Intra and inter observer 
reproducibility for LVEF was 
very high.  
Kim, (2007) (148) 104 Patients with chronic AF Validity LVEF was derived from the Simpson’s 
biplane method and correlated with plasma 
BNP levels 
LVEF correlated weakly with 
BNP. 
Ko, (2005) (147) 18 Patients with AF. Excluded 
if R-R intervals didn’t fall 
between 0.6 and 1s.  
Validity The relationship between RR-1 and RR-2 with 
the LVOT peak ejection velocity (Vpe) was 
determined. This was then correlated with 
fractional shortening.  
Fractional shortening correlated 
strongly with when the ratio of 
the slope of Vpe to RR-1=1 
second and when the slope of Vpe 
to RR-2= 1 second. 
Kusunose, (2012) 
(132) 
25 AF patients Validity and 
reproducibility 
PLSS measured using averages of 
instantaneous LS over 10 sec and index-beat. 
These variables were compared with 
simultaneously measured LV pressure 
parameters using invasive catheterisation. 
Index beat LS was correlated 
strongly with the maximal 
positive derivative of LV pressure 
(peak +dP/dt) 
Lee, (2012) (154) 98 Patients with persistent or 
permanent AF and resting 
ventricular rates ≤ 105 bpm. 
Reproducibility  Validation of the LV PLSS index against LV 
PLSS avg. LV systolic strain was obtained 
from two-dimensional speckle tracking 
echocardiography. 15 patients were randomly 
selected for interobserver and intraobserver 
variability.  
LV PLSS index significantly 
correlated with LV PLSS avg, 
with only a small difference 
between them. Similar levels of 
intra-observer and inter-observer 
variability between PLSSavg and 
PLSSindex measurements. 




Population Assessment Aims and methods Main findings related to AF 
Lee, (2009) (151) 107 Patients in AF. Exclusion: 
Patients with most RR 
intervals <0.6 or >1.0 
second, hemodynamically 
significant mitral stenosis or 
aortic stenosis  
Validity  Vpe with RR-1 interval was determined to 
form the parameter slop/Vpe1 (the ratio of the 
slope of Vpe co-ordinates measured when RR-
1 is 0.6-1 second at 1 second). Variables of 
heart failure were correlated with slope/Vpe1. 
The parameter slope/Vpe-1 is 
significantly associated with 
occurrence of heart failure.  
Modin, (2018 ) (137) 151 HFrEF patients with AF  Validity  Evaluate the predictive value of GLS, GLSc 
(GLS corrected for r to R interval), GCS and 
GCSc (GCS corrected for R to R interval) in 
predicting all-cause mortality. 
Per 1 % decrease in both GLS and 
GCS predicted an increase in risk 
of all-cause mortality.  
Oki, (1999) (146) 39 Included if: simultaneous 
cardiac catheterization and 
TDI can be performed, 
presence of AF, no 
significant valve disease, 
absence of regional LV wall 
asynergy. 
Validity TDI systolic LV posterior wall motion 
velocity was measured along the long and 
short axes (Sw1 and Sw2).  Simultaneous 
recording of LV pressure curve dP/dt using 
invasive catheterisation. 




1293 Patients who had suffered 
and acute myocardial 
infarction 
Validity  To determine the impact of presence of AF on 
in hospital, 30 day and long term mortality 
according to LVEF measured by the wall 
motion score index stratified in to <0.25, 
0.25≤LVEF≤0.35, .35<LVEF≤0.50 and 
LVEF>0.50.  
In patients with LVEF <0.25 in 
hospital mortality risk was 
increased in AF patients but no 
effect on long term mortality 
Shahgaldi, (2010) 
(144) 
23 23 AF patients and 55 
patients with sinus rhythm 
Reproducibility To compare single-Beat with four-beat full 
volume 3DE acquisition for the inter- and 
intraobserver assessment of LV volumes and 
LVEF. 
Lower intra and inter-observer 
variability in measuring LVEF 
when single beat 3D volume is 
used instead of 4 beat 3D 
volumes.    
Su, (2013) (135) 196 AF patients. Exclusion: 
severe valve disease and 
inadequate echo windows.  
Validity and 
reproducibility 
To determine the relationship between GLS as 
a predictor of CV events (CV death, non-fatal 
stroke and hospitalisation due to heart failure) 
in patients with AF 
A lower GLS was the highest 
predictor of CV events and 
Kaplan-Meir analysis showed that 
a GLS >-12.55% predicted 
increased risk of  CV events 




Population Assessment Aims and methods Main findings related to AF 
Su, (2011) (143) 54 Permanent AF Exclusion: 
LBBB, mitral annular 
calcification, presence of 
prosthesis valve, severe 
mitral regurgitation, lateral 




and validity  
To determine whether PEPa-derived MPI can 
be used to evaluate systolic and diastolic LV 
function by comparing with systolic mitral 
annular velocity and LVEF measured using 
the modified Simpson’s method. Intra and 
interobserver variability of PEPa-derived MPI 
was assessed in 13 patients.         
PEPa had a moderate negative 
correlation with Sa and LVEF, 





24 AF patients >18 years. 
Excluded if poor image 
quality.  
Validity  To compare LVEF and LV volumes measured 
by Real Time full-volume 3-dimensional 
Echocardiography with the 2D biplane 
Simpson method 
RT-VTTE LVEF correlated 
highly with vs 2D Simpson’s 
biplane LVEF with small bias and 
narrow limits of agreement.  
Wozakowska-
Kaplon, (2005) (149) 
67 Persistent AF. Excluded if: 
NYHA IV, LVEF= <45%, 
uncontrolled AF, untreated 
hypertension, unstable 
angina, myocardial 
infarction within 3 months, 
anaemia, renal or liver 
insufficiency, respiratory 
failure, and malignancy. 
Validity  To evaluate the relationship between ANP 
levels and LVEF 
LVEF correlated weakly with 
ANP 
CMR 
Goebel, (2017)(127)  20 Persistent AF Validity To determine whether free-breathing 
SPARSE-SENSE CMR can reliably assess LV 
volumes and function in comparison to SSFP  
SPARE-SENSE CMR correlated 
highly with SSFP in measuring 
LVEF 




Population Assessment Aims and methods Main findings related to AF 
Hundley, 1996(126) 10 AF patients with no 
significant valve disease or 
exclusion criteria for CMR 
Validity To assess the utility of CMR in measuring LV 
volumes, EF and cardiac output in patients 
with AF by comparing with left heart catheter 
derived LVEF and stroke volume using 
thermodilution and left ventriculography.  
LVEF derived from CMR 
correlated highly with 
measurements derived from 
invasive catheterisation. CMR 
derived SV correlated highly with 
both thermodilution and left 
ventriculography. CMR had 
higher inter-observer 
reproducibility for measurement 
of LVEF and SV. 
Therkelsen, 
(2005)(128) 
79 19 healthy volunteers, 19 
with permanent AF and 60 
with persistent AF. 
Reproducibility  To evaluate intra and inter study 
reproducibility of LVEF  
N=10 Low intra and inter-study 
variability for LVEF assessment 
 
Abbreviations: 3D= three dimensional; AF= atrial fibrillation; ANP= atrial naturetic peptide; BNP= brain naturetic peptide; CHF= congestive 
heart failure; CMR= cardiac magnetic resonance; CV= cardiovascular; LoA= limits of agreement; EDV= end diastolic volume; ERNA= 
Equilibrium Radionucleotide Angiography; ESV= end systolic volume; GCS= global circumferential strain; GLS= global longitudinal strain; 
HF= heart failure; ICC= intraclass correlation coefficient; LADd= left atrial dimension at end-systole; LV= left ventricular; LVEF= left 
ventricular ejection fraction; LVOT= left ventricular outflow tract; LS= longitudinal strain;  MAM= mitral annulus motion; NYHA= New York 
Heart Association; PEPa-derived-MPI= Pre-ejection period derived myocardial index; PLSS= peak longitudinal systolic strain;  SPARSE-
SENSE= compressed sensing and parallel imaging;  SPECT= single-photon emission computed-tomography; sw1= first peak systolic TDI 
waveform; sw2= second peak systolic TDI waveform; SR= sinus rhythm; SSFP= steady-state free precession imaging; TDI= Tissue Doppler 
Index; Vpe= peak left ventricular outflow tract ejection velocity 
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Chapter 3.  General Methods 
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3.1 RAte control Therapy Evaluation in permanent Atrial Fibrillation 
(RATE-AF) trial 
All data was collected from patients taking part in the RATE-AF trial; the baseline data was 
used for the results in this thesis.(163)  
3.1.1 Rationale 
The majority of patients with AF will require some form of rate control, with 40-50% being 
unsuitable for rhythm control and are instead indicated for long-term rate control.(164)  
However currently the choice of rate control medication is based on low-quality 
evidence(165) and in clinical practice medication is chosen according to expert consensus and 
a physician’s individual preference.  There are no randomised clinical trials assessing long-
term rate control in patients with AF and there is very limited data on how choice of rate 
control effects quality of life and functional outcomes.  The RATE-AF trial aimed to compare 
the efficacy of beta-blockers verses digoxin in symptomatic permanent AF patients, aged 60 
years and over, by assessing quality of life, functional capacity, systolic and diastolic LV 
function and biomarkers of treatment response. 
3.1.2 Ethics 
The RATE-AF trial has been approved by the East Midlands—Derby Research Ethics 
Committee (16/EM/0178) (see (NCT02391337) and received approval from the National 
Health Service Health Research Authority (IRAS project ID: 191437). 
3.1.3 Trial Team 
The Birmingham Clinical Trials Unit (BCTU) at the University of Birmingham managed the 
trial and visits took place in the NIHR/Wellcome Trust Clinical Research Facility based at the 
Queen Elizabeth Hospital, Birmingham.  The trial management group consisted of: Dr Dipak 
Kotecha (chief investigator), Dr Michael Griffith (principal investigator at site Queen 
97 | P a g e  
 
Elizabeth Hospital , Birmingham), Professor Paulus Kirchhof (principal investigator at site 
Birmingham City and Sandwell hospital), Prof Gregory Y H Lip (principal investigator at site 
Birmingham City and Sandwell hospital), Prof Jonathon Townend (principal investigator at 
site Queen Elizabeth Hospital , Birmingham), Dr Rick Steeds (principal investigator at site 
Queen Elizabeth Hospital , Birmingham), Prof Melanie Calvert, Dr Susan Jowett, Dr 
Jonathon Mathers,  Prof Jon Deeks, Gemma Slinn (team leader of trials management), Dr 
Rebekah Wale (trial manager)  and Samir Mehta (statistician).  The trial oversight committee 
was chaired by Prof John Camm and Dr Kazem Rahimi. 
The research assistant and PhD fellow Karina Bunting (KB) screened all cardiology out-
patient clinics and diagnostic referrals for potential subjects at University Hospital 
Birmingham between December 2016 and September 2018.  The research nurse (Patience 
Domingos) based at City and Sandwell hospital, also assisted in the screening of potential 
subjects from City and Sandwell hospital and Heartland’s hospital.  KB was responsible for 
recruiting and consenting all patients, for arranging and performing all study visits, reporting 
any serious adverse events and with the assistance of the research nurse for performing all 
study visit procedures as stated in the protocol with the exception of procedures and decisions 
related to medical management (performed by Dr Dipak Kotecha and Dr Simrat Gill).   
KB also maintained all the regulatory documents and was responsible for updating the site file 
with the ethics committee amendments and attending Data monitoring and Trial Steering 
committee meetings.   
3.1.4 Patient and public involvement (PPI) panel 
The PPI was responsible for carrying out the qualitative research to assess the utility of the 
quality of life (QoL) questionnaires in assessing patients’ symptoms.  This was carried out 
using patient focus groups of around 10 participants from each treatment arm.  Qualitative 
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data was gathered to assess QoL questionnaires difficulty in completion, relevance, reasons 
for non-completion and other feasibility issues from the patient’s perspective. 
3.1.5 Summary of trial design 
The trial sponsor was the University of Birmingham and it was funded by the National 
Institute of Healthcare Research (NIHR).  This was a Clinical Trial of an Investigational 
Medicinal Product trial, designed as a Prospective Open-labelled Blinded End-point trial to 
determine the effectiveness of beta-blockers verses digoxin in patients with permanent atrial 
fibrillation.  The primary end-point of the study was patient-reported quality of life using the 
Short Form (36) Health survey (SF-36) at 6 months.  The secondary end-points included 
changes in cardiac diastolic and systolic function, functional status, global and AF specific 
quality of life scores and cardiovascular biomarkers such as heart rate and changes in N-
terminal B-type Natriuretic peptide (NTproBNP) levels at 6 months (163), see Figure 24 for 
the trial schema.   
Figure 24.  RATE-AF trial schema 
 
The full protocol can be accessed online using the link listed in appendix 1.  Please also see 
the following link for the short film promoting the RATE-AF trial made by the chief 
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investigator (Dipak Kotecha) and a member of the patient representative group: 
https://www.youtube.com/watch?v=4oxe8AcVo0E. 
3.2  Recruitment  
Recruitment of patients began in December 2016 until the last patient was recruited in 
October 2018.  Patients were screened for eligibility across the Queen Elizabeth Hospital 
(Birmingham), City and Sandwell Hospital (Birmingham) and Heartlands Hospital 
(Birmingham).  General Practitioner (GP) practices across the Birmingham area were also 
invited to act as patient identification sites, to refer appropriate patients.  The trial was 
promoted at the Research Site Initiative Practice event at Edgbaston cricket ground on 9
th
 
February 2017, in which the trial was presented to GPs attending the event.   
The inclusion criteria were as follows: 
• Adult patients aged 60 years or older 
• Permanent AF, characterised (at time of randomisation) as a physician decision for 
rate-control with no plans for cardioversion, anti-arrhythmic medication, or ablation 
therapy 
• Symptoms of breathlessness (New York Heart Association Class II or more) 
• Able to provide written informed consent 
The exclusion criteria were as follows: 
• Established clinical indication for beta-blocker therapy, e.g. myocardial infarction in 
the last 6 months 
• Known contraindications for therapy with beta-blockers or digoxin, e.g. a history of 
severe bronchospasm that would preclude use of beta-blockers, or known intolerance 
to these medications 
• Baseline heart rate <60 bpm  
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• History of second or third-degree heart block 
• Supraventricular arrhythmias associated with accessory conducting pathways (e.g. 
Wolff-Parkinson-White syndrome) or a history of ventricular tachycardia or fibrillation 
• Planned pacemaker implantation (including cardiac resynchronisation therapy), 
pacemaker-dependent rhythm or history of atrioventricular node ablation 
• Decompensated heart failure (evidenced by need for intravenous inotropes, 
vasodilators or diuretics) within 14 days prior to randomisation 
• A current diagnosis of obstructive hypertrophic cardiomyopathy, myocarditis or 
constrictive pericarditis 
• Received or on waiting list for heart transplantation  
• Receiving renal replacement therapy 
• Major surgery, including thoracic or cardiac surgery, within 3 months of randomisation 
including patients with severe valve disease being considered for surgery 
• Severe, concomitant non-cardiovascular disease (including malignancy) that is 
expected to reduce life expectancy 
Suitable patients were screened for with the following methods: patients attending cardiology 
outpatient clinics, all 24-hour ECG ambulatory monitor reports, all ECGs taken within the 
department and all direct GP echocardiogram referrals for new AF.  Patients, identified as 
having a history of AF, were further screened using clinical letters to look for any reason to 
exclude the patient.  Once satisfied with the initial screening of the patient, patients were 
telephoned to ensure there were not any other reasons to exclude.  If at that stage patients met 
criteria, they were invited to take part in the study and a patient information leaflet was sent 
out to them (see appendix 2).  Suitable patients were also directly referred by GP practices, 
and from Birmingham City and Sandwell Hospital and Heartlands Hospital.      
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3.3  Informed Consent  
Having completed Good Clinical Practise and Informed consent training, KB was 
predominantly responsible for carrying out the consent process for all patients wishing to 
enrol in the trial.  Time was taken to ensure that the patient fully understood the trial and what 
was expected of them and the trial team.  Once satisfied that the patient was adequately 
informed the patient was asked to complete the consent form (see appendix 3).  The patient 
also had the option to take part in additional studies listed on the optional consent form (see 
appendix 4).  
3.3  Baseline visit 
3.3.1  Randomisation  
When patients came in for their baseline visit, initially a 12-lead Electrocardiogram (ECG) 
was performed to ensure the patient was still in AF.  The rest of the eligibility criteria was 
then systematically checked with the use of the randomisation form (see appendix 5).   
All patients had to provide informed consent before enrolling in the trial.  Once satisfied that 
the patient understood the trial and what was expected of them, informed consent was 
obtained. The patient was then enrolled in the trial and randomised to either digoxin or a beta-
blocker using a minimised randomisation protocol managed by BCTU.  As part of the 
randomisation process the patient was also given a study identification number which would 
be used to identify the patient on all trial related paperwork. 
3.3.2  Medical history and clinical examination 
The patient’s current medication was recorded in their file and specified any anticoagulants, 
antihypertensives, antiplatelets or inhalers for airways disease on the baseline case report form 
(CRF) see appendix 6.   
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The patient was also physically examined by the consultant cardiologist and any signs of heart 
failure were recorded in the baseline CRF; these included: abnormal heart sounds, raised 
jugular venous pressure, peripheral oedema and lung crepitations. 
 
3.3.3  Physiological measurements 
A 12-lead electrocardiograph (ECG) was performed during the randomisation process 
adhering to standard operating procedures as described by the Society for Cardiological 
Science and Technology.(166)  This was carried out to primarily ensure the patient was in AF 
and there were no other ECG features, which would exclude the patient from the study.  Heart 
rate (bpm), QRS duration (ms) and QT duration (ms) were recorded in the baseline CRF.  The 
ECG was performed with the patient in the supine position and care was taken to allow the 
patient to rest for one to two minutes before recording the ECG, in order to obtain an accurate 
resting heart rate. 
The blood pressure was measured, using two consecutive blood pressures taken from brachial 
position using a validated oscillometric blood pressure machine.  In cases in which the 
automated machine was unable to accurately measure the blood pressure, a manual blood 
pressure was taken using a sphygmomanometer and stethoscope.  The blood pressure was 
taken at rest, before the walk test to ensure an accurate measurement of resting blood pressure 
was obtained.  Heart rate was measured using the radial pulse and by listening to the apex 
beat using a stethoscope.  These measurements were obtained consecutively in the same order 
to minimise any ascertainment bias.  
Anthropometric measurements of weight (kg) using digital stand-on weighing scales, height 
(cm) using a portable stadiometer and waist circumference using a body tape measure, were 
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recorded.  To ensure a consistent position for waist measurement, all waist measurements 
were taken just above the hipbones in expiration.    
 3.3.4  Echocardiogram 
All patients underwent an echocardiogram at baseline, which were all carried out by myself 
(BSE accredited).  All echocardiograms were carried out on a Phillips EPIQ 7 with an X-3 
transducer.  The structure and function of the heart was assessed according to the British 
Society of Echocardiography’s normal protocol.(167)  In the presence of pathology for 
example valve disease, I took extra measurements as described by the BSE protocol 
accordingly.  Extended loops (up to10 beat per loop) and multiple frames were obtained as 
described in Table 12, so that variability analysis could be carried out.  Intra-operator and 
inter-operator reproducibility of the index beat verses the averaging of 3, 5 and 10 consecutive 
beats was demonstrated using the measurement of GLS and E/e’.  For intra-operator 
reproducibility at the end of the initial protocol the patient was asked to re-position and the 
first operator took a second set of acquisitions, with at least ten available loops or traces to 
measure GLS and E/e’ using a single index beat and an average of 3, 5 and 10 consecutive 
beats.  For inter-operator reproducibility a second operator acquired at least ten available 
loops or traces to measure GLS and E/e’. 
All images obtained were optimised by: 
• Using maximal frequency transducer to increase axial resolution 
• Reducing sector width to area of interest in order to increase frame rate 
• Reducing depth to increase the size of the image on the screen 
• Bringing the focus to the point of interest to increase lateral resolution 
• Optimize compression to achieve optimum grey-scale range 
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• Adjusting Time Gain Compensation’s in order to optimize the distribution of gain at 
different penetration depths. 
• Optimizing gain and resolution to identify endocardial boarders and structures. 
• Asking the patient to inhale or exhale in order to optimise image and reduce motion 
artefact 
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Table 12.  The baseline echocardiogram protocol 










PLAX 2D LV, AV and MV 3 1 n/a IVSd and LVIDs 
2D zoom LVOT and Aortic root 3 1 n/a LVOT diameter and root 
dimensions 
M-mode Optimised on-axis LV  5 6 50 mm/s (slow) LVIDd and LVIDs 
Optimised on-axis 
AoR and LA 
5 6 50 mm/s (slow) LA dimension 
Colour  Colour over MV 3 1 60 cm/s *quantify any MR 
Colour over AV 3 1 60 cm/s *quantify any AR 
PLAX RV 
inflow  
2D TV and RV inflow 3 1 n/a n/a 
Colour   Colour over TV   3 1 60 cm/s *quantify any TR 
CW  TV inflow and any 
regurgitation 
n/a 1 75 mm/s (med) *TR Vmax  
PLAX RV 
outflow 
2D PV and RV outflow 
tract 
3 1 n/a n/a 
Colour Colour over PV 3 1 60 cm/s *quantify any PR 
CW  PV inflow and any 
regurgitation 
n/a 1 75 mm/s (med) *quantify any PR or PS 
PW PV inflow 3 1 75 mm/s(med) PV Vmax 
PSAX 2D Aortic valve level 3 1 n/a n/a 
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 Basal level 3 1 n/a n/a 
Mid-level 3 1 n/a n/a 
Apical level 3 1 n/a n/a 
A4C 2D Optimised RV 3 1 n/a RVIDd and RA area 
LA 10 3 n/a LA volume, LA 
transverse dimension and 
LA longitudinal 
dimension 
Optimised LV 11 (/6- 
depending 










Longitudinal Strain and 
Simpson’s single plane 
end-diastolic and end-
systolic volume **  
2D x-plane Optimised LV 6 2 
 
n/a Simpson’s biplane end 
diastolic and end-systolic  
volume 
Optimised LA 6 2 n/a LA biplane volumes 
3D HVR Optimised LV 8 2 n/a 3D end-diastolic and end-
systolic volumes  
3D volume Optimised LV 4 3 n/a 3D end-diastolic and end-
systolic volumes 
TDI and PW Lateral tissue Doppler 
velocity spectrum  
10 3 25 mm/s (min) s’ and e’ velocities *** 
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Septal tissue Doppler 
velocity spectrum  
10 3 25 mm/s (min) s’ and e’ velocities *** 
PW  Mitral valve inflow 10 3 25 mm/s (min) E and E deceleration time 
Pulmonary venous 
flow 
3 10 50 mm/s (slow) Systolic and diastolic 
velocity and diastolic 
deceleration time 
Colour m-mode Flow through the 
mitral valve  




M-mode Motion through RV 
base 
10 3 25 mm/s (min) TAPSE 
Colour  Colour over Tricuspid 
valve 
3 1 60 cm/s *quantify regurgitation 
Colour over Mitral 
valve 
3 1 60 cm/s *quantify regurgitation 
A5C Colour Colour over aortic 
valve  
3 1 60 cm/s *quantify regurgitation 
CW Aortic valve flow n/a 1 75 mm/s (med) AV Vmax ** 
PW LVOT flow 5 6 50 mm/s (slow) LVOT Vmax and LVOT 
VTI *** 
LVOT and MV flow 3 10 75 mm/s (med) IVRT 
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A2C 2D Optimised LV 11 / (6- 
depending 
on need for 
breath hold) 
3 / (6- 
depending on 
need for breath 
hold) 
n/a Simpson’s single plane 
end-diastolic and end 
systolic volume and   
Longitudinal strain  
A3C 2D Optimised LV 11 / (6- 
depending 
on need for 
breath hold) 
3 / (6- 
depending on 
need for breath 
hold) 
n/a Longitudinal strain 
Subcostal 4C 2D 4 chambers of the heart   3  1 n/a n/a 
Subcostal SAX 2D IVC  3  1 n/a IVC diameter 
IVC collapse with 
respiration 
Suprasternal  1 3 IVC collapse with 
respiration 
Suprasternal 2D Arch 3 1 n/a Arch dimensions 
Colour  Colour over Desc Ao 3 1 60 cm/s n/a 
CW Flow down Desc Ao n/a 1 75 mm/s (med) n/a 
PW Flow at prox Desc Ao  n/a 1 75 mm/s (med) n/a 
Patient sits up and operator gets up and leaves the room before returning to do the measurements to test intra-operator variability.  
All following loops should be labelled “IOV1” 
A4C 2D Optimised LV 11/ (6- 
depending on 
need for 
1 / (2- 
depending on 
need for breath 
n/a Longitudinal strain ** 
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breath hold) hold) 
TDI and PW Lateral tissue velocity 
spectrum  
10 1 25 mm/s (min) s’ and e’ velocities *** 
Septal tissue velocity 
spectrum 
10 1 25 mm/s (min) s’ and e’ velocities  *** 
PW Mitral valve inflow 11 1 25 mm/s (min) E and E deceleration time 




1 / (2- 
depending on 
need for breath 
hold) 
n/a Longitudinal strain  
A3C 2D Optimised LV 
 




1 / (2- 
depending on 
need for breath 
hold) 
n/a  Longitudinal strain 
On every 8 patients a second operator should take the following acquisitions and all loops should be labelled “IOV2” 




1 (2- depending 
on need for 
breath hold) 
n/a Longitudinal strain 
TDI and PW Lateral tissue velocity 
spectrum 
10 1 25 mm/s (min) s’ and e’ velocities *** 
Septal tissue velocity 
spectrum  
10 1 25 mm/s (min) s’ and e’ velocities *** 
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PW Mitral valve inflow 10 1 25 mm/s (min) E and E deceleration time 




1 (2- depending 
on need for 
breath hold) 
n/a Longitudinal strain 




1 (2- depending 
on need for 
breath hold) 
n/a Longitudinal strain 
Abbreviations:, 3D= three dimensional; A4C= Apical 4 Chamber; A2C= Apical 2 Chamber, A3C= Apical 4 Chamber; AoR= Aortic root; AR= 
aortic regurgitation; AV= Aortic Valve; CW= continuous wave; Desc Ao= descending aorta; IVC= inferior vena cava; IVRT= isovolumic 
relaxation time; IVSd= Inter-ventricular septum diameter, LA= Left atrium; LVIDd= left ventricular internal diameter in diastole; LVIDs= left 
ventricular internal diameter in systole; LV= left ventricle; LVOT= Left Ventricular Outflow Tract; LVPWd= Left Ventricular Posterior Wall 
diameter; MR=mitral regurgitation, MV=mitral valve, MR= mitral regurgitation; RV= right ventricle, PLAX= Parasternal Long Axis; PR= 
pulmonary regurgitation; PS= pulmonary stenosis, PSAX= parasternal short axis PV= pulmonary valve; PW= pulsed wave; RA= right atrium; 
RVIDd= right ventricle internal diameter in diastole; TAPSE= tricuspid annular plane systolic excursion; TR= tricuspid regurgitation; TV= 
tricuspid valve; Vmax=maximal velocity; Vp= propagation velocity; VTI= velocity time integral. 
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All measurements were carried out post-process using the Philips Q-station analysis software 
(version 2014, 4535 617 07481 Rev A).   
Anonymization of echocardiograms 
All echocardiogram studies were given a code separate to the patient’s study identification 
number, so that the analyser was blinded to the patient details when analysing the scans a 
minimum of 6 months following the echocardiogram.  This excluded observer bias, as the 
echocardiogram was not identifiable at the point of analysis.  
Parameters used to assess systolic function 
Simpson’s Biplane Ejection Fraction.  This method calculates the ejection fraction by 
measuring the end-diastolic volume and end systolic volume in the plane of the 2-chamber 
and 4-chamber view.  Volume is calculated using the disc summation method with the 
assumption that the LV is ellipsoid in shape.(28, 29)  To measure a Simpson’s biplane firstly 
an optimised loop of the LV in the apical 4 and 2 chamber was obtained.  The loop was 
scrolled to end-diastole when the ventricle cavity was at its largest (usually on the R wave); 
the endocardial boarder starting from the annulus to the apex was traced to summate the end 
diastolic volume using the disc summation method.  Then the loop was scrolled to end-
systole, when the ventricle cavity was at its smallest (usually at the end of the T wave); then 
again the endocardial boarder was traced to summate the end-systolic volume.  As described 
in chapter 1 the volumes are used to calculate the LVEF: (EDV-ESV)/EDV x100.  
Left ventricular speckle tracking strain.   
Optimised 10 beat loops of the left ventricle in the apical 4, 2 and 3 chamber view were taken, 
ensuring a frame rate between 40 and 90 frames/ second by reducing the sector width and 
optimising the depth, whilst still ensuring the entire myocardial wall was well seen.(168)  
Automated cardiac motion quantitation analysis (aCMQ) was selected to initiate the speckle 
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tracking process.  First the loops were scrolled back to ensure that analysis was started on the 
first cardiac cycle.  Next, the apical window strain was being assessed in was selected and 
then by using the “draw” function three anatomical points were marked out: two on the mitral 
annulus and one on the apex.  This enabled the speckles to align with the myocardium; the 
speckles could be manually adjusted where necessary to ensure they were tracking the 
myocardium correctly.  Once satisfied that the longitudinal strain value had been correctly 
measured, the value was accepted.  The next beat was then selected for longitudinal strain 
analysis.          
3-D volume ejection fraction.  3-D imaging can be performed with a matrix-array transducer 
to acquire an image of the ventricle sampling from every plane, to form a pyramidal dataset.  
From the images a 3-D end-diastolic and end-systolic LV volume can be calculated, which is 
then used to determine the ejection fraction.  The image of the left ventricle in the apical 4-
chamber view was optimised and then 3D “full volume” software was initiated so that a 3D 
pyramidal view of the ventricle could be acquired.  Sector width was adjusted to ensure that it 
was wide enough that the entire ventricle can be viewed in both planes and narrow enough so 
that the frame rate was maximised.  The acquisition setting was changed to 3D HVR so that 
10 single 3D loops could be acquired without the issue of stitching artefact.  
Analysis was carried out using the Q-station 3D full volume analysis.  The first cycle was 
selected by using the “previous R wave” instruction to scroll the images back to the start of 
the 10 beat acquisitions.  The end-diastolic volume frame was selected and then the axis were 
aligned to ensure the image of the ventricle was optimised in all planes.  The same process 
was carried out for end-systolic volume.  The anatomical markers were next selected 
beginning with the septal annulus, followed by the lateral annulus, anterior annulus, inferior 
annulus and the apex.  When satisfied that the markers were correct, 3D sequence analysis 
was selected which used the anatomical markers to track the endocardial boarder throughout 
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the cardiac cycle.  If unsatisfied with the automated endocardial tracking this could be 
adjusted using the “draw endocardial boarder” setting.  Once satisfied with the endocardial 
boarder tracking, 3D sequence analysis was run again.  The End-systolic volume, end-systolic 
volume, stroke volume and LVEF were measured.  Then the next R wave was selected to 
begin measuring on the sequential beat.    
Tissue Doppler Indices (TDI).  The Tissue Doppler imaging was activated to allow the speed 
of the myocardium to be visualised on a colour scale.  Pulsed wave Doppler was then placed 
at the lateral and septal annulus to detect low velocity, high amplitude signals from the 
moving myocardium.  TDI measurements were taken from the lateral and septal annulus.  
Sequential frames were taken to ensure that at least 10 measurements were obtainable.  The s’ 
was measured at the upward deflection following the R wave and e’ was measured at the 
initial downward deflection between the T wave and R wave.    
Fractional shortening (FS).  For images in which the LV was on axis, M-mode was run 
through the width of the LV, ensuring that it was parallel to the mitral annulus to avoid over-
estimating the size of the internal cavity.  The LVIDd was measured on the R wave (at the 
point when the internal diameter was at its widest) and the LVIDs was measured at the end of 
the T wave (at the point when the internal diameter was at its narrowest).  In cases where the 
LV was off-axis the measurements were drawn on a 2-D image.  Fractional shortening was 
then calculated using the below equation:  
FS= LVIDd- LVIDs/ LVIDd x 100 
Parameters used to assess diastolic function  
E wave, deceleration time and E/e’.  The E wave is the measurement of the peak velocity of 
the mitral valve inflow.  It is obtained by measuring the speed of blood through the mitral 
valve, using pulsed-wave Doppler at the mitral valve tips.  The peak of the E wave is 
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measured as the E Vmax and the downwards slope of the E wave Doppler trace is measured 
as the deceleration time.  To calculate E/e’, the E Vmax is divided by the TDI derived e’, 
which is obtained as described above.  
E/Vp.  Vp is a measure of the speed of blood as it goes from mitral valve to apex.  This was 
obtained by placing colour Doppler with the Nyquist limit baseline brought up to 40 cm/s, 
over the left ventricle and mitral valve.  Colour M-mode was then passed through the mitral 
valve to the apex, with the sweep speed set to 100 mm/s, so that speed of colour through the 
left ventricle was demonstrated as a colour m-mode trace.  The slope of the blue element was 
measured, which determined the speed of blood flow in early diastole from the mitral tips to 
the apex.  The E Vmax peak was then divided by the Vp slope to obtain E/Vp.  
Pulmonary Venous Doppler.  An optimised image of the left atrium was obtained and then the 
probe was angled to bring the pulmonary vein’s orifices into view, this was facilitated with 
colour Doppler.  Pulsed wave Doppler was then applied to the orifice of the pulmonary veins.  
This generated a trace in which if available the initial upwards wave was measured as systolic 
flow (usually at the point of the T wave) and the second upwards deflection as diastolic flow 
(usually just before the R wave during diastasis).  The downwards slope of the diastolic wave 
was measured as the diastolic deceleration time.  
Isovolumic Relaxation Time (IVRT).  This was obtained by placing the sample volume for 
pulsed wave Doppler where the LVOT blood flow and mitral valve inflow, so that the LVOT 
and E wave Doppler trace could be seen on the same acquisition.  The sweep speed was 
extended to 100 mm/s to make it easier to measure the interval more easily.  IVRT was 
measured as the time between the offset of the LVOT trace and inflow of the mitral valve E 
wave.   
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LA biplane volume and left atrial ejection fraction.  Images of the left atrium in the apical 2 
and 4 chamber were optimised, ensuring to not fore-shorten its size.  The image was then 
frozen and the frame was scrolled back to end-systole (just before the mitral valve opens), so 
that the left atrium was at its biggest.  Then using the Simpson’s area-length volume method, 
the internal boarder of the left atrium was traced using planimetry which generated a volume.  
To measure left atrial ejection fraction (LAEF), the frame was scrolled to end-diastole (just 
after the mitral valve closes), when the LA is at its smallest.  LAEF was then calculated using 
the equation: LAEF= (LA volume(end-systole) – LA volume (end-diastole))/ LA volume(end-systole) x 
100.       
3.3.5  NTproBNP and other blood tests 
At baseline, 6 months and 12 months all patients had their NTproBNP (ng/l) measured.  This 
is a biomarker used to assess heart strain and so elevated levels are indicative of heart failure.   
Venous peripheral blood was taken and NT-proBNP was measured on the Abbott Alinity 
analyser, in a UKAS accredited clinical laboratory following manufacturer’s standard 
operating procedure biochemistry laboratory for analysis.  Other blood biomarkers recorded at 
baseline were: potassium, sodium, urea, creatinine, eGFR, calcium, phosphate, magnesium, 
albumin, haemocrit, haemoglobin and INR (if the patient was taking warfarin).   
3.3.6  Quality of life assessment  
The patient was questioned on how their AF and heart failure affected their daily life; from 
this it was possible to classify their European Heart Rhythm Association (EHRA) and New 
York Heart Failure Association (NYHA) class.  EHRA score was used to determine how the 
symptoms of AF (palpitations, breathlessness, dizziness and fatigue) affect the patient’s 
quality of life: 
1: None; AF does not cause any symptoms 
116 | P a g e  
 
2a: Mild; normal daily activity not affected; patient not troubled by symptoms 
2b: Moderate; normal daily activity not affected; patient troubled by symptoms 
3: Severe; normal daily activity affected by symptoms relating to AF 
4: Disabling; normal daily activity discontinued  
The severity of breathlessness was determined by the NYHA functional class score: 
 I:  No limitation of physical activity.  Ordinary physical activity does not cause undue 
fatigue, palpitation or dyspnoea. 
II:  Slight limitation of physical activity. Comfortable at rest.  Ordinary physical activity 
results in fatigue, palpitation or dyspnoea. 
III:  Marked limitation of physical activity. Comfortable at rest.  Less than ordinary activity 
causes fatigue, palpitation or dyspnoea. 
IV:  Unable to carry out any physical activity without discomfort.  Symptoms of heart failure 
at rest.  If any physical activity is undertaken, discomfort increases. 
Patients were asked to complete the quality of life questionnaires: SF-36, EQ-5D-5L & 
AFEQT (appendices 7-9).  The SF-36 questionnaire assesses general health (appendix 7).  It 
is divided in to the following domains: Physical functioning (10 questions), role limitations 
due to physical health (4 questions), role limitations due to emotional problems (3 questions), 
Energy/fatigue (4 questions), Emotional well-being (5 questions), Social functioning (2 
questions), Pain (2 questions) and General health (5 questions).  Each answer to the question 
has a weighted value which is transformed to a percentage.  The overall score is calculated on 
a scale of 0-100; a higher percentage suggests a better level of health.(169)  
EQ-5D-5L also assesses general health (appendix 8).  It consists of a descriptive system of 
questions divided into: mobility, self-care, usual activities, pain/discomfort, 
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anxiety/depression.  Each question has five possible answers, of which the patient must only 
choose one defined as: (1) “no problems”, (2) “slight problems”, (3) “moderate problems”, (4) 
“severe problems”, and (5) “extreme problems”.  It also has an analogue scale which asks the 
patient to score their health out of 0-100; 0 being the “worst health you can imagine” and 100 
being the “best health you can imagine”. 
The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire aims to assess the 
impact of atrial fibrillation on patients’ quality of life (appendix 9).  The questionnaire is split 
into four sections: questions 1-4 assesses patient symptoms, 5-12 assesses effect on daily 
activities and questions 13-18 assesses treatment concerns.  Each question has multiple choice 
answers on a scale of 1-7 (1 being “not at all” and “7” being extremely).  Scores are 
transformed as follows into a score out of 100; the higher the transformed the score the less 
AF affects the patients’ quality of life (Table 13).   
Table 13. Transformation of raw scores from AF-EQT questionnaire 








3.3.7  Functional and cognitive assessment 
To assess the patient’s cognitive function the patient was asked a series of questions and tasks 
to perform from the mini-mental state examination (appendix 10).  The functional capacity 
was assessed by asking the patient to attempt the 6 minute walk test and also by completing a 
the IPAQ scoring system(170) in which the patient was asked: 
 Number of minutes they spend sitting down during a week day based on the last 7 
days 
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 Number of days they have walked for more than 10 minutes at a time in the last 7 
days 
 Total number of minutes spent walking in the last 7 days 
 Number of days they have done moderate physical activity in the last 7 days, defined 
as “making them breathe somewhat harder than normal and may have included 
carrying light loads, bicycling at a regular pace, or doubles tennis”  
 Total number of minutes spent doing moderate physical activity in the last 7 days 
 Number of days they have done vigorous physical activity in the last7 days, defined 
as “activities that made them breathe much harder than normal and may include 
heavy lifting, digging, aerobics, or fast bicycling. 
 Total number of minutes spent doing vigorous physical activity 
6 minute walk test 
All baseline patients attempted the 6 minute walk test to measure exercise tolerance.  The 
patients were asked to walk up-and-down between two points measuring 30 metres apart for 
up to 6 minutes.  The patient was instructed to continue walking until told to stop at 6 
minutes, unless the patient felt they no longer could continue, at which point the stopwatch 
was stopped and the distance and duration of walking at that point was measured.  As soon as 
the test ended, the patient’s heart rate was measured by taking a manual radial pulse to get the 
peak heart rate on exertion.  The following information was recorded: 
 Time walking (minutes:sec) 
 Distance travelled (metres) 
 Peak heart rate (beats per minute) 
o (if applicable) Reason for wanting to stop before 6 minutes: 
 Breathless 




 Chest pain  
 Other pain e.g. joint pain 
 Other (please specify) 
 1 
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3.4  Up-titration Visit and 24hr ambulatory ECG 
Following the patients baseline visit up to four weeks later the patient came back for their up-
titration visit.  The aim of this visit was to assess the patient’s heart rate and symptoms to see 
whether the patient’s rate control medication dose needed to be adjusted.  The following 
procedures were carried out: 
1. Assessment of any adverse events: A consultation with the patient to determine whether 
they have had any adverse symptoms related to the medication, which was recorded in the 
Up-titration CRF (Appendix 11)  In the case of a serious adverse event, this was reported 
using the serious adverse event form (Appendix 12) and sent  to the sponsor (Birmingham 
Clinical Trials Unit) within 24 hours.   
2. Compliance assessment: Patients were asked if they had taken their medication as directed 
on a daily basis.  If the patient had not been compliant, the percentage compliance was 
calculated according to how many doses the patient recalls missing. 
3. Vital signs and patient demographics: As described at baseline an ECG was performed, 
patient’s weight, two consecutive blood pressures and a radial and apical pulse rate 
assessment were measured.  For patients taking digoxin a blood test was taken to record 
their digoxin level. 
4. Quality of Life and functional capacity questionnaires were given to the patient to 
complete as described at baseline. 
5. A symptom directed physical examination was carried out by the consultant cardiologist.    
6. Medications were reviewed by the consultant cardiologist and adjusted accordingly.  A 
sequential up-titration appointment was arranged if medication was changed at their up-
titration visit. 
7. Once the patient was on the optimal medication for rate control, a date was arranged to fit 
a 24hr ambulatory ECG to them.
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3.5  6 month Protocol 
 At the patient’s 6 month visit the following procedures were carried out: 
1.  As described at baseline the patients answered quality of life questionnaires and had a 
cognitive and functional capacity assessment. 
2.   As described at up-titration any adverse events were recorded in the CRF (appendix 13) 
and serious adverse events reported to the sponsor.  
3.  As described at baseline the patient’s current medication and rate-control medication were 
recorded. 
4.  Blood samples were taken as described at baseline with the addition of digoxin level 
5.  Vital signs and patient demographics: As described at baseline an ECG, two consecutive 
blood pressures and a radial and apical pulse rate assessment.  The patient’s weight and waist 
circumference were also measured.  The consultant cardiologist carried out a physical 
examination and recorded any signs of heart failure in the CRF.  
6.  As described at their baseline visit the patient underwent a 6 minute walk test 
7.  Any visits the patient had to their GP practice and whether or not it was cardiovascular or 
AF related were recorded 
3.6  12 month Protocol  
At the patient’s 12 month visit the same procedures as stated at 6 months were performed, 
with the addition of an echocardiogram.  All patients at their 12 month visit underwent an 
echocardiogram to assess for any changes in systolic or diastolic function.  The same protocol 
listed in Table 12 was carried out with the exception of extra measurements taken for intra 
and inter-operator reproducibility.  At the end of the visit the patient was thanked for their 
contribution in the trial and the consultant cardiologist wrote to their GP giving advice on 
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how to continue their treatment for atrial fibrillation.  At the time of writing of this thesis, all 
160 patients had completed their 12-month visits and the final database for the RATE-AF trial 
was locked in preparation for data analysis by the BCTU statistics team.  All results in this 
thesis relate to the baseline trial data.
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3.7  Analysis Plan 
All echocardiographic data were stored in Excel (version 2010) and all statistical analysis was 
carried out in STATA (version 14).  A summary of all statistical tests used are summarised in 
Table 14. 
3.7.1 The index beat vs averaging consecutive beats 
i) To assess the variability within index beats vs averaging 3, 5 and 10 
consecutive beats 
This will be assessed in the following echocardiographic parameters: Simpson’s biplane 
LVEF, GLS and E/e’.  As stated in the protocol, a minimum of 30 measurements will be 
taken for each parameter.  From this data three index beats will be measured and then sets of 
3, 5 and 10 consecutive beats.  A coefficient of variation using the formula: √exp(σ2)-1 x100 
(with σ = the standard deviation) will be used to assess the variability within the beats 
measured.  The measuring method with the lowest coefficient of variation will have the 
lowest variability.  To test for differences in coefficient variation between the measuring 
methods a Wilcoxon signed rank test will be used with a p value ≤0.05 considered statistically 
significant.    
ii) To assess the inter and intra-operator reproducibility of the index beat 
vs averaging 3, 5 and 10 consecutive beats  
 
This will be assessed in the following parameters: E/e’ and GLS.  For intra and inter-operator 
reproducibility the first measurement taken using the a single index beat and the average of 3, 
5 and 10 beats, will be compared with the operators second set of measurements taken using a 
single index beats and the average of 3, 5 and 10 beats.  Bland and Altman analysis will be 
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used to assess the agreement between the two sets of: index beats and average of 3, 5 and 10 
beats.  
Further analysis will be carried out using a mixed effects multi-level linear regression model 
adjusting for the patient and measurement time.  From this the intra class correlation 
coefficient will be derived along with 95% confidence intervals for each of the four 
measurement methods.     
iii) Time taken to measure on an index beat verses averaging consecutive 
beats 
Time was measured in seconds for the total amount of time taken to measure E/e’ using a 
single index beat and average of 5 and 10 consecutive beats.  The mean time taken for each 
measuring method was calculated and differences in time were compared using a paired t-test.  
3.7.2  The Validity of systolic and diastolic parameters measured by the index beat 
(i) NTproBNP/AFEQT/PCS vs Systolic and diastolic parameters measured 
using the index beat and average of 3, 5 and 10 beats 
Baseline NT-pro-BNP/AFEQT/PCS will be correlated with LVEF, GLS and E/e’ measured 
by the average of three index beats and the average of three, five and ten consecutive beats 
using a Spearman’s correlation coefficient.  Histograms were plotted to identify variables that 
were not normally distributed; skewed variables were transformed to their Log2 value.  
Univariate linear regression analysis was carried out initially, followed by step-wise multi-
variate linear regression.  Co-variables with a p value <0.1 were included in the model.    
ii)    Difference in validity between the index beat and conventional 
averaging of 3, 5 and 10 beats 
To determine whether there was a significant difference in the strength of correlation between 
the different measuring methods (average of three index beats verses average of 3, 5 and 10 
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consecutive beats) the difference in correlation coefficients was tested using the corcor 
function in STATA.  A two-sided p value of ≤0.05 was considered to show a statistically 
significant difference. 
Table 14.  Summary of all statistical tests used 
Results chapter Statistical test Where it was used? 
Chapter 4 Mean (±standard deviation) The patient demographics and time 
taken to obtain measurements 
Median (IQR) The patient demographics  
Coefficient of Variation Variability within index beats vs 
average of 3, 5 and 10 consecutive 
beats 
Bland and Altman analysis  Inter and intra observer variability 
of index beats vs average of 3, 5 and 
10 consecutive beats 
Mixed effects multi-level linear 
regression analysis 
Inter and intra observer variability 
of the index beat vs average of 3, 5 
and 10 consecutive beats, adjusting 
for the patient. 
Paired T-test To test difference between time 
taken to obtain measurements 
Chapter 5 Spearman’s Correlation  Correlation between systolic 
parameters and diastolic parameters 
vs NT-pro-BNP and physical 
component score 
Linear regression To determine the beta coefficient of 
how LVEF, GLS and E/e’ predicts 
NTproBNP, AFEQT score and the 
PCS. 
Step-wise multiple variable 
linear regression 
To determine the beta coefficient of 
how LVEF, GLS and E/e’ predicts 
NTproBNP, AFEQT score and the 
PCS, when adjusting for the co-
variables  
Correlation of correlation 
coefficients  
To assess whether there is a 
significant difference between 
correlations made using the index 
beat, average of 3, 5 and 10 beats 
with NTproBNP and patient 
symptoms 
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Chapter 4.  A simple method to improve the 
reproducibility of echocardiography in patients with atrial 
fibrillation 
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4.1  Introduction 
Echocardiography is an important component of atrial fibrillation (AF) management, 
including stratification of stroke risk, rate and rhythm control, and the identification of heart 
failure.(3) Around 50% of patients with AF have or will develop heart failure (21, 22), but 
assessment of systolic and diastolic function are challenging in AF due to the irregular R to R 
interval.  Current guidelines recommend averaging 5 to 10 consecutive beats (171-173), 
although there is no evidence-base behind this decision and multiple beat analysis is time 
consuming and may not be appropriate in the context of AF.(37) Accurate and reproducible 
measurement of systolic and diastolic function is essential so that heart failure can be 
correctly classified and managed appropriately.   
 
The index beat method has been suggested as a more physiological approach for 
echocardiography in the context of AF for many decades, (12)  (154) following small animal 
and human studies beginning in the 1970’s.  It was found that there was a relationship 
between the length of R to R interval and left ventricular systolic function and 
contractility.(174)   It was found that the preceding R to R interval (RR1) is positively 
correlated and the pre-preceding R to R interval (RR2)is negatively correlated to contractility 
as measured by end-systolic LV maximal elastance (Emax).  Therefore the length of RR1 and 
RR2 were found to contribute significantly to the Emax, whereas the R to R intervals preceding 
RR1 and RR2 were found to not contribute significantly.(175)  The influence of the R to R 
interval on contractility is believed to be caused by preload (as a result of the Frank Starling 
mechanism) and uptake of calcium during the relaxation phase.  Calcium is released in 
response to an action potential, which is taken up by the contractile elements activating 
mechanical contraction.  Relaxation occurs when the calcium is removed from the cell by 
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either being transported across the membrane out of the cell or taken up into storage 
compartments.  This is assumed to be a time dependent process and so the longer the R to R 
interval the more time for calcium to be taken up and so more would be released in response 
to the sequential action potential, triggering a greater force of contraction.(176)  As 
ventricular filling and stroke volume for a particular beat are determined by the previous two 
R to R intervals, the index beat method selects a cardiac cycle for analysis where the 
preceding (RR1) and pre-preceding (RR2) R to R interval are of similar duration (that is, the 
ratio of these intervals is approximately one), see Figure 25 for an example of an index beat.  
Figure 25.  Measurement of Mitral E wave Vmax on an index beat (blue arrow) by 
selecting the beat which follows a preceding and pre-preceding R to R interval within 60 
ms of each other (red arrows)   
 
However, current guidelines continue to recommend averaging of 5 to 10 consecutive 
beats.(171-173)  The aim of this study was to systematically compare the reproducibility of an 
index beat approach compared to conventional averaging of three, five and ten beats.  There 
was complete blinding of patients and measurements, and without any pre-selected exclusion 
Index 
beat 
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of patients for image quality as is typical in other studies.  It was hypothesised that the index 
beat method would be more reproducible and efficient, facilitating better management of 
patients with AF.    
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4.2  Method 
4.2.1 Patient population 
All patients enrolled in the RAte control Therapy Evaluation in permanent AF (RATE-AF) 
randomised controlled trial were included after written informed consent (NCT02391337).  
The trial has received favourable ethical review from the UK Heath Research Authority (East 
Midlands - Derby Research Ethics Committee; 16/EM/0178) and has oversight from a Trial 
Steering Committee and Data Monitoring Committee with independent chairs.  Rationale and 
methods for the RATE-AF trial have previously been described in chapter 3(163); in brief, 
patients in the National Health Service aged 60 years or older with permanent AF and 
symptoms of heart failure (New York Heart Association class II or above) were randomised 
to digoxin or beta-blockers for initial rate control of AF.  Permanent AF was defined as a 
physician decision for rate control and no plans for any antiarrhythmic drugs or intervention.  
Patients were excluded if their heart rate was less than 60 beats/min, or had prior evidence of 
second or third degree heart block.  Other exclusion criteria were minimised to enable 
generalisable ‘real-world’ results.  The trial was publically funded by the UK National 
Institute for Health Research (NIHR).   
 
4.2.2  Echocardiography 
12-lead electrocardiograms confirmed the presence of AF.  All patients then underwent 
transthoracic echocardiography using a Philips EPIQ 7 and X5-1 transducer.  All 
echocardiograms were performed by an experienced echocardiographer accredited with the 
British Society of Echocardiography.  Patients were positioned in the left lateral decubitus 
position and images were acquired during quiet respiration according to an echocardiography 
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protocol written and ratified prior to the trial commencing (the full protocol is described in 
chapter 3).   
A minimum of 30-beat loops were obtained of the apical 2, 3 and 4-chambers.  All images 
were optimised to maximise frame rate while still ensuring all left ventricular segments were 
visible.  A minimum of 30 traces of Tissue Doppler derived lateral and septal e’ were 
obtained; care was taken to ensure that the lateral and septal annulus was aligned 
perpendicular to the ultrasound beam in order to minimise the angle of incidence.  A 
minimum of 30 traces of mitral inflow using pulse wave Doppler were also acquired, with 
colour Doppler used to ensure the sample volume was placed at the level of the mitral leaflet 
tips within the inflow.  The recorded images were unlabelled and had no identifiable features. 
All measurements were analysed offline by the same operator a minimum of 6 months after 
the scan date.  The operator was blinded to any identifiable patient, trial or clinical details by a 
process of assigning each echocardiogram a unique random code.  There were no predefined 
exclusions made for quality of imaging; all patients were included to minimise selection bias.  
All analyses were performed on Philips Q-station (version 3.5; Philips Healthcare, Andover, 
Massachusetts).  For left ventricular ejection fraction (LVEF), Simpson’s biplane LVEF was 
measured from the apical 4 and 2-chamber views.  Longitudinal strain was taken from the 
apical 2, 3 and 4-chamber views and then averaged to generate overall global longitudinal 
strain (GLS).  The mean frame rate for GLS acquisition was 57 Hertz (SD 7.0).  For E/e’, 
mitral valve peak E velocity was measured and then divided by the tissue Doppler imaging 
(TDI)-derived e’ (averaged from the lateral and septal walls).  
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4.2.3  Index beat and conventional averaging method 
The index beat was identified as the cardiac cycle which followed a preceding and pre-
preceding R to R interval of similar duration (within 60 ms of each other; Figure 26).  
 Figure 26.  Measuring the mitral valve E max using conventional averaging of 
consecutive beats verses the index beat method.  Mitral valve inflow E max measured on 
the index beat (top); the beat with similar preceding and pre-preceding R to R intervals 
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R to R intervals were measured using a calliper in the reporting software and according to the 
velocity of acquisition of the corresponding electrocardiogram (1cm was equal to 200ms).  
The index beats were selected consecutively from the beginning of each set of 
echocardiogram data to avoid any selection bias.  Conventional analysis involved using 
consecutive beats to obtain the average of 3, 5 and 10 cardiac cycles. 
4.2.4  Intra-operator reproducibility 
At the end of the echocardiogram the same operator immediately afterwards, repositioned the 
patient and took a second set of 10 images of the left ventricle in the apical 2, 3 and 4 
chamber and second set of 10 traces of mitral valve peak E velocity and the TDI-derived e’ 
(averaged from the lateral and septal walls).  These images (using methods described above) 
were then analysed to measure GLS and E/e’ using a single index beat and average of 3, 5 and 
10 beats.  These measurements were compared with the operator’s initial measurements of 
GLS and E/e’ using a single index beat and average of 3, 5 and 10 beats to assess intra-
operator reproducibility. 
4.2.5  Inter-operator reproducibility and time comparison 
Similar to the intra-operator protocol, a second accredited operator obtained a second set of 10 
images of the left ventricle in the apical 2, 3 and 4 chamber and second set of 10 traces of 
mitral valve peak E velocity and the TDI-derived e’ (averaged from the lateral and septal 
walls.  The second operator’s measurements of GLS and E/e’ using a single index beat and 
average of 3, 5 and 10 beats were compared with the operator’s initial measurements of GLS 
and E/e’ to assess inter-operator reproducibility.  
A second accredited operator re-analysed the E/e’ images in 18 randomly selected patients for 
assessment of inter-operator reproducibility.  The operator was blinded to the previously 
recorded measurements as well as all clinical details of each echocardiogram.  The time taken 
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for the second operator to select and measure E/e’ using a single index beat and guideline-
recommended 5 and 10 consecutive beats was recorded, with time commencing from the first 
visualisation of Doppler images.      
4.2.6  Statistical analysis 
Summary results are presented as percentage, mean with standard deviation or median with 
interquartile range (IQR; displayed as 25th to 75th quartiles).  All echocardiographic 
measurements were transformed to their natural log value to assess within beat variability.  
The coefficient of variation within three index beats and within each set of consecutive beats 
(3, 5 and 10) was calculated using the following formula √exp(σ2)-1 x100, where σ is the 
standard deviation within the set of beats.  A Wilcoxon signed rank test was used to compare 
the differences in coefficient of variation between the index beat method and 3, 5 and 10 
consecutive beats.  Statistical analysis was performed using Stata (version 14.2; StataCorp, 
Texas, USA); a 2-tailed p value of ≤0.05 was considered statistically significant.  For intra- 
and inter-operator reproducibility, Bland and Altman analysis was carried out to obtain the 
mean bias and the limits of agreement.  A mixed effects multi-level linear regression model 
was also used for intra and inter-operator reproducibility; adjusting for the random effects of 
the patient and measurement time.  From the model the intraclass correlation (ICC; with 95% 
confidence interval) was calculated at the patient level for each measurement method.  The 
average time taken to measure E/e’ (SD) was calculated and paired t-test was used to compare 
the time taken between measuring methods; a p-value ≤0.05 was considered significant. 
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4.3  Results 
One hundred and 60 patients were included, with median age of 75 years (IQR 69-82), heart 
rate of 96 beats/minute (86-112) and blood pressure of 134/84 mmHg (IQR 123/76-148/93), 
see Table 15.   
Table 15.  Baseline Demographics of patients at baseline echocardiogram    
Characteristic n= 160 
Age, median years (IQR) 75 (69-82) 
Women, n (%) 74 (46.3%) 
Years in AF, mean years (SD)  3.8 (6.2) 
EHRA score 3/4, n (%) 77 (48.1%) 
Previous heart failure clinical diagnosis, n (%) 59 (36.9%) 
Signs of heart failure at randomisation, n (%) 84 (52.5%) 
NYHA class III/IV, n (%)  61 (38.1%) 
Previous myocardial infarction, n (%) 13 (8.1%) 
Previous stroke, n (%) 19 (11.9%) 
Previous TIA, n (%) 15 (9.4%) 
COPD, n (%)  29 (18.1%) 
Diabetes mellitus, n (%) 38 (23.8%) 
Previous rhythm control, n (%) 23 (14.4%) 
Heart rate, median bpm (IQR) 96 (86-112) 
Systolic BP, median mmHg (IQR) 134 (123-148) 
Diastolic BP, median mmHg (IQR) 84 (76-93) 
Body mass index, median kg/m
2
 (IQR) 30 (26-34) 
NTproBNP, median pg/mL (IQR) 1057 (744-1522) 
Estimated GFR, median mL/min (IQR) 67 (55-77) 
Anticoagulant medication, n (%) 135 (84.4) 
Antiplatelet medication, n (%) 9 (5.6%) 
Antihypertensive medication, n (%) 116 (72.5%) 
Inhalers for airways disease, n (%) 40 (25.3%) 
Abbreviations: AF= atrial fibrillation; BP= blood pressure; COPD= chronic obstructive 
pulmonary disorder; EHRA= European Heart Rhythm Association; GFR= glomerular 
filtration rate; NTproBNP= N-terminal pro-B type natriuretic peptide; NYHA= New York 
Heart Failure Association functional classification; TIA= transient ischaemic attack 
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Median LVEF was 59% (IQR 52-64), GLS -14 (IQR -12 to -15) and E/e’ 9.4 (IQR 7.8-11.7); 
18 patients had insufficient image quality for LVEF measurement and 21 patients for GLS, 
this was predominantly due to patient body habitus (mean BMI= 38 kg/m2) and COPD (33%, 
n=6).  Other echocardiogram parameters of interest are summarised in Table 16.   
Table 16: Echocardiography parameters 
Echocardiographic measurement 
Baseline  
Left ventricular end diastolic volume, median ml (IQR)*  76 (57-99) 
Left ventricular end systolic volume, median ml (IQR)* 30 (22-42) 
Stroke volume, median ml (IQR)*  55 (45-64) 
Left ventricular ejection fraction, median % (IQR) * 59 (52-64) 
Global longitudinal strain, median % (IQR)* -14 (-12 to -15) 
Lateral s’, median cm/s (IQR)* 6.7 (5.6-7.9) 
Septal s’, median cm/s (IQR)* 6.1 (5.1-7.2) 
Average e’, median cm/s (IQR)* 9.3 (8.1-10.9) 
Mitral E velocity, median cm/s (IQR)*  89.7 (77.1-102.8) 
Mitral deceleration time, median ms (IQR)* 212 (188-234) 
Average E/e’, median (IQR)*   9.4 (7.8-11.7) 
Isovolumic relaxation time, median ms (IQR)  97 (89-108) 
Pulmonary vein ratio, mean (SD)   0.7 (0.1) 
Pulmonary vein deceleration time, median (IQR) 242 (223-258) 
Left atrial volume indexed to BSA, median ml/m2 (IQR) 38 (32-49) 
Left atrial ejection fraction, median % (IQR) 23 (15-33) 
TAPSE mm, median (IQR) 18.7 (17.1-21.8) 
* based on average of 3 index beats.  18 patients had insufficient image quality for a 
Simpson’s biplane LVEF measurement and 21 patients had insufficient image quality for 
GLS.   
Abbreviations: IQR= inter-quartile range; TAPSE= tricuspid annular plane systolic excursion  
  
137 | P a g e  
 
4.3.1  Within beat coefficient of variation  
LVEF- The index beat approach had the smallest coefficient of variation (Confidence interval 
95%) for LVEF of 23% (21-24), compared to 45% (42-48) for the 3 consecutive beats, 45% 
(43-48) for 5 consecutive beats and 48% (46-50) for 10 consecutive beats (Figure 27 and 
Table 17).  The difference between the coefficient of variation using the index beat and 3, 5 
and 10 consecutive beats was found to be statistically significant, p=<0.001.  For measuring 
on the index beat the mean RR2 (pre-preceding R to R interval) was 552 ms and the mean 
RR1 (preceding R to R interval) was 555 ms with a mean RR1/RR2 ratio of 1.00.  
GLS: The index beat approach had  the smallest coefficient of variation (Confidence interval 
95%) of 34% (32-36) compared to 51% (42-59) for of 3 consecutive beats, 55% (48-61) for 5 
consecutive and 57% (56-63) for 10 consecutive beats (see Figure 27 and Table 17).  The 
difference between the coefficient of variation using the index beat and 3, 5 and 10 
consecutive beats was found to be statistically significant, <0.001.  For measuring on the 
index beat the mean RR2 was 568 ms and the mean RR1 was 570 ms with a mean RR1/RR2 
ratio of 1.00. 
E/e’: The index beat approach had the smallest coefficient of variation (Confidence interval 
95%) of 34% (32-36), compared to 53% (49-56) for 3 consecutive beats, 59% (56-63) for 5 
consecutive beats and 61% (58-64)for 10 consecutive beats (see Figure 27 and Table 17).  
The difference between the coefficient of variation using the index beat and 3, 5 and 10 
consecutive beats was found to be statistically significant, <0.001.  For measuring on the 
index beat the mean RR2 was 653 ms and the mean RR1 was 655 ms with a mean RR1/RR2 
ratio of 1.00
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Table 17. Coefficient of variation for within beat variability of the three index beats verses 3, 5 and 10 consecutive beats  
 3 index beats   3 consecutive beats 5 consecutive beats  10 consecutive beats 
 CV (%) (95% 
Conf. Interval) 
CV (%) (95% 
Conf. Interval) 
Difference from 
three index beats 
z (p value) 
CV (%) (95% 
Conf. Interval) 
Difference from 
three index beats 
z (p value) 
CV (%) (95% 
Conf. Interval) 
Difference from 
three index beats 
z (p value) 
LVEF  23 (21 to 24) 45 (42 to 48) -9.59 (p<0.001) 45 (43 to 48) -10.17 (p<0.001) 48 (46 to 50) -10.28 (p<0.001) 
GLS 34 (32 to 36) 51 (42 to 59) -5.67 (p<0.001) 55 (48 to 61) -8.41(p<0.001) 57 (52 to 61) -9.30(p<0.001) 
E/e’ 34 (32 to 36) 53 (49 to 56) -8.37 (p<0.001) 59 (56 to 63) -10.25 (p<0.001) 61 (58 to 64) -10.69 (p<0.001) 
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Figure 27.  Within beat variability of three index beats, 3, 5 and consecutive beats.  A bar 
chart displaying the coefficient of variation for within beat variability of LVEF Simpson’s 
biplane, GLS and E/e’ using three index beats, 3, 5 and 10 consecutive beats.  Abbreviations: 
LVEF= Left ventricular ejection fraction; GLS= global longitudinal strain. 
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4.3.2  Intra and inter-operator reproducibility 
Intra-operator reproducibility of a single index beat method verses average of 3, 5 and 10 beat 
method was tested in 50 patients using the parameters GLS and E/e’.  Their median age was 
79 years (IQR 73-85), heart rate 96 beats/min (IQR 90-107) and blood pressure 134/80 
mmHg (IQR 123-146/ 75-86), see Table 18.  For GLS the index beat method had the smallest 
bias and narrow limits of agreement, -0.5 (-3.6 to 2.6) compared to the conventional 
averaging of 3 beats -1.1 (-4.8 to 2.7), 5 beats -1.1 (-4.4 to 2.3) and 10 beats -1.0 (-4.0 to 2.0) 
(Figure 28).  The index beat method also had the highest ICC with reasonable confidence 
intervals 0.82 (0.72 to 0.90), followed by the average of 10 beat method 0.80 (0.68 to 0.88), 
then average of 5 beats 0.76 (0.63 to 0.86) and average of 3 beat method 0.75 (0.61 to 0.85), 
see Table 19. 
Similar findings were also seen for E/e’, with the index beat method having the smallest bias 
and similar limits of agreement to the average of 10 beat method; -0.2 (-4.2 to 3.9) for the 
index beat method and -0.4 (-4.2 to 3.4) for the average of 10 beats.  Whereas the intra-
operator reproducibility of averaging 3 and 5 beats had a higher bias and wider limits of 
agreement; -0.7 (-6.2 to 4.8) and -0.6 (5.3 to 4.2) respectively (Figure 28).  The index beat 
method had the highest ICC with narrow confidence intervals 0.91 (0.84 to 0.95), followed by 
the average of 10 beat method 0.88 (0.80 to 0.93), average of 5 beat method 0.80 (0.68 to 
0.88) and average of 3 beat method 0.74 (0.60 to 0.85), see Table 19.  
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Table 18.  Baseline demographics of patients included in the intra and inter-operator 
reproducibility study  
Characteristic 








Age, median years (IQR) 75 (69-82) 79 (73-85) 74 (66-84) 
Women, n (%) 74 (46%) 25 (50%) 8 (44%) 
Years in AF, mean years (SD)  3.8 (6) 3.2 (6) 4.3 (8) 
EHRA score 3/4, n (%) 77 (48%) 22 (44%) 8 (44%) 
Previous heart failure clinical diagnosis, n (%) 59 (37%) 13 (26%) 5 (28%) 
Signs of heart failure at randomisation, n (%) 84 (53%) 27 (54%) 10 (56%) 
NYHA class III/IV, n (%)  61 (38%) 21 (42%) 8 (44%) 
Previous myocardial infarction, n (%) 13 (8%) 3 (6%) 2 (11%) 
Previous stroke, n (%) 19 (12%) 5 (10%) 0 (0%) 
Previous TIA, n (%) 15 (9%) 8 (16%) 0 (0%) 
COPD, n (%)  29 (18%) 8 (16%) 3 (17%) 
Diabetes mellitus, n (%) 38 (24%) 12 (24%) 5 (28%) 
Previous rhythm control, n (%) 23 (14%) 7 (14%) 4 (22%) 
Heart rate, median bpm (IQR) 96 (86-112) 96 (90-107) 99 (93-113) 
Systolic BP, median mmHg (IQR) 134 (123-148) 134 (123-146) 132 (125-152) 
Diastolic BP, median mmHg (IQR) 84 (76-93) 80 (75-86) 81 (76-86) 
Body mass index, median kg/m
2
 (IQR) 30 (26-34) 29 (27-33) 29 (26-34) 







Estimated GFR, median mL/min (IQR) 67 (55-77) 67 (55-73) 70 (52-83) 
Anticoagulant medication, n (%) 135 (84%) 40 (80%) 14 (78%) 
Antiplatelet medication, n (%) 9 (6%) 2 (4%) 1 (6%) 
Antihypertensive medication, n (%) 116 (73%) 37 (74%) 14 (78%) 
Inhalers for airways disease, n (%) 40 (25%) 7 (14%) 2 (11%) 
Abbreviations: AF= atrial fibrillation; BP= blood pressure; COPD= chronic obstructive pulmonary disorder; 
EHRA= European Heart Rhythm Association; GFR= glomerular filtration rate; NTproBNP= N-terminal pro-B 
type natriuretic peptide; NYHA= New York Heart Failure Association functional classification; TIA= transient 
ischaemic attack
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Figure 28.  Bland and Altman plots to show GLS and E/e’ intra-operator reproducibility in 50 patients. Bland and Altman plots displaying 
intra-operator reproducibility of GLS and E/e’ measured using a single index beat (left), average of 5 beats (middle) and average of 10 beats 
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Table 19.  Intra-operator reproducibility  
 
 E/e’ Intra-operator reproducibility GLS Intra-operator reproducibility  
 Bias (limits of agreement) ICC (95% Conf. Interval) Bias (limits of agreement) ICC (95% Conf. Interval) 
Index Beat  -0.2 (-4.2 to 3.9) 0.91 (0.84 to 0.95) -0.5 (-3.6 to 2.6) 0.82 (0.72 to 0.90) 
Average of 3 beats  -0.7 (-6.2 to 4.8) 0.74 (0.60 to 0.85)  -1.1 (-4.8 to 2.7) 0.75 (0.61 to 0.85) 
Average of 5 beats -0.6 (5.3 to 4.2) 0.80 (0.68 to 0.88) -1.1 (-4.4 to 2.2)  0.76 (0.63 to 0.86) 
Average of 10 beats  -0.4 (-4.2 to 3.4) 0.88 (0.80 to 0.93) -1.0 (-4.0 to 2.0) 0.80 (0.68 to 0.88) 
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Inter-operator reproducibility was tested in 18 randomly selected patients for GLS and E/e’ 
Their median age was 74 years (IQR 66-84), heart rate was 99 beats/min (IQR 93-113) and 
blood pressure was 132/ 81 mmHg (IQR 125-152/76-86), see Table 18.  For GLS the index 
beat had the smallest bias but the widest limits of agreement -0.3 (-5.5 to 5.0), compared to 
the average of 3 beats -0.8(-5.7 to 4.1), average of 5 beats -0.7 (-5.5 to 4.1) and average of 10 
beats -0.7 (-5.3 to 3.9), see Table 20 and Figure 29.  The index beat method also had the 
lowest ICC 0.72 (0.45 to 0.88), compared to the average of 3 beats 0.74 (0.50 to 0.90), 5 beats 
0.75 (0.50 to 0.90) and 10 beats 0.77 (0.54 to 0.91).  However for E/e’ the inter-operator 
reproducibility of E/e’ was highest for the index beat with the smallest bias and narrowest 
limits of agreement -0.3 (-2.9 to 2.2), followed by the average of 10 beats with -0.9 (-6.1 to 
4.2), then average of 5 beats with -1.1 (-6.5 to 4.2) and then average of 3 beats -1.1 (-5.4 to 
3.2).  The ICC was also highest for the index beat 0.94 (0.87 to 0.98), followed by the average 
of 3 beats ICC= 0.83 (0.64 to 0.93), the average of 10 beats ICC=0.93 (0.62 to 0.93) and 
average of 5 beats ICC= 0.78 (0.56 to 0.91), see Table 20 and Figure 29. 
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Figure 29.  Bland and Altman plots to show the inter-operator reproducibility of GLS and E/e’ when using an index beat verses average 
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Table 20.  Inter-operator reproducibility  
 E/e’ Inter-operator reproducibility GLS Inter-operator reproducibility  
 Bias (limits of agreement) ICC (95% Conf. Interval) Bias (limits of agreement) ICC (95% Conf. Interval) 
Index Beat  -0.3 (-2.9 to 2.2)  0.94 (0.87 to 0.98) -0.3 (-5.5 to 5.0) 0.72 (0.45 to 0.88) 
Average of 3 beats  -1.1 (-5.4 to 3.2) 0.83 (0.64 to 0.93) -0.8 (-5.7 to 4.1) 0.74 (0.50 to 0.90) 
Average of 5 beats -1.1 (-6.5 to 4.2) 0.78 (0.56 to 0.91) -0.7 (-5.5 to 4.1) 0.75 (0.50 to 0.90) 
Average of 10 beats  -0.9 (-6.1 to 4.2)  0.82 (0.62 to 0.93) -0.7 (-5.3 to 3.9) 0.77 (0.54 to 0.91) 
147 | P a g e  
 
4.3.3  Efficiency of index beat method  
The index beat method took the least amount of time to measure E/e’ at 35.4 seconds (SD 
4.8).  This was 21% quicker than measuring E/e’ using the average of 5 beats which took 44.7 
seconds (SD 5.7; p<0.001) and 64% quicker than averaging 10 beats which took 98.1 seconds 
(SD 12.8; p<0.001); (Table 21).   
Table 21: Time taken to select and measure E/e’ using an index beat verses averaging 5 







 Average time (SD) (ms) Mean E/e’ (SD) 
Index beat 35.5 (4.8) 10.6 (4.1) 
Average of 5 beats 44.7 (5.7) 10.5 (4.4) 
Average of 10 beats 98.1 (12.8) 10.2 (4.3) 
148 | P a g e  
 
4.4 Discussion 
In this study, the index beat method has been demonstrated to be more reproducible in 
patients with AF than conventional averaging of consecutive beats for systolic and diastolic 
parameters and also saves time.  The within-beat coefficient of variability and intra/inter-
observer reproducibility were favourable using this more physiological approach to imaging 
in patients who have a variable stroke volume and filling time.  Using the index beat method 
routinely in clinical practice has the potential to improve workflow and productivity, enhance 
the reliability of echocardiography, and provide more confidence in the diagnosis and 
classification of heart failure in patients with AF.  
Heart failure is common in patients with AF, and accurate assessment of systolic and diastolic 
left ventricular function is essential for patient management.  Although current guidelines 
recommend averaging 5 to 10 consecutive beats(171, 172), this is based on consensus opinion 
and lacks reliable evidence.(177)  Measuring consecutive beats is not only time-consuming 
and extends the time taken for echocardiography, but also the average value will vary 
according to what beats are selected, making reliability in clinical practice uncertain.(154, 
178)  AF is characterised by a loss of atrial contraction and so ventricular filling relies heavily 
on the length of the R to R interval, with variation in intervals leading to considerable 
challenges to achieve reproducible measurements.(179)  In addition to cycle length, stroke 
volume is critically dependent on preload, and this is also variable in the setting of AF.(174)  
The real value of the index beat method, whereby cycles are chosen of similar length, may be 
to achieve a more physiologically appropriate measurement, be that of systolic or diastolic 
function.  In this context, the end-diastolic volume should be similar and so (via the Frank-
Starling mechanism) the contractility will also be similar, producing less variability between 
index beats for LVEF.(179-181) This will also apply to GLS, a useful parameter in detecting 
early myocardial dysfunction.(154, 182)  E/e’ a surrogate of filling pressure, is still reliant on 
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previous cycle lengths.(102, 183)  The extremely high levels of variation using a 10 
consecutive beats (CV 61% for E/e’) highlight the limitations of current guideline-
recommended practice.  
 
Intra-operator reproducibility for both GLS and E/e’ was shown to be highest when 
measuring on a single index beat or averaging 10 beats.  Previous studies assessing strain rate 
have found a strong correlation between the index beat and averages of 10 and 15 beats with 
high levels of agreement.(132, 145)  However it was found that measuring a single index beat 
was considerably quicker than measuring 10 consecutive beats, even for a technically 
straightforward measurement like E/e’.  For more technically challenging measurements(184), 
it is probable that there would be an even greater advantage in time saved.  It was also 
demonstrated that the index beat method has a high level of reproducibility between different 
operators, an important contribution to value within the clinical setting, enhancing the 
practicality of serial scans. 
 
A major concern with nearly all previous studies as identified in chapter 2 is the pre-selection 
of patients with “good echocardiography windows”.  This is the first study in which the index 
beat method has been interrogated in all patients, in this case healthcare referrals for rate 
control enrolled within a pragmatic randomised controlled trial.  The trial-based setting 
allowed ‘double-blinding’ of the imaging process, with anonymised scans stored, analyses 
performed offline with a separate random code to the study identification number, 
measurements performed 6 months after acquisition, and no data available to the operators on 
patient details or clinical status.  All patients were confirmed as being in AF at the time of 
echocardiography.  Although randomised trials are usually selective in population, the RATE-
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AF trial was designed to mimic routine practice as evidenced by the patient characteristics, 
including a median age of 75 years.  The results are therefore relevant to the real world and 
suggest the index beat method should replace the recommended averaging of 5 to 10 
consecutive beats in echocardiography guidelines.  Further study is warranted to establish the 
association with long-term adverse clinical events.  In the study, patients will undergo repeat 
echocardiography at 12 months, and then further follow-up using electronic healthcare 
outcomes.(163)  Qualitative assessment is also desirable to establish how to effectively 
introduce the index beat approach in cardiology departments and the training required to aid 
clinical productivity.   
The study was limited by non-simultaneous acquisition of Doppler and chamber images, and 
although this is currently standard practice globally, there are dual-Doppler probes available, 
which would be valuable in AF.(185)  With pressure on echocardiography services increasing 
due to growing patient populations and wider indications, the index beat method could 
provide a reproducible method for patients in AF that also increases the efficiency of 
echocardiography.       
 
4.5 Conclusion 
The index beat approach, by selecting cardiac cycles which better represent overall systolic 
and diastolic function, has clear advantages for echocardiography in patients with AF.  In a 
blinded analysis without preselection for image quality, I have shown that this method has 
better reproducibility and is quicker than conventional averaging of multiple consecutive heart 
beats.  Further analysis is required to determine the optimum length of the preceding and pre-
preceding R to R intervals chosen to measure the index beat on, to establish whether or not 
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there is a cut-off point for tachycardia and bradycardic heart rates that makes this method not 
applicable.   
Although the index beat method has been shown to be more reproducible and time efficient, it 
remains unclear as to whether using an index beat is a reflection of the overall haemodynamic 
burden on the heart. It may be that the conventional method of averaging consecutive beats 
correlates better with the other biomarkers of heart function and the clinical status of the 
patient.  The validity of the index beat method has never been compared with conventional 
averaging of consecutive beats.  In the following chapter the validity of using the index beat 
method to measure LVEF Simpson’s biplane, GLS and E/e’ by correlating it with clinical 
outcomes, (NTproBNP and patient reported quality of life) is explored.
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Chapter  5.  Validity of systolic and diastolic parameters 
versus patient quality of life and NTproBNP 
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5.1 Introduction  
Depending on type of AF 30-60% of patients are also diagnosed with some form of heart 
failure.(16)  Therefore it is essential that cardiac dysfunction is promptly diagnosed so that 
correct treatment can be initiated to improve prognosis.  The systematic review (chapter 2) 
has demonstrated a lack of information on the validity of systolic parameters in patients with 
AF.  Although there have been more validity studies for diastolic parameters, (37) the effect 
of diastolic function on clinical status and neurohormonal biomarkers of heart failure is less 
clear.  In chapter 4 the index beat was the most reproducible method of obtaining systolic and 
diastolic measurements, however it has not been validated against clinical status of the patient 
or whether it correlates accurately with the heart failure biomarker NTproBNP.  The aim of 
this study was to investigate the relationship between systolic and diastolic parameters using 
the average of three index beats and the average of 3, 5 and 10 consecutive beats with both 
patient symptoms and N-terminal pro-B-type natriuretic peptide (NTproBNP) as a biomarker 
of left ventricular dysfunction. 
5.1.1 Background of NTproBNP     
B-type natriuretic peptide (BNP) and NTproBNP are widely used as clinical indicators of 
cardiac dysfunction.  An elevated level of NTproBNP indicates a poor prognosis, increasing 
the risk of death, cardiovascular death and hospitalisation.(186)  BNP has clear utility for the 
detection of heart failure in sinus rhythm patients but the recommendations for patients in AF 
are unclear, for AF itself increases BNP levels independently of BNP status.(187)   
BNP is a cardiac hormone released from both ventricular and atrial myocytes in response to 
myocardial wall stress.(186)  The BNP gene is located on chromosome 1 and is synthesised 
under pathological conditions.  NTproBNP and BNP are synthesised in both atrial and 
ventricular myocytes (188) in response to mechanical stress (high intra-cardiac pressure or 
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increase in ventricular volume), hypoxia and neurohormonal factors.  Myocardial wall stress 
activates mechanosensors, which in turn trigger the activation of the mitogen-activated 
protein kinase (MAPK) pathway, resulting in the production of the signalling protein p38 
MAPK.  Mechanical stretch also results in the production of angiotensinogen II and 
endothelin-1 complexes, that also activate p38 MAPK via the extracellular signal regulated 
kinase (Figure 30).  p38 MAPK activates nuclear factor kappa B (NF-kB), which binds to 
shear stress responsive elements, which stimulate the BNP-gene promoter resulting in the 
transcription of the 134 amino acid pre-proBNP.  When the N-terminal of pre-proBNP is 
removed, it forms the 108 amino acid proBNP.  The convertase enzymes furin or corin then 
cleave the proBNP to form the inactive 76 amino acid NTproBNP and the active 32 amino 
acid BNP.(189)  These compounds are then released into the surrounding plasma and bind to 
the natriuretic peptide receptor A, which increases the production of cyclic Guanyl cyclase 
(cGMP).  cGMP stimulates diuresis, vasodilation, inhibition of the RAAS and increases 
cardiac and vascular myocyte growth.  Therefore, it acts to reduce intra-cardiac pressures 
within the heart (left ventricular end-diastolic pressure) and hence reduce cardiac wall 
stress.(190)  
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Figure 30.  Pathway to show the synthesis of BNP and NTproBNP (adapted from Cao Z. et al, 2019(189)) Abbreviations: BNP= brain 
naturetic peptide; cGMP cyclic guanylyl cyclase= NPR-A= natriuretic peptide receptor A; NTproBNP= N-terminal pro-brain naturetic 
peptide; ET-1= endothelin-1; ERK= extracellular signal regulated kinase MAPK= mitogen-activated protein kinase; NF-kB= nuclear 
factor kappa B; p38= protein 38; SSRE= shear stress responsive elements
Mechanical stress 
Mechanosensors activated Angiotensin II 
↑ BNP promoter activity 
↑ Pre-proBNP 
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It is known that the level of NTproBNP is elevated in patients with AF and is predominantly 
released from the atrial myocytes,(187) however the data correlating NTproBNP with systolic 
and diastolic parameters using echocardiography, in patients in AF at the time of the scan are 
limited.  A single study was identified in the systematic review (chapter 2) that validated 
systolic function in AF patients, by comparing LVEF with BNP and showed a weak 
correlation.(139)  There have been no studies comparing GLS with BNP/NTproBNP in which 
the patient was in AF at the time of the scan.    
5.1.2  Physical Component Score (PCS) 
Both AF and heart failure have a significant adverse impact on patient’s quality of life.  
However the exact relationship between symptoms and cardiac function and blood biomarkers 
such as NTproBNP remains largely unknown.(191)  The ALPHA study investigated the 
relationship between AF and functional status using the New York Heart Association 
(NYHA) score, which is a combined evaluation of dyspnoea, fatigue and palpitations.  Even 
after adjusting for age, gender, LVEF and aetiology of heart failure, the study found a greater 
likelihood of symptoms in a higher NYHA class in patients with AF compared to those with 
sinus rhythm; OR 2.5 (95% C.I. 2.08-3.00, p <0.001).(192)  
The questionnaire SF-36 is used globally to assess health-related quality of life.  It is 
composed of eight different scales measuring: physical functioning, physical role, bodily pain, 
general health, vitality, social functioning, emotional role and mental health.  From these 
eights sections, a physical component score (PCS) and mental component score can be 
calculated.(193)  The items from each component are scored on a scale and then averaged 
together; the higher score represents a superior level of health.(194)  
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5.1.3  Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire 
The AFEQT questionnaire was specifically developed to assess the effect of AF on quality of 
life and has reasonable validation compared to other questionnaires.(195)  It is divided into 
six domains around patient perception of symptom burden, social ability, physical 
functioning, emotional status, AF-specific treatment concerns and satisfaction.  Answers are 
scored on a scale of 1-7, which are transformed to a 0-100 scale.  The higher the score, the 
better the quality of life in relation to AF.(196)  
5.2  Method 
All patients recruited to the RATE-AF trial underwent baseline echocardiography to assess 
systolic and diastolic left ventricular function.  As described in chapter 4 the parameters 
LVEF by Simpson’s biplane, global longitudinal strain and the diastolic index E/e’ were 
measured using the average of three index beats and the average of three, five and ten 
consecutive beats. 
All patients had blood taken at baseline to measure NTproBNP level.  NTproBNP was 
measured in the Queen Elizabeth Hospital’s UKAS accredited clinical laboratory using the 
Abbott Alinity analyser following the manufacturer’s standard operating procedure.  To 
record patient reported quality of life, all patients answered the SF-36 quality of life 
questionnaire and AFEQT questionnaire at baseline.  Questions in SF-36 related to physical 
functioning status were summed to form the physical component score (PCS) according to the 
method published by the SF-36 group.   
5.2.1 Data synthesis and statistical analysis 
Values of LVEF, GLS and E/e’ derived from the average of three index beats, average of 3 , 5 
and 10 consecutive beats were determined using previously described methods in chapter 4.  
Histograms with a kernel density line embedded were plotted to determine whether the 
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variables’ data were normally distributed (Figure 31); NTproBNP, LVEF and E/e’ were 
skewed so these parameters were transformed to the Log value of 2 (Log2).  
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Spearman’s correlation coefficient was used to determine the association between the 
echocardiography values and NTproBNP, PCS and AFEQT score.  To determine whether 
there was a significant difference in correlation coefficients with the independent variable, 
when using  the average of three index beats, average of 3, 5 and 10 consecutive beats, the 
cross-correlation coefficient test was used (corcor).  A 2-sided p-value of ≤0.05 was 
considered a significant difference in correlation coefficients.  
Stepwise multiple linear regression was carried out for each dependent variable; for 
NTproBNP  the co-variables age, gender, years in AF, heart rate, systolic blood pressure, 
weight, creatinine, history of myocardial infarction were used.  For PCS and AFEQT score 
history of COPD/ emphysema and NTproBNP were also added to the model.  These variables 
were chosen, as clinically they are known to have an effect on these outcomes. A p-value of 
0.1 or less was used as a cut-off value to include independent variables into the multiple linear 
regression model.  Variables that were retained in the step-wise model were used for multiple 
linear regression analysis with each echocardiography parameter.  The Log2 of LVEF 
Simpson’s biplane, GLS and Log2 of E/e’ measured by the average of three index beats, 
average of 3, 5 and 10 consecutive beats were correlated using multiple linear regression with 
Log2 NTproBNP, PCS and AFEQT score.  Beta coefficients with a p value ≤ 0.05 were 
considered statistically significant.   
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5.3  Results 
160 patients underwent echocardiography with a median (IQR) NTproBNP of 1057 pg/ml 
(744-1522), PCS of 28 (19-36) and AFEQT score of 60 (48-71), see Table 22. 
Table 22.  Baseline patient demographics of variables used in the multiple linear 
regression models 
Characteristic n= 160 
NTproBNP, median pg/mL (IQR) 1057 (744-1522) 
PCS, median (IQR) 28 (19-36) 
AFEQT score, median (IQR) 60 (48-71) 
Heart rate, median bpm (IQR) 96 (86-112) 
Systolic BP, median mmHg (IQR) 134 (123-148) 
Age, median years (IQR) 75 (69-82) 
Women, n (%) 74 (46.3%) 
Years in AF, mean years (SD)  3.8 (6.2) 
Previous myocardial infarction, n (%) 13 (8.1%) 
COPD, n (%)  29 (18.1%) 
Weight, median kg (IQR) 87 (70-101) 
Creatinine median umol/l (IQR) 86 (73-101) 
Left ventricular ejection fraction (average of three index beats), median % (IQR)  59 (52-64) 
Left ventricular ejection fraction, (average of 3 beats) median % (IQR)  55 (50-60) 
Left ventricular ejection fraction, (average of 5 beats) median % (IQR) 56 (50-60) 
Left ventricular ejection fraction, (average of 10 beats) median % (IQR) 55 (49-59) 
Global longitudinal strain, (average of three index beats) median % (IQR) -13 (-11 to -15) 
Global longitudinal strain, (average of 3 beats) median % (IQR) -14 (-12 to -15) 
Global longitudinal strain, (average of 5 beats) median % (IQR) -13 (-11 to -15) 
Global longitudinal strain, (average of 10 beats) median % (IQR) -13 (-11 to -14) 
Average E/e’, (average of three index beats) median (IQR) 9.4 (7.8-11.7) 
Average E/e’, (average of 3 beats) median (IQR)  9.5 (7.7-11.8) 
Average E/e’, (average of 5 beats) median (IQR) 9.4 (7.7-12.0) 
Average E/e’, (average of 10 beats) median (IQR) 9.5 (8.0-12.3) 
Abbreviations: AF= atrial fibrillation; AFEQT= Atrial Fibrillation Effect on Quality of Life; 
BP= blood pressure; COPD= chronic obstructive pulmonary disorder; IQR= inter-quartile 
range; kg= kilograms; NTproBNP= N-terminal pro-B-type naturetic peptide; PCS= physical 
component score; SD= standard deviation 
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5.3.1 The association between systolic and diastolic function on echocardiography with 
NTproBNP in AF patients measured using the index beat, average of 3, 5 and 10 
averaged beats 
LVEF Simpson’s biplane was obtainable in 143 patients out of the baseline population of 160 
patients; 17 patients were excluded due to insufficient image quality.  Spearman’s correlation 
showed a weak association between Log2 NTproBNP and Log2 LVEF measured by 
Simpson’s biplane across all four measuring methods (average of three index beats, average 
of 3, 5 and 10 beats).  There was no significant difference between the correlation 
coefficients, meaning that NTproBNP is weakly associated with LVEF regardless of which 
measuring method is used (Table 23).  
Table 23.  Spearman’s rho to show the association between LVEF Simpson’s biplane 
measured by the average of three index beats, average of 3, 5 and 10 beats with 
NTproBNP and the difference in correlation coefficient with NTproBNP between the 
average of three index beats and average of 3, 5 and 10 beats 
LVEF Simpson’s biplane 
measuring method  
Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats -0.08 (p=0.32) - 
Average of 3 beats -0.12 (p=0.17) -0.34 (p=0.73) 
Average of 5 beats -0.12 (p=0.15) -0.28 (p=0.78) 
Average of 10 beats -0.10 (p=0.25) -0.20 (p=0.84) 
 
Univariable linear regression analysis showed that for every unit increase in Log2 NTproBNP 
there was a reduction in the Log2 LVEF Simpson’s biplane measured (Table 24), suggesting 
that a reduction in LVEF is associated with an increase in NTproBNP.  However the r2 value 
from the univariable regression model was weak across all measuring methods (average of 3 
index beats, average of 3, 5 and 10 consecutive beats) for quantifying LVEF, suggesting a 
weak association see Table 24. 
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Multiple linear regression including the co-variables age, gender, years in AF, heart rate and 
creatinine was carried out.  When adjusted for these co-variables a reduction in LVEF still 
predicted an increase in NTproBNP.  An increase in NTproBNP was also significantly 
associated with an increase in age, creatinine level and female sex.   
It was observed in Figure 32 that data points of LVEF below 40%, the locally weighted 
smoothing line followed a negative correlation with increasing LVEF there is a reduction in 
NTproBNP.  However above 40% the line flattens out and it was noted that the data points 
were widely clustered around the line, with some having a higher level of NTproBNP.  
Therefore suggesting that NTproBNP is less associated with LVEF in hearts with an LVEF 
above 40%.   
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Table 24.  Univariable linear regression analysis and multiple linear regression analysis comparing Log2 NTproBNP with Log2 LVEF 
Simpson’s biplane measured by the average of three index beats and average of 3, 5 and 10 beats (adjusted for age, years in AF, gender, 
heart rate and creatinine). 
 
Measurement 





Multiple linear regression 
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Figure 32.  Scatter plots with a locally weighted smoothing line to show the association between LVEF Simpson’s biplane measured by 
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GLS was obtainable in 139 patients; 21 patients’ images were excluded from the analysis due 
to insufficient image quality.  Spearman’s rho correlation showed a weak association between 
GLS and NTproBNP across all measuring methods.  There was no significant difference 
between the correlation coefficients, meaning that NTproBNP is weakly associated with GLS 
regardless of which measuring method is used (Table 25). 
Table 25.  Spearman’s rho to show the association between GLS measured by the 
average of three index beats, average of 3, 5 and 10 beats with NTproBNP and the 
difference in correlation coefficient with NTproBNP between the average of three index 
beats and average of 3, 5 and 10 beats 
 
GLS measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats 0.06 (p=0.46) - 
Average of 3 beats 0.11 (p=0.21) -0.04 (p=0.97) 
Average of 5 beats 0.10 (p=0.22) -0.31 (p=0.75) 
Average of 10 beats 0.11 (p=0.21) -0.03 (p=0.98) 
 
Univariate analysis showed that for a unit increase in Log2 NTproBNP correlated with an 
increase in GLS and so reduction in contractility.  However the r2 value was very weak, 
despite being statistically significant (Table 26).  
Multiple linear regression analysis showed a similar trend for GLS, with an increase in Log2 
NTproBNP resulting in a significant increase in GLS.  Age, gender and creatinine also had a 
significant beta coefficient with the Log2 of NTproBNP.  A single unit increase in Log2 
NTproBNP was associated with female gender, older age and increase in creatinine level 
(Table 26).  
Figure 33 shows a weak association between GLS and NTproBNP.  It was also noted that the 
majority of patients had a GLS below normal limits (-15.5% ±2.1). 
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Table 26.  Univariable linear regression analysis and multiple linear regression analysis comparing Log2 NTproBNP with GLS 
measured by the average of three index beats and average of 3, 5 and 10 beats (adjusted for age, years in AF, gender, heart rate and 
creatinine). 
Measurement 
method of GLS 
Univariable linear 
regression 
Multiple linear regression 





GLS (%) Age 
(years)   
Years in 
AF (years) 
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Figure 33.  Scatter plots with a line of best fit to show the association between GLS measured by the average of three index beats, 3, 5 
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E/e’ was obtainable in all 160 patients.  Spearman’s correlation of E/e’ and NTproBNP 
showed a moderate positively correlated association of statistical significance.  There was no 
significant difference between the correlations derived from the average of three index beats 
and average of 3, 5 and 10 beats, meaning that NTproBNP is moderately associated with GLS 
regardless of which measuring method is used (Table 27). 
Table 27.  Spearman’s rho to show the association between Log2 E/e’ measured by the 
average of three index beats, average of 3, 5 and 10 beats with NTproBNP and the 
difference in correlation coefficient with NTproBNP between the average of three index 
beats and average of 3, 5 and 10 beats 
 E/e’ measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats 0.40 (p=<0.001) - 
Average of 3 beats 0.41 (p=<0.001) -1.08 (p=0.28) 
Average of 5 beats 0.43 (p=<0.001) -1.91 (p=0.06) 
Average of 10 beats 0.43 (p=<0.001) -1.02 (p=0.31) 
 
 Univariate analysis showed that for every unit increase in Log2 NTproBNP, there was an 
increase in the Log2 E/e’, suggesting that an increase in NTproBNP is associated with an 
increase in E/e’.  Multiple linear regression analysis when adjusted for age, gender, years in 
AF, heart rate and creatinine showed again that with a unit increase in Log2 NTproBNP there 
was a significant increase in Log2 E/e’.  An increase in Log2 NTproBNP was associated with 
a small but significant increase in age, heart rate and creatinine levels and also with female 
gender (Table 28).  
Figure 34 shows a positive correlation between E/e’ and Log2 NTproBNP; as E/e’ increases 
Log2 NTproBNP increases. 
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Table 28.  Univariable linear regression analysis and multiple linear regression analysis comparing Log2 NTproBNP with Log2 E/e’ 
measured by the average of three index beats and average of 3, 5 and 10 beats (adjusted for age, years in AF, gender, heart rate and 
creatinine) 
 
          
Measurement 
method of E/e’ 
Univariable linear 
regression 
Multiple linear regression 





Log2 E/e’ Age 
(years)   
Years in 
AF (years) 
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Figure 34. Scatter plots with a line of best fit to show the association between E/e’ measured by the average of three index beats, 3, 5 and 

































Log2 E/e' average of three index beats

































2 3 4 5
Log2 E/e' average of 5 beats

























































































0 10 20 30 40





















0 10 20 30 40





















0 10 20 30 40





















0 10 20 30 40
E/e' average of 10 beats
log2_ntprobnp Fitted values
172 | P a g e  
 
 
Information on baseline patient symptoms were collected using the SF-36 questionnaires 
(physical component score) and AFEQT questionnaire (AFEQT score).  These parameters 
were compared with LVEF by Simpson’s biplane, GLS and E/e’ measured using the average 
of three index beats and average of 3, 5 and 10 consecutive beats.  
5.3.2  The association between systolic and diastolic function on echocardiography with 
AFEQT score in AF patients measured using the index beat, average of 3, 5 and 10 
averaged beats 
Spearman’s correlation coefficient showed a weak association between Log2 LVEF and 
AFEQT score suggesting LVEF and AFEQT are not associated.  There was no significant 
difference in the correlations derived from the average of three index beats and average of 3, 5 
and 10 beats, meaning that AFEQT score is weakly associated with LVEF regardless of 
which measuring method is used (Table 29 and Figure 35).  
Table 29.  Spearman’s rho to show the association between Log2 LVEF measured by the 
average of three index beats, average of 3, 5 and 10 beats with AFEQT score and the 
difference in correlation coefficient with AFEQT score between the average of three 
index beats and average of 3, 5 and 10 beats 
 LVEF measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats -0.08 (p=0.34) - 
Average of 3 beats -0.06 (p=0.48) 0.80 (p=0.42) 
Average of 5 beats -0.11 (p=0.18) 0.73 (p=0.47) 
Average of 10 beats -0.07 (p=0.44) <-0.01 (p=1.00) 
 
Stepwise multiple linear regression was initially performed with the parameters: history of 
COPD/emphysema, history of asthma, NTproBNP, age, years in AF, heart rate, systolic blood 
pressure, weight, gender, creatinine and history of myocardial infarction.  The co-variables 
that were retained in the model (p values ≤0.10) were gender and creatinine.  
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Univariable regression of AFEQT score with the Log2 of LVEF showed that for every 
increase in a unit of Log2 LVEF there was a reduction in the AFEQT score (worsening 
symptoms), however this was statistically insignificant and the r2 values were very weak.  
Multiple linear regression for AFEQT score and Log2 LVEF (adjusted for gender and 
creatinine level) was again shown to have a statistically insignificant beta coefficient (Table 
30).  Therefore this data suggests that AFEQT score was not associated with LVEF 
measurement.  However being of female gender was significantly associated with a lower 
AFEQT score.  Therefore this is suggestive that AF has a greater impact on the quality of life 
of females compared to male patients.  Also a lower creatinine level was associated with a 
higher AFEQT score, suggestive of AF having a greater impact on the quality of life in 
patients with impaired renal function (Table 30). 
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Table 30.  Univariable linear regression analysis and multivariable linear regression analysis comparing AFEQT score with Log2 LVEF 









Multivariable linear regression 
 ( β coefficient)  
β coefficient R-squared Log2 LVEF Gender Creatinine 
(umol/l) 
R-squared 
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Figure 35.  Scatter plots with line of best fit to show the correlation between LVEF Simpson’s biplane measured by the average of three 
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Spearman’s correlation rho showed a weak correlation between GLS and AFEQT score which 
was not statistically significant across all measuring methods.  There was no significant 
difference between the correlation derived from measuring GLS using the average of three 
index beats and average of 3, 5 and 10 beats, meaning that there is no association between 
GLS and AFEQT score regardless of which measuring method is used (Table 31 and Figure 
36).  
Table 31.  Spearman’s rho to show the association between GLS measured by the 
average of three index beats, average of 3, 5 and 10 beats with AFEQT score and the 
difference in correlation coefficient between the average of three index beats and 
average of 3, 5 and 10 beats 
GLS measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats 0.07 (p=0.39) - 
Average of 3 beats 0.05 (p=0.54) -0.04 (p=0.97) 
Average of 5 beats 0.07 (p=0.40) -0.07 (p=0.95) 
Average of 10 beats 0.03 (p=0.72) 0.26 (p=0.79) 
 
Univariate analysis comparing GLS with AFEQT showed a weak correlation, with every 
increase in a unit of AFEQT score associated with an increase in GLS (making it less 
negative) suggesting a reduction in contraction.  However the beta coefficient for this 
observed increase was not statistically significant across all measuring methods of obtaining 
GLS (Table 32).  Multiple linear regression analysis again demonstrated a small positive beta 
coefficient for GLS, suggesting that increasing AFEQT score is associated with an increase in 
GLS, however this was non-significant across all measuring methods.  The only statistically 
significant beta coefficient from the model was gender suggesting that being male was 
associated with an increase in the AFEQT score (Table 32).  This suggests again suggests that 
quality of life related to AF is more reduced in female patients. 
177 | P a g e  
 
 
Table 32. Univariable linear regression analysis and multivariable linear regression analysis comparing AFEQT score with GLS 





method of GLS 
Univariable linear 
regression 
Multivariable linear regression 
 ( β coefficient)  
β coefficient R-squared GLS Gender Creatinine 
(umol/l) 
R-squared 
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Figure 36. Scatter plots with line of best fit to show the correlation between GLS measured by the average of three index beats, 3, 5 and 
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Spearman’s correlation coefficient showed a very weak association between Log2 E/e’ and 
AFEQT score of no statistical significance.  There was also no significant difference between 
the correlation derived from measuring E/e’ using the average of three index beats and 
average of 3, 5 and 10 beats, meaning that there is no association between E/e’ and AFEQT 
score regardless of which measuring method is used (Table 33 and Figure 37) 
Table 33.  Spearman’s rho to show the association between Log2 E/e’ measured by the 
average of three index beats, average of 3, 5 and 10 beats with AFEQT score and the 
difference in correlation coefficient between the average of three index beats and 
average of 3, 5 and 10 beats 
E/e’ measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats -0.02 (p=0.81) - 
Average of 3 beats -0.02 (p=0.76) -0.77 (p=0.44) 
Average of 5 beats -0.04 (p=0.58) -0.26 (p=0.79) 
Average of 10 beats -0.01 (p=0.87) -0.26 (p=0.79) 
 
Univariate analysis of AFEQT score with Log2 E/e’ showed a very weak correlation of no 
statistical significance.  The beta coefficient demonstrated that an increase in AFEQT score is 
associated with a reduction in Log2 E/e’ with the exception of parameters measured by the 
average of 3 beats in which it showed an increase in Log2 E/e’; despite these variations beta 
coefficient all were shown to be statistically insignificant (Table 34). 
Multiple linear regression showed a non-significant association between an increase in 
AFEQT score and an increase in Log2 E/e’.  As seen previously the only variable which was 
significantly associated with an increase in AFEQT score was gender; being male was 
associated with a higher AFEQT score (Table 34).  
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Table 34. Univariable linear regression analysis and multivariable linear regression analysis comparing AFEQT score with Log2 E/e’ 




method of E/e’ 
Univariable linear regression Multivariable linear regression 
 ( β coefficient)  
β coefficient R-squared Log2 E/e’ Gender Creatinine 
(umol/l) 
R-squared 
Average of three 
index beats 
-0.42 (p=0.871) <0.01 (p=0.871) 1.63 (p=0.524) 11.42(p<0.001) -0.10 (p=0.079) 0.10 
(p=0.001) 
Average of 3 beats 0.54 (p=0.843) <0.01 (p=0.843) 2.41 (p=0.368) 11.64(p<0.001) -0.11 (p=0.063) 0.10 
(p=0.001) 
Average of 5 beats  -0.15 (p=0.958)  <0.01 (p=0.958) 2.14 (p=0.435) 1.68 (p<0.001) -0.11 (p=0.066) 0.10 
(p=0.001) 
Average of 10 
beats  
-0.21 (p=0.939) <0.01 (p=0.939) 2.14 (p=0.414) 11.65(p<0.001) -0.11 (p=0.065) 0.10 
(p=0.001) 
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Figure 37. Scatter plots with line of best fit to show the correlation between E/e’ measured by the average of three index beats, 3, 5 and 






















0 10 20 30 40























0 10 20 30 40























0 10 20 30 40























0 10 20 30 40
E/e' average of 10 beats
afeqt Fitted values
182 | P a g e  
 
5.3.3  The association between systolic and diastolic function on echocardiography with  
physical component score (PCS) in AF patients measured using the index beat, average 
of 3, 5 and 10 averaged beats  
Spearman’s correlation showed a weak statistically insignificant association between PCS and 
Log2 LVEF.  There was no significant difference in the correlation between LVEF derived 
from the average of three index beats and LVEF derived from the average of 3, 5 and 10 
beats, meaning that the association is weak regardless of what measuring method is used 
(Table 35 and Figure 38). 
Table 35.  Spearman’s rho to show the association between Log2 LVEF measured by the 
average of three index beats, average of 3, 5 and 10 beats with PCS and the difference in 
correlation coefficient between the average of three index beats and average of 3, 5 and 
10 beats 
LVEF measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats -0.13 (p=0.14) - 
Average of 3 beats -0.07 (p=0.39) -0.31 (p=0.75) 
Average of 5 beats -0.12 (p=0.15) 0.02 (p=0.98) 
Average of 10 beats -0.11 (p=0.18) -0.30 (p=0.76) 
 
Stepwise linear regression was carried out including the physical component score (PCS) and 
the co-variables age, gender, years in AF, heart rate, systolic blood pressure, weight, 
creatinine, history of a myocardial infarction, NTproBNP and history of COPD/ emphysema.  
The variables age, gender, COPD/emphysema and weight were retained in the model 
(p=<0.1). 
Univariate analysis suggested that for a unit increase in PCS there was a reduction in LVEF 
but this was shown to be statistically insignificant and the r2 was weak.  Multiple linear 
regression showed that for a unit increase in PCS there is a reduction in LVEF Simpson’s 
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biplane, however this was not statistically significant.  Similarly to AFEQT the only 
significant beta coefficient was gender; being male was associated with a higher PCS (Table 
36).  Therefore suggesting that quality of life in relation to physical health status was better in 
male AF patients.  
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Table 36.  Univariable linear regression analysis and multivariable linear regression analysis comparing PCS with Log2 LVEF 
measured by the average of three index beats and average of 3, 5 and 10 beats (adjusted for age, gender, COPD/emphysema and 









Multivariable linear regression 
 ( β coefficient)  
β coefficient R-squared Log2 LVEF Age (years ) gender COPD/ 
emphysema  
Weight (kg) R-squared 
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Figure 38.  Scatter plots with line of best fit to show the correlation between LVEF Simpson’s biplane measured by the average of three 
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Spearman’s correlation coefficient showed a weak statistically insignificant association 
between GLS and PCS.  There was no significant difference in the correlation between GLS 
derived from the average of three index beats and GLS derived from the average of 3, 5 and 
10 beats, meaning that the association is weak regardless of what measuring method is used 
(Table 37). 
Table 37.  Spearman’s rho to show the association between GLS measured by the 
average of three index beats, average of 3, 5 and 10 beats with PCS and the difference in 
correlation coefficient between the average of three index beats and average of 3, 5 and 
10 beats 
GLS measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats 0.09 (p=0.28) - 
Average of 3 beats 0.005 (p=0.96) 0.93 (p=0.35) 
Average of 5 beats 0.04 (p=0.61) 0.53 (p=0.60) 
Average of 10 beats 0.02 (p=0.82) 0.60 (p=0.55) 
Univariate analysis of GLS and PCS demonstrated a weak association of no statistical 
significance.  Multiple linear regression again showed a non-significant relationship between 
PCS and GLS.  The co-variable age showed a significant beta coefficient suggesting that for a 
unit increase in PCS there is reduction in age, so younger people have a better physical health 
status.  Weight was also shown to be significantly associated with PCS; with a reduction in 
weight associated with a higher physical health status.  Finally similar to the AFEQT score, 
male gender was associated with a statistically significant increase in PCS (Table 38). 
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Table 38.  Univariable linear regression analysis and multivariable linear regression analysis comparing PCS with GLS measured by the 
average of three index beats and average of 3, 5 and 10 beats (adjusted for age, gender, COPD/emphysema and weight).     
 
Measurement 
method of GLS 
Univariable linear 
regression 
Multivariable linear regression 
 ( β coefficient)  
β coefficient R-squared GLS Age (years) gender COPD/ 
emphysema  
Weight (kg) R-squared 
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Figure 39.  Scatter plots with line of best fit to show the correlation between GLS measured by the average of three index beats, 3, 5 and 
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Spearman’s correlation coefficient showed a very weak statistically insignificant association 
between Log2 E/e’ and PCS.  There was no significant difference in the correlation between 
E/e’ derived from the average of three index beats and E/e’ derived from the average of 3, 5 
and 10 beats with PCS, meaning that the association is weak regardless of what measuring 
method is used (Table 39) 
Table 39.  Spearman’s rho to show the association between Log2 E/e’ measured by the 
average of three index beats, average of 3, 5 and 10 beats with PCS and the difference in 
correlation coefficient between the average of three index beats and average of 3, 5 and 
10 beats 
E/e’ measuring method  Spearman’s rho (p value) Difference in correlation 
from index beat method 
z (2-tailed p value) 
Average of 3 index beats -0.02 (p=0.80) - 
Average of 3 beats -0.02 (p=0.80) -0.03 (p=0.97) 
Average of 5 beats -0.04 (p=0.61) 0.47 (p=0.64) 
Average of 10 beats -0.03 (p=0.67) 1.04 (p=0.30) 
 
Univariate analysis of Log2 E/e’ and PCS suggested that for a unit increase in PCS there is a 
reduction in Log2 E/e’ however this was not significant and the r2 value was very weak.  
Multiple linear regression analysis again showed no significant association between Log2 E/e’ 
and PCS.  However from the model age was significantly associated with PCS, with a 
younger age associated with a higher physical health status.  The presence of COPD/ 
emphysema was also associated with a reduction in physical health status.  As seen before 
being of male gender and a lower weight was associated with a higher physical health status 
(Table 40).   
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Table 40. Univariable linear regression analysis and multivariable linear regression analysis comparing PCS with Log2 E/e’ measured 






method of E/e’ 
Univariable linear 
regression 
Multivariable linear regression 
 ( β coefficient)  
β coefficient R-squared Log2 E/e’ Age (years) gender COPD/ 
emphysema  
Weight (kg) R-squared 
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Figure 40. Scatter plots with line of best fit to show the correlation between E/e’ measured by the average of three index beats, 3, 5 and 
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5.3.4  Comparisons between systolic and diastolic measurements  
There was a negative moderate correlation between GLS and LVEF; as LVEF reduced GLS 
became less negative, r= -0.59, p<0.001.  It was also noted that two thirds of the patients had 
a normal LVEF (≥55%) however out of these patients, 43% of them had a reduced GLS 
(below 15.5% ±2.1) (Figure 41).  
Figure 41.  Scatter plot with line of best fit to show correlation between GLS and LVEF 
Simpson’s biplane measured by the average of three index beats with Spearman’s 
correlation displayed  
 
There was no significant correlation between LVEF and E/e’, r=-0.14, p=0.103.  However it 
was noted that there were some patients with a normal LVEF and a high E/e’ (Figure 42). 
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Figure 42.  Scatter plot with line of best fit to show correlation between LVEF Simpson’s 
biplane and E/e’ measured by the average of three index beats with Spearman’s 
correlation displayed 
 
Figure 43. Scatter plot with line of best fit to show correlation between LVEF Simpson’s 
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5.4  Discussion  
This study on validity demonstrated that elevated NTproBNP was most strongly correlated 
with the diastolic parameter E/e’ with a positive moderate in strength correlation .  LVEF 
Simpson’s biplane and GLS were both shown to be weakly associated with NTproBNP.  
LVEF, GLS and E/e’ all correlated poorly with patient reported quality of life, as measured by 
the PCS and AFEQT score.  There was also no significant difference in the correlations with 
predicted NTproBNP, PCS and AFEQT score when comparing correlations with 
echocardiographic measurements made using the average of three index beats and average of 
3, 5 and 10 consecutive beats.  This means that any measurement method can be used and 
there will be no difference in clinical outcome. 
The data on the validity of systolic parameters in patients with AF are very limited.  From 
chapter 4 the index beat method was found to be more reproducible or equally reproducible 
to averaging 10 consecutive beats, but its validity in clinical practice remained uncertain.  
This study is the first time validity of the index beat method has been directly compared with 
a biomarker or symptom burden of patients with AF.  
NTproBNP is released from cardiac myocytes in response to myocardial wall stress and 
increased ventricular filling pressures.(197)  It is known that NTproBNP levels are raised in 
patients with AF compared to patients without AF.(198)  In AF there are several pathological 
mechanisms that can contribute to raised NTproBNP levels, making direct correlations 
between specific systolic and diastolic measurements less clear.  Studies have found that in 
the presence of AF atrial myocytes secrete BNP due to atrial remodelling and atrial stretch 
activating the BNP gene.(199) This is the first study in which the more stable BNP precursor 
(NTproBNP) has been compared with LVEF Simpson’s biplane and GLS in patients in AF at 
the time of their echocardiogram.  LVEF Simpson’s biplane correlated weakly with 
195 | P a g e  
 
NTproBNP with a negative association; the lower the LVEF the higher the NTproBNP level.  
The more impaired the heart, the more stress the ventricular wall endures and it has been 
found that brain naturetic peptides are secreted proportional to the extent of stress the 
ventricular wall is under, in an effort to reduce the intra-ventricular pressure.(200)  Radial 
contractility alone is not responsible for strain on the heart.  This has been demonstrated 
before with Kim et al. who found that in a population of AF patients with preserved LVEF 
(LVEF >50%) there was no significant association with BNP levels (r= -0.251, 
p=0.065).(139) This demonstrates that strain on the heart is not associated with left 
ventricular dysfunction alone and may instead be associated more with diastolic dysfunction 
or may be a sign of early systolic dysfunction which can’t be detected solely on ejection 
fraction. 
Results from this study have shown that the association between the diastolic parameter E/e’ 
and predicted NTproBNP is moderately correlated, with increasing E/e’ predicting an increase 
in NTproBNP.  The association between E/e’ and raised NTproBNP levels have previously 
been observed in studies comparing E/e’ with Log BNP which showed  a very strong 
association in AF patients with preserved systolic function.(102) The mechanism for this is 
less clear but it is believed that it results from increased filling pressures, which may be due to 
dilated left atrium incurring greater volumes.  NTproBNP may be directly released from the 
atria in response to raised left atrial pressures as well.  The dilated left atrium may also 
contribute to a general increase in intra-cardiac volume, which can contribute to volume 
overload in the absence of systolic dysfunction.(139, 201)  Therefore in this study patients 
despite having a preserved LVEF may have a raised NTproBNP level due to diastolic 
dysfunction and raised left atrial pressures causing volume overload, as a result of long-
standing AF.    
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GLS was shown to be weakly associated with NTproBNP; with a less negative strain (reduced 
longitudinal function of the ventricle) predicting an increase in NTproBNP.  This is in 
contrast to studies in patients with sinus rhythm, which has found that GLS has a strong 
correlation with NTproBNP, which is stronger than the association observed with 
LVEF.(197)  In this study despite having a weaker strength of correlation the points were 
distributed evenly along the line of best fit, suggesting that NTproBNP is linearly proportional 
to the reduction in GLS.  The normal GLS value for a Philips machine in a patient population 
of 60 years and over in sinus rhythm is -16.7% (± 2.1)(49); it was observed that the mean 
GLS from this population of permanent AF patients was -13.7% which is reduced.  This has 
previously been demonstrated that GLS was significantly reduced in AF patients compared to 
patients in sinus rhythm matched for age, sex, heart rate, LVEF and LV mass.(202)  There 
was also a proportion of patients who despite having a normal LVEF had reduced GLS and a 
raised NTproBNP.  This suggests that AF patients may have a normal ejection fraction but the 
heart may still be under strain, causing raised levels of NTproBNP as a result of myocardial 
wall stress.  GLS measures the function of the longitudinal muscle fibres, which are found in 
the subendocardial layer of the LV wall.  The subendocardial layer is susceptible to damage 
caused by haemodynamic overload resulting in raised ventricular filling pressures, which 
often can occur with AF.  Therefore GLS may be useful in detecting early systolic 
dysfunction caused by the haemodynamic problems of AF alone, which may precede overt 
LV systolic dysfunction.(202)  It has also been found that reduced GLS is a predictor of the 
development of AF, so it is possible that reduced GLS was present in these patients before the 
onset of AF.(203) GLS was shown to not be associated with E/e’, suggesting that reduction in 
GLS is unlikely to be due to diastolic dysfunction; this has been observed in patients with 
sinus rhythm before in which E/’e was not affected by GLS. (204) 
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Despite GLS being weakly associated with NTproBNP in patients with AF other studies have 
identified GLS as a strong predictor of mortality risk.  Therefore it should not be excluded as 
a useful predictor of clinical outcome.(115, 136, 137)   
Across all echocardiographic parameters the correlation with NTproBNP when measured by 
the index beat and average of consecutive beats did not significantly differ.  This suggests that 
although the index beat method is more reproducible (chapter 4) there was no difference in 
clinical validity when compared to conventional averaging of consecutive beats.  Therefore 
this means that the index beat method can confidently be used to measure systolic and 
diastolic parameters without compromising the correlation with clinical outcome.  
No systolic and diastolic parameters were found to predict either PCS or AFEQT score.  It 
would be expected clinically that patients with worsening parameters of systolic and diastolic 
dysfunction would have a greater symptom burden of dyspnoea, fatigue and reduced exercise 
tolerance.(205)  However this data suggests that echocardiographic parameters do not 
correlate with symptoms in AF patients or it may be that the quality of life scoring system 
used does not accurately delineate symptoms related to cardiac function from other 
conditions.  It may be that symptoms limiting physical activity are related to other conditions 
such as arthritis, lung disease and general frailty in this patient population.  It is also known 
that 25-30% of patients with AF do not experience any symptoms at all.  Previous studies 
comparing LVEF with physical functioning score from the SF-36 questionnaire in patients 
with sinus rhythm, have found that significant associations were only detected in patients with 
severely reduced ejection fraction.(205, 206)  There has only been one study previously 
comparing LVEF with PCS from the SF-36 questionnaire; Dorian et al found that LVEF 
poorly correlated with PCS and was unrelated to quality of life and NYHA class.(207)  In this 
study only 11 patients out of the 143 in which LVEF Simpson’s biplane could be measured 
had an LVEF <40% which may account for the lack of association detected.  As with all 
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results from patient self-reported quality of life questionnaires, it is all subjective and 
although a patient may clinically have similar symptoms, their perception on their severity 
may be significantly different.(208)  
However, gender did significantly predict symptoms, with women having more symptoms 
related to physical activity.  This has been observed before in a study looking at difference in 
patient symptoms assessed by the AFEQT score between genders in the AF population, in 
which it was found that women with AF have more symptoms of dyspnoea, palpitations and 
fatigue and a lower quality of life.(209) Female gender and increased age is also associated 
with reduced PCS in patients with cardiovascular disease.(210)  
In comparison to validity studies in patients with sinus rhythm NTproBNP and quality of life 
scores in patients with AF do not correlate as strongly.  Different clinical outcomes such as 
the more traditionally used cardiovascular events, hospitalisation and mortality may serve as a 
better clinical correlate. 
The limitations of the results from this chapter are that this is baseline data only and from a 
relatively small sample size.  Also the quality of life questionnaires did not adjust for non-
cardiovascular conditions such as arthritis and respiratory problems, which may account for 
the lack of association seen when correlating with parameters of systolic and diastolic 
function.  Measurement error is also inherent in a single time point QoL measure.  
5.5  Conclusion  
There was no significant difference in the validity of using the average of three index beats 
with averaging consecutive beats when compared with NTproBNP and quality of life 
measures.  E/e’ was the strongest predictor of NTproBNP levels, suggesting diastolic 
dysfunction contributes significantly to myocardial wall stress.  The systolic parameters 
LVEF and GLS were shown to have a weak correlation with NTproBNP, particularly in those 
199 | P a g e  
 
patients with a preserved ejection fraction, where in some patients NTproBNP levels were 
elevated despite an LVEF within normal range. Therefore in AF patients this suggests that the 
level of NTproBNP cannot be used to predict the degree of systolic dysfunction. 
Echocardiographic parameters of systolic and diastolic function, have been found to not be 
associated with quality of life in AF patients, using the SF-36 PCS and AFEQT score. Further 
studies comparing echocardiographic parameters with alternative measures of patient 
functional status are required, to establish whether echocardiographic parameters are 
associated with patient symptoms. 
 
In the following chapter the findings from this thesis are brought together and future 
directions of where further research is required are discussed.  
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Chapter 6.  General Discussion and future work 
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AF is the most prevalent cardiac arrhythmia in the population and as the patient population 
gets older, it is predicted to further increase in prevalence.  One of the key problems with AF 
is the development of heart failure; from recent registries, it is now believed that up to 50% of 
patients with AF have some form of heart failure.(16, 22)  Therefore it is essential that we can 
accurately determine left ventricular systolic and diastolic function, so that the type of heart 
failure can be correctly categorised and managed appropriately.  For this to be achieved 
measurements used to evaluate systolic and diastolic function must be reproducible and 
clinically valid.  However, the assessment of systolic and diastolic function in patients with 
AF is challenging due to the variable length in cardiac cycles (R to R intervals) and loss of 
atrial contraction.  This means that achieving reproducible results is difficult.  Current 
guidelines suggest based on consensus opinion; averaging 5 beats for systolic function and 
averaging 5 to 10 beats for diastolic function.(171)  Recent studies have shown that these 
recommendations are not optimum.(177)  Furthermore, there is uncertainty as to whether the 
parameters validated in patients with sinus rhythm, have the same validity for patients in atrial 
fibrillation.  
Therefore the aim of this thesis was to investigate the optimal method to achieve reproducible 
measurements by comparing the validity and reproducibility of the index beat method with 
conventional averaging of consecutive beats.  The validity of systolic and diastolic parameters 
in relation to clinical biomarkers of heart failure (NTproBNP) and patient symptoms was also 
assessed. 
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6.1  Summary of findings and Future directions 
6.1.1  Systematic review of imaging methods to assess systolic function in AF patients 
Before beginning the systematic review (chapter 2) it was known that there were very few 
studies assessing the validity of systolic function in echocardiography for AF patients, but the 
validity of other imaging modalities was unknown.(37)  The systematic review showed that 
across imaging techniques, echocardiography had the most studies on validity in AF with very 
few studies for CMR and nuclear imaging and no studies at all for cardiac CT.  From the 
echocardiography studies on clinical outcomes, GLS was identified as being a better predictor 
of cardiovascular mortality and events, compared to measurements of LVEF and was shown 
to correlate well with invasively derived dP/dt (a measurement of contractile function).  
However the more widely used parameter of systolic function LVEF, has not been externally 
validated, raising concerns as to whether the LVEF cut-off values for AF patients are the 
same as those validated in patients with sinus rhythm.  Previous reproducibility studies 
suggested that measurements of systolic function were highly reproducible and the index beat 
method was as good as using the average of all beats taken (10 to 13).  However, these 
conclusions were drawn from studies in which the patient population had been highly selected 
for good quality acoustic windows, meaning that these findings may differ in the general AF 
population.  Also the use of the index beat in measuring systolic parameters had not been 
externally validated.  The data for CMR and nuclear was very small, with no studies 
comparing systolic measures with clinical outcomes in AF patients.  There have also been no 
inter-imaging modality studies in this group of patients, so measurements of systolic function 
cannot be reliably inter-changed between modalities.  
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Future Directions 
The systematic review has revealed a significant lack of validity studies of systolic 
measurements using cardiac imaging in AF patients, with no studies comparing systolic 
measurements between modalities.  This presents a need for prospective cross-sectional 
studies comparing measurements of systolic function between imaging modalities.  For 
example the measurement of LVEF needs to be derived from echocardiography, nuclear 
SPECT and MUGA, CMR volumes and cardiac CT and then compared to confirm whether or 
not the measurement can be used interchangeably between modalities to guide patient 
management.  This will ensure that results are correctly interpreted and any serial monitoring 
of ventricular systolic function using different imaging modalities will accurately detect any 
change in systolic function.   
It was also shown that the LVEF measurement by echocardiography has not been externally 
validated in AF patients.  Therefore given that this measurement is often used to guide clinical 
management of patients,(3) external validity studies are urgently needed.  The challenge in 
this study would be identifying a gold-standard value for systolic function.  In patients with 
sinus rhythm the invasive angiography parameter dP/dt is considered the gold-standard 
method of determining contractility.(143)  Prospective studies are needed in AF patients to 
simultaneously compare echocardiographic systolic parameters measured by the index beat 
and averaging of consecutive beats with invasively derived dP/dt, to determine which systolic 
parameters correlate best with contractility.  To do this I would propose obtaining dP/dt traces 
using a left ventricle catheter, while simultaneously obtaining echocardiography traces of 
lateral and septal TDIs and 30 beat loops of the apical 4, 3 and 2 chamber view to measure 
GLS, s’ and LVEF post-procedure.  Right heart catheterisation will similarly be used to 
correlate E/e’ using TDI with pulmonary capillary wedge pressure.  Around 1200 patients 
undergo either left heart catheterization or percutaneous coronary intervention at the Queen 
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Elizabeth Hospital per year of which 10% are in AF.  These patients awaiting left heat 
catheterization would be approached to take part in the study. 
 
6.1.2  A simple method to improve the reliability of echocardiography in patients with 
atrial fibrillation   
The first aim was to explore the reproducibility of the index beat method against conventional 
averaging of consecutive beats (chapter 4).  The study showed that the index beat method 
had a significantly lower within beat variability compared to averaging 3, 5 and 10 
consecutive beats across LVEF Simpson’s biplane, GLS and E/e’.  Intra and inter operator 
studies showed that a single index beat method was more reproducible than averaging 3 and 5 
consecutive beats and was either as reproducible or more reproducible than averaging 10 
consecutive beats.  This finding reflects what has previously been reported in the literature 
with the index beat method correlating strongly with an average of 10 beats or more.(101, 
132, 154)   Furthermore the index beat method was also found to be significantly more time 
efficient than conventional averaging of 5 and 10 beats.  Therefore not only is the index beat 
more reproducible it will also save the echocardiographer time in obtaining measurements, 
increasing the efficiency of echocardiography departments.   
Finally in chapter 5 the index beat method’s validity was compared with the average of 3, 5 
and 10 beats by correlating them with NTproBNP and patient reported quality of life in the 
form of the AFEQT sore and physical component score (PCS) derived from the SF-36 
questionnaire.  There was no difference in the associations between the index beat method and 
conventional methods and so not only is the index beat method more reproducible and more 
time efficient, it does not compromise clinical validity.  
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Future directions 
The index beat method was shown to be more reproducible and more time efficient without 
compromising clinical validity when compared to conventional averaging of 3, 5 and 10 
consecutive beats.  However, this is not the first time the index beat method has been 
mentioned in the literature as a reproducible alternative to averaging of 5 and 10 beats.(37)  It 
remains unclear as to why this method has not been introduced into routine clinical practice or 
mentioned as an alternative in clinical guidelines.  This may be due to a lack of knowledge 
about the index beat method or uncertainty of its validity in clinical practice.  This means 
going forward initially this method would be introduced into the cardiology department at the 
Queen Elizabeth hospital Birmingham, starting with in depth training on how to perform the 
index beat method.  To follow this, the index beat method would be introduced into clinical 
practice and a pilot study would be developed to assess the feasibility of the index beat 
method, ultimately expanding the study to other centres.  Feasibility outcomes could be 
duration of the echocardiogram study and/or analysis and qualitative assessment, of whether 
the index beat method improves the clinical management of patients.  The feasibility 
outcomes could then be compared with other matched centres still using the conventional 
averaging of consecutive beats.  To measure on an index beat, does require more attention 
from the echocardiographer, than simply measuring a random number of consecutive beats.  If 
from the study this proves a challenge, selection of the index beat could be facilitated with 
artificial intelligence; by accurately tracking the R to R intervals on the ECG, automated 
recognition of the index beat could be enabled.  This would help echocardiographers in using 
the index beat method in clinical practise and minimize operator error of incorrectly selecting 
an index beat. In order for this to be successful, collaboration with industry (such as Philips 
and General Electric healthcare) would be required to introduce this on to the echocardiogram 
machines used in clinical practice.    
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6.1.3  Validity of systolic and diastolic parameters vs patient symptoms and NTproBNP 
A problem highlighted from the systematic review was an uncertainty of how 
echocardiographic parameters affected clinical outcome.  In chapter 5 LVEF Simpson’s 
biplane, GLS and E/e’ were correlated with NTproBNP and the patient symptoms (PCS and 
AFEQT score).  The value E/e’ has been shown to correlate most strongly with NTproBNP, 
suggesting that diastolic dysfunction contributes significantly to myocardial wall stress, 
despite a lot of patients having a normal ejection fraction.  Also noted from the validity 
studies was a reduced GLS despite having an LVEF within normal limits.  Data from the 
systematic review has shown that GLS is a better predictor of cardiovascular events than 
LVEF(135), however in this study it was shown to be weakly associated with NTproBNP.  
 It was found that all three parameters of systolic and diastolic function were not associated 
with patient symptoms (measured by AFEQT score and PCS).  This may have been due to 
echocardiographic measures being a poor predictor of patient symptoms or an issue with the 
questionnaires used to assess patient symptoms.      
Future Directions 
To further validate the index beat against conventional averaging of beats, a superior method 
to patient reported quality of life needs to be used to assess its association with clinical 
outcome.  Measurements of systolic and diastolic function using the index beat method verses 
average of 5 or 10 beats, need to be correlated with information such as the composite of 
cardiovascular death, heart failure hospitalisation and other major cardiac events.  This would 
require a greater population of patients to achieve a sufficient power and so collaboration with 
other echocardiography centres might be needed in order to collate echocardiogram studies. 
To better understand how echocardiographic measurements are associated with patient 
symptoms, more robust methods of assessing functional status need to be considered.  The 
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parameter peak oxygen consumption (VO2 max), which can be derived from 
cardiopulmonary exercise-testing can be used to evaluate the capacity of the cardiorespiratory 
system in patients.(211)  In comparison to quality of life scores, this may provide a more 
accurate assessment of patient symptoms related to the cardiovascular system. 
Echocardiographic parameters of systolic and diastolic function should be correlated with 
VO2 max, to determine which parameters are more associated with a decline in functional 
status in the AF population. For systolic parameters this has never been carried out for 
patients in AF at the time of their echocardiogram.   
This thesis has concentrated on the effects of left ventricular systolic and diastolic dysfunction 
on myocardial stress and patient symptoms.  However the contribution of the right heart and 
pulmonary vascular resistance on symptoms has not been assessed. Previous studies have 
shown that the co-existence of pulmonary hypertension and AF reduces the functional 
capacity and increases heart failure symptoms in patients more than in those without AF.(212)  
It would be useful to determine from this RATE-AF population, the association of right 
ventricular function and pulmonary hypertension with symptoms and NTproBNP, and how 
this is related to the patients with preserved and impaired systolic function. It may reveal that 
it is the degree of right ventricular dysfunction and pulmonary hypertension that manifests 
symptoms rather than degree of left ventricular systolic and diastolic function.   
 In addition to this the left atrial size and function has not been assessed in this thesis.  The 
left atrium acts as a reservoir for blood returning from the pulmonary circulation, a conduit to 
transport blood into the left ventricle and a pump to propel blood into the LV contributing to 
cardiac output.(213)  In patients with AF the LA remodels resulting in dilatation and 
reduction in contractile function.  Studies have shown that a reduction in left atrial function 
measured by an abnormal strain could be related to heart failure and the onset of 
symptoms.(214, 215)  Therefore attention should be paid to how left atrial function correlates 
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with NTproBNP, patient symptoms and functional status.  Studies have shown that a 
reduction in LA ejection fraction and increase in LA volume has been associated with an 
increase in the risk of mortality.(216)  Measurements of left atrial ejection fraction, volume 
and strain in patients with permanent AF should be correlated with clinical measures in future 
studies. 
A greater number of studies have validated diastolic function parameters against pulmonary 
capillary wedge pressure,(37) and this study has also proven E/e’ to be more strongly 
associated with myocardial wall stress, compared to LVEF and GLS.  However there remains 
uncertainty in clinical practice on how to accurately assess diastolic function in patients with 
AF at the time of their echocardiogram.  It is common to find the statement “unable to assess 
diastology due to patient in AF” on echocardiogram reports, despite parameters such as E/e’ 
and pulmonary diastolic deceleration time been shown to correlate highly with pulmonary 
capillary wedge pressure.  Prospective studies correlating pulmonary capillary wedge 
pressures with parameters of diastolic function need to be carried out in order to create an 
official guideline (similar to the ASE’s diastolic dysfunction algorithm(36)) for the diagnosis 
of diastolic dysfunction in AF patients.  This study has clearly highlighted the impact of 
diastolic dysfunction causing stress on the heart in AF patients.  Therefore, it is important that 
this be stated in echocardiogram reports, as diastolic dysfunction may play a critical role in 
AF patients’ development and worsening of heart failure.  
As part of the RATE-AF trial the diastolic composite was designed for the outcome of 
diastolic function, which was based on current data in the literature(37) (see Figure 44.  As a 
starting point to formulate an algorithm for the assessment of diastolic dysfunction in patients 
with AF, the composite could be validated against pulmonary capillary wedge pressures in 
those patients in AF undergoing right heart catheter assessment.   
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Does the patient have two or more of the 
following diastolic parameters? 
 IVRT (ms) <= 65 ms 
 Mitral Valve E deceleration time  (ms) 
<=120ms 
 Average E/e’(taken from lateral and 
septal wall) >= 11 
 Pulmonary Vein  diastolic deceleration 
time (ms) <=220 
 
 
Does the patient have any one of 
the following diastolic parameters? 
 Average E/e’ (taken from 








No diastolic  
dysfunction 
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6.2  Conclusion 
The use of the index beat method has been proven to be more reproducible and time efficient 
than conventional averaging of consecutive beats, without compromising validity when 
correlating with natriuretic peptides and patient-reported quality of life scores ( 
Figure 45).  Further studies are needed to validate the index beat method with more robust 
clinical parameters such as exercise tolerance and long-term clinical outcomes.   
Accurate echocardiography studies to determine systolic and diastolic function in AF patients 
will lead to early diagnosis of heart failure and so correct management of these patients.  If 
AF patients are optimally managed for their heart failure, this will ultimately lead to an 
improvement in patient’s quality of life, fewer hospital admissions and could improve the 
long-term prognosis of AF patients.      
Figure 45.  Summary figure to show the outcome of testing the reproducibility, validity 
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Appendix 1:  Link to the RATE-AF protocol  
Please follow the link below for the latest version (version 2.0) of the RATE-AF protocol: 
https://www.birmingham.ac.uk/Documents/college-mds/trials/bctu/RATE-AF/RATE-AF-
Protocol-v2.0-23Jan2018-clean.pdf
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Appendix 2: Content of patient information leaflet for RATE-AF trial   




PATIENT INFORMATION LEAFLET 
 
 
We would like to invite you to take part in our research study 
Before you decide, we would like you to understand why the research is being done and what 
it would involve for you.  One of our team will go through the information sheet with you 
and answer any questions (this should take about ten minutes).  You can talk to others about 
the study if you wish.  Please ask us if there is anything that is not clear.   
What is the purpose of the study? 
Atrial fibrillation is a common condition where the heart rhythm is irregular.  It usually 
requires medication to control heart rate, but we currently don’t know which medication is 
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better for patients.  The aim of this study is to find out which, of two treatments (digoxin or 
bisoprolol), improves quality of life and the function of your heart.  
Why have I been invited? Can I say no? 
You have been invited as you have atrial fibrillation and need medication to help to control 
of your heart rate.  Your doctors will be starting treatment and we would like your consent to 
randomly assign you to one of these two medications (digoxin or bisoprolol) as your initial 
therapy. 
It is up to you to decide whether to join the study or not.  If you decide not to take part, your 
standard of care will not be affected and you will receive medications to control heart rate as 
part of your clinical care.       If you agree to take part, we will then ask you to sign a consent 
form.  You are free to withdraw at any time, without giving a reason. 
Are there any benefits to taking part? 
You will be seen more regularly than normal because you are taking part in a study and you 
will have access to the study team.  However, there will also be questionnaires, tests and 
visits to the hospital that might be an inconvenience.  Although there may be no direct 
benefit to you, we hope this study will benefit all future patients with atrial fibrillation. 
What will happen to me if I take part?  
Sometimes we don’t know which way of treating patients is best.  To find out, we need to 
compare different treatments by putting patients into groups with each receiving a different 
treatment.   
Before any study procedures take place, you will be asked to sign a consent form to enter the 
study.  This will stay on record in your study file, be noted in your medical records and 
available for review by the study monitors, with a copy made for you to keep. 
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A computer will decide at random (like tossing a coin) which treatment you will have. Half 
of the people taking part will be prescribed digoxin and the other half will be prescribed 
bisoprolol.   
 
Once the treatment is assigned, you and your doctors will know which treatment you are 
given.  We will avoid giving patients the other drug unless absolutely needed.  Additional 
treatments can still be given according to your needs. 
At the beginning of the study, we will assess your quality of life (using questionnaires) and 
your heart function (using an ultrasound scan).  We will reassess your quality of life at 6 
months and 12 months after starting treatment, and look again at your heart function at 12 
months.  During the study, we will also take blood samples (approximately 20 mL which is 
equivalent to four teaspoons), monitor your heart rate and check your physical fitness with a 
walking test.      
How many visits are there and how long will it take? 
The initial visit will last a couple of hours, so that we can go through this information leaflet 
in detail and accurately record all of your details.  Once you start the treatment, we will 
arrange one or two short visits in the first month (usually around 30 minutes each) to see 
whether you need a higher dose of the medication or any additional treatments, in order to 
get your heart rate to less than 100 beats per minute.  At 6 months the visit will take about an 
hour, and at 12 months about two hours.  All visits will be scheduled at the Queen Elizabeth 
Hospital in Birmingham. 
Expenses and payments  
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Although you won’t be paid to take part in the study, we are able to cover all your expenses 
to attend the study visits.  In most cases, we are happy to book a taxi for you to attend and go 
home afterwards, as well as support any costs for food and drink. 
How will I receive the medications? 
For the first few months, we will supply your medication from our pharmacy.  Once you are 
stable on your treatment, you can receive prescriptions from your GP in the normal way.  All 
patients in this study are over the age of 60 and receive free NHS prescriptions. 
You should take the study medication regularly as directed and continue all other regular 
medication, including blood thinning tablets. 
Are the medications and tests safe? 
The two treatments we are using (digoxin and bisoprolol) are safe and have been used for 
many years as part of the normal treatment for atrial fibrillation.  As with any drug, there are 
potential side effects, but serious complications are very rare.  The most common side effects 
from digoxin include stomach upset, dizziness, blurred vision and headache, and for 
bisoprolol include tiredness, headache, dizziness, and breathlessness.  Some patients with 
atrial fibrillation need pacemakers to support their heart rhythm.  We will carefully monitor 
your heart rate and any side effects, and take action where needed.  This may include 
changing a treatment or withdrawing you from the study.  There will be an independent 
safety committee that will oversee the trial. 
All the tests you will receive are safe and part of normal clinical care for patients with atrial 
fibrillation.  The ultrasound scans (echocardiogram) are similar to what mothers receive in 
pregnancy (but assess the heart instead).  The walking tests take about 6 minutes, are very 
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relaxed and patients can stop when they need to.  Monitoring of heart rate uses a small 
device attached to the chest, which records for 24 hours.  
What happens when the research study stops? 
After the study finishes, your care will continue either with your cardiologist or GP.  The 
treatments you started on may continue, or you may change to other treatments if these prove 
to be better. 
What if new information becomes available? 
Sometimes we get new information about the treatment being studied.  If this happens, your 
research doctor will tell you and discuss whether you should continue in the study.  If the 
study is stopped for any other reason, we will tell you and arrange your continuing care. 
What will happen if I don’t want to carry on?  
You can withdraw from the study at any time without giving a reason.  However, we would 
like to keep in contact with you to let us know your progress.  Information collected until 
your withdrawal may still be used.  Any stored blood or tissue samples that can still be 
identified as yours will be destroyed if you wish. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (see contact details on the last 
page).  If you remain unhappy and wish to complain formally, you can do this by contacting 
the Patient Advice and Liaison Services (PALS) at the Queen Elizabeth Hospital on 0121 
371 3280 or PALS@uhb.nhs.uk.   
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In the event that something does go wrong and you are harmed during the research due to 
someone’s negligence, then you may have grounds for legal action and compensation against 
the sponsor (the University of Birmingham) but you may have to pay your legal costs.  The 
normal NHS complaints mechanisms will still be available to you, if appropriate. 
Will my details be kept confidential?  
All information which is collected about you, including from your medical records, will be 
kept strictly confidential, and any stored information about you will have your name and 
address removed so that you cannot be recognised.  We will take all reasonable steps 
available in order to protect your privacy. 
Personal and research data will be stored for up to 25 years.  Any future use of this data will 
follow the same principles as discussed above, and only shared within the research 
team.  Outside of this team (including in any articles we publish about the research), all data 
will refer to groups of patients, anonymised to protect privacy.   
Involvement of your family doctor 
Your GP will need to be kept informed of your participation in the study.  By consenting to 
take part, you agree to us sharing your progress in the study with your GP, as needed for 
your clinical care. 
What will happen to any samples I give?  
Blood samples will be used to develop new tests that may help doctors choose the right 
treatment for patients in the future.  We will store the blood you give, at the University of 
Birmingham Human Biomaterials Resource Centre and possibly in Research Laboratories 
overseas, within Europe.  Samples will only be labelled with a code to ensure your privacy.  
Samples will be stored for four years and then securely destroyed. 
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Will any genetic tests be done? 
If you agree, after receiving your blood samples we will isolate the genetic material (DNA).  
In the future, we hope that genetic factors can help doctors to use appropriate medications for 
each individual patient that avoids side effects.  Storing this DNA will help us to see 
differences in group of patients (not individuals) who benefit or don’t benefit from the 
treatments.  Your personal details will always remain confidential; we will never disclose 
any individual details and all future research will undergo ethical review. 
Are there any additional ways I can help?  
We will be asking ten patients to help look at the quality of life questionnaires in detail to see 
if they are a good way to capture information that helps to look after patients with atrial 
fibrillation.    Three half-day sessions will be planned over the 12-month period and any 
volunteers will receive financial compensation for their time. 
We are also planning future studies in patients with atrial fibrillation.    You can give consent 
for us to contact you about future research (you can specify whether and how you wish to be 
contacted). 
What will happen to the results of the research? 
The results of the quality of life questionnaires, the heart scans and some of your blood tests 
will not be used to direct your clinical care during the study.  These will remain concealed to 
the study doctors to keep an unbiased assessment of the two treatments.  However, if any 
troubling symptoms come to light during the study visits, the research nurses will alert the 
study doctors and take appropriate action. 
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At the end of the study, we plan to publish the study findings in a medical journal.  You will 
not be identified in any publication.   Following this, we will send out a summary of the 
findings to you. 
Who is organising and funding the research?  
The study is sponsored by the University of Birmingham and is being funded by the National 
Institute for Health Research (part of the Department of Health).  No member of the research 
team is being paid for including you in this study. 
Who has reviewed the study?  
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests.  This study has been reviewed and given 
favourable opinion by the East Midlands - Derby Research Ethics Committee.   
Who else is taking part? 
We aim to include 160 patients with atrial fibrillation in this study.  The results will help us 
to plan a future large study to demonstrate whether these treatments can help to reduce 
admissions to hospital. 
 
Key points about this research: 
Patients with atrial fibrillation usually need medications to control 
heart rate  
We currently don’t know which medication is the best to improve 
quality of life and heart function  
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This study will randomly assign patients to initial treatment with two 
common drugs and test them over 12 months 
The study mirrors normal clinical care for this condition and will 
involve questionnaires, blood tests, a walking test and heart ultrasound 
scans  
Our aim is to improve the care of patients with atrial fibrillation and 
help doctors choose the right medication for the right person 
Thank you for taking the time to read this information leaflet and for considering taking part 
in this research project. 
If you have any questions, please contact the study research team on:  
Phone: 07867 551 957 
Email: Karina.Bunting@uhb.nhs.uk 
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Appendix 3: Consent form
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Appendix 4: Optional Consent form
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Appendix 5: Randomisation form
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Appendix 6: Baseline CRF 
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 Appendix 7: SF-36 quality of life questionnaire 
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English version for the UK 
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Under each heading, please tick the ONE box that best describes your health TODAY. 
MOBILITY  
I have no problems in walking about 
 
I have slight problems in walking about 
 
I have moderate problems in walking about 
 
I have severe problems in walking about 
 
I am unable to walk about 
 
SELF-CARE  
I have no problems washing or dressing myself 
 
I have slight problems washing or dressing myself 
 
I have moderate problems washing or dressing myself 
 
I have severe problems washing or dressing myself 
 
I am unable to wash or dress myself 
 
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure 
activities)  
I have no problems doing my usual activities 
 
I have slight problems doing my usual activities 
 
I have moderate problems doing my usual activities 
 
I have severe problems doing my usual activities 
 
I am unable to do my usual activities 
 
PAIN / DISCOMFORT  
I have no pain or discomfort 
 
I have slight pain or discomfort 
 
I have moderate pain or discomfort 
 
I have severe pain or discomfort 
 
I have extreme pain or discomfort 
 
ANXIETY / DEPRESSION  
I am not anxious or depressed 
 
I am slightly anxious or depressed 
 
I am moderately anxious or depressed 
 
I am severely anxious or depressed 
 
I am extremely anxious or depressed 
 
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The worst health 






We would like to know how good or bad your health is TODAY. 
This scale is numbered from 0 to 100. 
100 means the best health you can imagine. 
0 means the worst health you can imagine. 
Mark an X on the scale to indicate how your health is TODAY. 
Now, please write the number you marked on the scale in the box below. 
 
 
The best health 
you can imagine 
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Appendix 9:  AFEQT questionnaire  
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Appendix 10.  Mini mental health state questionnaire 
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Appendix 11.  Up-titration CRF 
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Appendix 12:  Serious adverse event reporting form 
 
272 | P a g e  
 
 
273 | P a g e  
 
 
274 | P a g e  
 
275 | P a g e  
 
Appendix 13:  Follow up CRF form 
 
276 | P a g e  
 
 
277 | P a g e  
 
 
278 | P a g e  
 
 
279 | P a g e  
 
 
280 | P a g e  
 
 
